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“open-inactive” simulations (purple) and crystal structures of the homologous 
protein ASH1L (gray, PDB: 3OPE, 4YNM). 56 
 
4.1 Histogram of SPAM-calculated binding affinities for water sites in each solvent 
type.  ∆GSPAM is binned in 1 kcal/mol increments.  A decrease in the number of 
water-occupied sites is observed between the water-only (red) and water with 
probe simulations (colored lines), indicating the displacement of these sites by the 
probe molecules. Notably, there is a sharp decrease for water with positive 
∆GSPAM, but some waters with weakly favorable ∆GSPAM are also displaced. 66 
 
4.2 Above) Colored mesh depicts water occupancy from simulations of each probe and 
water mixture.  At high occupancy levels, few water sites are identified. These are 
sites which are repeatedly occupied by water molecules even in the presence of 
probe molecules.  Water sites that first appear at lower sigma values are less 
frequently occupied by water in the presence of probe molecules.  Left) The 
distribution of normalized occupancies for water sites (local maxima) within the 
active-site region.  Data is taken from water occupancy in the presence of all probe 




4.3 Aldose Reductase: Water density is shown at the 20 σ level, colored according to 
the probe type included in the simulation.  ΔGSPAM values from the water-only 
simulations are given in kcal/mol.  ΔGSPAM values for all waters within the active-
site region ranged from -1.79 to 5.76 kcal/mol.  Crystallographic waters 
(PDB:1ADS, 3U2C:WAT1338) are shown for reference.  Selected sites are labeled.  
The ligands epalrestat (PDB:4JIR,EPR) and sulindac (PDB:3U2C,SUZ) are shown for 
comparison.  A) Cluster of water sites which are predicted by the MixMD 
simulations to be always conserved.  B) Water site which is displaced by all probes 
except for acetonitrile.  In some apo and ligand bound structures, a water 
molecule is found at site C, (PDB:3Q67:WAT710, 3U2C:WAT1338 transparent red 
sphere).  When bound in this conformation, the oxygen of the ligand is positioned 
at site D.  D) Water occupancy maxima not found in crystal structures. E) Water 
site displaced by all probe types in MixMD and ligands in crystal structures. 71 
 
4.4 β-Secretase: Crystallographic waters from the apo structure of BACE (PDB: 1W50) 
and the bridging water in the ligand bound structure (PDB:4FM7, WAT909) are 
shown for reference. ΔGSPAM for the circled water site is -4.69 kcal/mol in the 
water-only simulations.  ΔGSPAM values in the active site region ranged from -4.69 
to 6.68 kcal/mol.  A) MixMD correctly predicts the displacement of the circled 
water site by acetate/methylammonium, N-methylacetamide, and pyrimidine 
probes.  The ligand from PDB:4RCD(3LL) is shown for comparison.  Water density is 
shown at the 20 σ level, colored according to the probe type included in the 
simulation. The inset figure shows the Methylammonium density at 150 σ. B) This 
site may also be conserved and bridge interactions between the ligand and 
protein, as predicted by the simulations with acetonitrile and isopropyl alcohol.  
The ligand from PDB:4FM7 (OUP) is shown for comparison. 73 
 
4.5 β-lactamase: Water density is shown at the 20 σ level, colored according to the 
probe type included in the simulation.  Crystallographic waters from the apo 
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structure (PDB:1ZG4) are shown for reference.  ΔGSPAM values from the water-only 
simulations are shown in units of kcal/mol.  ΔGSPAM values for the active-site region 
ranged from -5.58 to 3.62 kcal/mol.  While MixMD correctly predicts many of the 
waters in the active site of β-lactamase as being displaced, there are two known 
discrepancies.  These are attributed to the limited set of probe types used and the 
inability to account for covalent interactions within an MD simulation. (PDB:1BT5-
IM2, 1ERM-BJI) 74 
 
4.6 BRD4: Water density is shown at the 20 σ level, colored according to the probe 
type included in the simulation.  Crystallographic waters from the apo structure 
(PDB:2OSS) are shown for reference.  ΔGSPAM values from the water-only 
simulations are shown in units of kcal/mol.  ΔGSPAM values for the active site region 
ranged from -0.73 to 3.61 kcal/mol.  A) Site predicted by MixMD to be displaced, 
shown with an example ligand (PDB:3UVW, peptide) displacing the site.  B) Water 
site found in 97% of comparable structures, predicted by MixMD to be 
displaceable is shown with an inhibitor displacing this site (PDB:4O7F, 2RQ). 76 
 
4.7 Dihydrofolate Reductase: Water density is shown at the 20 σ level, colored 
according to the probe type included in the simulation. Crystallographic waters 
from the apo structure (PDB:1DG8) are shown for reference.  ΔGSPAM values from 
the water-only simulations are shown in kcal/mol.  ΔGSPAM values within the active-
site region ranged from -1.42 to 5.13 kcal/mol.  A) Water that is found in 100% of 
comparable crystal structures, predicted to be conserved by MixMD.  B) Water site 
known to be displaced by nitrogen, predicted by MixMD to be displaced by N-
methylacetamide.  C) Water site known to be displaced by nitrogen, predicted by 
MixMD to be displaced by N-methylacetamide, acetate/methylammonium, and 




4.8 Heat Shock Protein 90: Water density is shown at the 20 σ level, colored according 
to the probe type included in the simulation. Crystallographic waters (PDB: 1AH6) 
are shown for reference.  ΔGSPAM values from the water-only simulations are 
shown in kcal/mol.  ΔGSPAM values within the active-site region ranged from -1.65 
to 5.70.  Geldanamycin (PDB:2YGA,GDM) is shown for reference A) Water site 
found in 100% of homologous structures, predicted to be conserved by MixMD.  B) 
Water site displaced by carbonyl of geldanamycin, predicted to be displaced by N-
methylacetamide. 79 
 
 4.9 Neuraminidase: Crystallographic waters (PDB:4HZV) within 10 Å of the MixMD-
identified hotspot are shown, along with water density from the MixMD 
simulations shown at the 20 σ level, colored according to the probe type included 
in the simulation. ΔGSPAM values from the water-only simulations are shown in 
kcal/mol.  ΔGSPAM values within the active-site region ranged from -3.35 to 8.56 
kcal/mol.  A) Cluster of conserved water sites found in 100% of homologous 
structures, predicted by MixMD to be conserved. B) Water sites displaced by 
carboxyl of ligand (Zanamivir shown, PDB:4I00, ZMR) are correctly predicted by 
MixMD to be displaced.  The inset figure shows the occupancy of the acetate 
probe which correctly predicts displacement of these sites. 80 
 
4.10 Penicillin Binding Protein: Crystallographic waters (PDB:2EX2) within 10 Å of the 
MixMD identified hotspot are shown, along with water density from the MixMD 
simulations shown at the 20 σ level, colored according to the probe type included 
in the simulation. ΔGSPAM values from the water-only simulations are shown in 
kcal/mol.  ΔGSPAM values within the active-site region ranged from -1.09 to 9.55 
kcal/mol.  A) Water site found in 100% of related crystal structures, predicted to 
be conserved in the presence of all probe types tested.  B) Water site displaced by 
ligand (PDB:2EX6, AIX shown) is predicted to be displaced by all probes other than 




4.11 Penicillopepsin: Crystallographic waters (PDB:3APP) within the active site are 
shown, along with the water density from the MixMD simulations at the 20 σ level, 
colored according to the probe type included in the simulation. ΔGSPAM values from 
the water-only simulations are shown in kcal/mol.  ΔGSPAM values within the active-
site region ranged from -1.17 to 7.71 kcal/mol.  A) Water site displaced by 
phosphonate-containing ligand (PDB:1BXO, PP7) is correctly predicted as 
displaceable by the MixMD simulations.  B) Important water site found in 100% of 
related structures which participates in a network of stabilizing interactions is 
predicted as being conserved. 83 
 
4.12 Thrombin: Crystallographic waters within the active site (PDB:3U69) are shown, 
along with the water density from the MixMD simulations at the 20 σ level, 
colored according to the probe type included in the simulation.  ΔGSPAM values 
from the water-only simulations are shown in kcal/mol.  ΔGSPAM values within the 
active-site region ranged from -0.33 to 5.63 kcal/mol.  A) Water site that is found 
in 74% of comparable crystal structures and is predicted to be selectively displaced 
by acetonitrile and isopropyl alcohol.  B) Water site is predicted to be always 
conserved, found in 100% of comparable crystal structures.  C) Water site that is 
predicted to be always displaced, shown with a peptide-inhibitor. (PDB:3U8O). 85 
 
5.1 The closed form structure of Src Kinase (PDB:2SRC) is shown.  In the closed 
conformation, a phosphorylated tyrosine (circled) at the very c-terminus of the 
kinase domain binds to the SH-2 domain.  In the open form, this interaction is 
absent and the SH-2 and SH-3 domains rotate away from the kinase domain. Most 
kinase inhibitors target the ATP-binding site within the kinase domain. 91 
 
5.2 Individual trajectories are aligned and overlaid with a 0.5 Å cubic grid.  B) At each 
grid point, the occupancy of probe molecules is counted for each frame in the 
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trajectory.  For example, the occupancy of the center of aromatic probes is 
counted at each grid point.  C) This yields a time-averaged occupancy value at each 
grid point.  D) Low occupancy grid points are removed (eg. those less than 10% of 
the max occupancy).  The remaining points are clustered with the DBSCAN 
algorithm to identify discrete interaction sites.  This process is repeated for each 
individual probe or interaction type. 94 
 
5.3 The DBSCAN algorithm is used to identify clusters of highly occupied grid points.  
Top) For each cluster of probe density, the highest occupied point is selected as 
the center and the RMSD of every other point to the center is calculated, to yield 
the radius of the pharmacophore feature.    Middle) When multiple probes overlap 
within the specified cutoff, the average of all grid points within the cluster is used 
to define the center of the pharmacophore feature, and the radius is determined 
from the RMSD of all points to this center. Bottom) Maxima separated by a greater 
distance than the cutoff have minimal overlap, and are more appropriately 
represented as separate features. 96 
 
5.4 MixMD occupancy for acetonitrile (orange), imidazole (purple), isopropyl alcohol 
(blue), n-methylacetamide (yellow), and pyrimidine (magenta).  The active and 
allosteric sites can be identified by the surrounding probe density, initially seen at 
very high occupancies (left).  Visualizing the probe density at medium occupancy 
levels shows the extent of the binding site and full range of potential interactions 
(right).  Ligands are shown in green for reference (PDB: 3KFA, 3MS9), but were not 
included in the simulations. 99 
 
5.5 A) The region of ABL kinase mapped with the highest occupancy of MixMD density 
was selected for pharmacophore modeling.  B) The occupancy for each interaction 
type was counted for each grid point.  C) Grid points are clustered into 




5.6 Percent of active compounds (n=13) satisfying the pharmacophore model of the 
ABL kinase active site relative to the percentage of inactive compounds 
(n=10,750).  Pharmacophore models requiring 6-9 matches with 1-2x radii were 
tested. 100 
 
5.7 Left) MixMD density is shown for acetonitrile (orange), isopropyl alcohol (blue), 
and pyrimidine (magenta) contoured at 20 σ.  The SH-2 and SH-3 domains form 
two pockets with the kinase interface, which ranked among the top sites (circled) 
by MixMD probe occupancy.  Right) Pharmacophore models for the SH-2 and SH-3 
kinase interfaces of Src.  Spheres are colored according to the pharmacophore 
feature type.  Coordinates and radii of the pharmacophore features are given in 
Tables 5.4 and 5.5. 102 
 
6.1 The DBSCAN clustering procedure identifies connected regions of probe density 
arising from multiple probe types (represented by different colors). Grid points 
within the distance parameter ε are grouped into the same cluster.  The resulting 
clusters can then be ranked based on the probe occupancy within the cluster. 112 
 
6.2 The mean shift clustering algorithm groups points based on their distribution in 
space.  Densely occupied regions correspond to the center of a cluster (dark blue), 
while sparsely occupied regions indicate cluster edges (light blue). 113 
 
6.3 Radial distribution functions of the oxygen in water show expected behavior in all 
cases.  Probe-probe radial distribution functions deviate slightly from 1, but are 
within the acceptable ranges previously established by our group.  All values 




6.4 Cluster ranking by total occupancy for ABL kinase.  The active site ligand B91 
(PDB:3KFA) and allosteric ligand (myristate, PDB:1OPJ) are shown for reference.  
The top two sites for each solvent set are shown as dark blue clusters, with the 
total occupancy within these clusters given in bold.  In every case, ranking by total 
occupancy identifies the active and allosteric sites as the highest ranked sites.  The 
boxplot shows the distribution of total occupancies for each cluster and solvent 
set.  The top two sites (corresponding to the active and allosteric sites) are 
noticeably higher in occupancy than the remaining clusters (light blue). 117 
 
6.5 Cluster ranking by total occupancy for androgen receptor.  The top ranked sites by 
occupancy are shown in dark blue, with the total occupancies for these clusters in 
bold.  All other clusters are shown in light blue.  Active (PDB:3V4A, PK1) and 
allosteric (PDB:2PIU,4HY and PDB:2PIX, FLF) ligands are shown for reference.   The 
SRC-2 coactivator peptide is shown in magenta (PDB:2QPY).  The active site is the 
top ranked site in all cases.  In the solo and solvent combination A simulations, the 
two allosteric sites are the next highest ranked sites.  However, in solvent 
combination B the total occupancies for the remaining sites are close together, 
making it difficult to discern the allosteric sites from ranking alone. 119 
 
6.6 BACE contains an extended binding cleft, with inhibitors 7H3 (PDB: 5TOL) and 5E7 
(PDB:5DQC) shown for reference.  In every case, MixMD correctly identifies the 
active site as the region with the highest total occupancy, shown in dark blue.  The 
total occupancies of the top clusters are given in bold, with the remaining clusters 
shown in light blue.  The top cluster identified from solvent combinations A and B 
is smaller than that of the solo simulations, but overlaps with the subsites of BACE 
that have been targeted by small, high-affinity ligands. 121 
 
6.7 The active site of DHFR is correctly identified as the top-ranked site (shown in dark 
blue) across all three sets of MixMD simulations.  The total occupancy for the top 
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sites is given in bold, with the remaining clusters shown in light blue.  
Methotrexate and the ligand 1DN are shown for reference (PDB:1DF7, MTX and 
PDB:4LEK,1DN). 122 
 
6.8 Acetonitrile (orange), imidazole (purple), and isopropyl alcohol (blue) grid points 
with greater than 10% occupancy are shown for the active-site region of ABL 
kinase.  Local maxima are shown as spheres, with surrounding grid points shown.  
Imatinib (PDB:1OPJ) and B91 (PDB:3KFA) are shown for reference.  In the solo 
simulations, acetonitrile, imidazole, and isopropyl alcohol were each run 
individually.  In the combined set B simulations, these three solvents were run in 
combination.  Relative to the solo simulations, the occupancy in the combined 
simulations identifies fewer local maxima.  For example, the isopropyl occupancy 
seen in the left portion of the ABL active site is absent in the combined solvent 
simulations, and it is replaced by imidazole and acetonitrile occupancy. 124 
 
6.9 MixMD Probeview identified the active site as one of the highest ranked hotspots 
in ABL kinase.  Grid points with 10% or greater occupancy within the active site are 
shown for each solvent across the three MixMD setups.  Local maxima are shown 
as spheres, with surrounding grid points shown. Imatinib (PDB:1OPJ) and B91 
(PDB:3KFA) are shown for reference.  Solo simulations accurately map the active 
site region, in agreement with known ligands.  Imidazole shows the most extensive 
mapping, with local maxima corresponding to aromatic portions of the ligands.  
Solvent combinations A and B map the active site as well, but with fewer local 
maxima due to competition between solvents.  For example, in solvent 
combination B the N-methylacetamide occupancy seen within the left-hand side of 
the ligand in the solo simulations is displaced by pyrimidine.  This is consistent with 
ligand-bound structures which place aromatic rings at this site.  However, N-
methylacetamide serves to identify hydrogen-bonding interactions, which may not 




6.10 MixMD Probeview identified the allosteric site as one of the highest ranked 
hotspots in androgen receptor.  Grid points with 10% or greater occupancy within 
this site are shown for each solvent across the three MixMD setups.   Local 
maxima are shown as spheres with surrounding grid points shown.  The active site 
of AR has minimal solvent exposure, and so differences in sampling between 
solvent sets are expected.  For this reason, we have shown local maxima for one of 
the allosteric sites.  The allosteric site ligand, flufenamic acid (PDB:2PIX), is shown 
for reference.  Solo simulations show each probe accurately maps the allosteric 
site ligand but with different occupancy strengths. Acetonitrile, isopropyl alcohol, 
and imidazole all had similar top occupancies for the solo simulations, with the 
two charged probes, methylammonium and acetate, having the least occupancy. 
Solvent combinations A and B mirror the solo simulations, but with a few 
noticeable differences. First, the charged probes fail to map the ligand at all in 
both solvent combos A and B. This is likely due to the site’s preference for other 
types of interactions, leading to the charged probe’s displacement.  Isopropyl 
alcohol shows strong mapping in combination A, whereas in combination B it is 
displaced by acetonitrile and imidazole.  Visualizing the occupancy at lower levels 
reveals that isopropyl alcohol does sample this site, but is below the 10% cutoff. 
Additionally, acetonitrile has only one local maximum in solvent combination A, 
but two in combination B. 129 
 
6.11 MixMD Probeview identified the active site as the highest ranked hotspots in 
BACE.  Grid points with 10% or greater occupancy within the active site are shown 
for each solvent across the three MixMD setups.  Local maxima are shown as 
spheres, with surrounding grid points shown.  Ligands LY2811376 (PDB:4YBI, 4B2), 
5E7 (PDB:5DQC), and 7H3 (PDB:5TOL) are shown for reference.  Solo simulations 
show each probe accurately mapping the active site in agreement with known 
ligands. The neutral probes mapped the active site ligand extensively, while the 
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two charged probes, acetate and methylammonium, had significantly less mapping 
within the site. Solvent combinations A and B mapped the active site similarly to 
the solo simulations, with the charged probes being the primary difference. In the 
combined simulations, the charged probes were displaced in favor of the neutral 
probes. 131 
 
6.12 MixMD Probeview identified the active site as the highest ranked hotspots in 
DHFR.  Grid points with 10% or greater occupancy within the active site are shown 
for each solvent across the three MixMD setups, with the exception of the charged 
probes for which nearby sites are shown.  Local maxima are shown as spheres, 
with surrounding grid points shown.  Methotrexate and the ligand 1DN are shown 
for reference (PDB:1DF7, MTX and PDB:4LEK,1DN).  Mapping of the binding site 
was similar between all solvents sets, although solvent combination B showed 
preferential binding to portions of the active-site by acetonitrile and isopropyl 
alcohol when run in combination with imidazole.  The charged probes indicate 
favorable interactions outside of the core region of the ligand, which mimic the 
interactions made by the carboxylate groups of methotrexate. 133 
 
A.1 The current MixMD procedure utilizes a layered cosolvent approach, where the 
crystal structure of the protein is surrounded with a layer of small molecule probes 
followed by a box of water molecules. 141 
 
A.2 Starting structures were generated using the PACKMOL utility to randomly place 
pyrimidine probe molecules around HEWL.  Ten such starting structures were 
generated, each shown in a different color.  This setup procedure resulted in 
varied probe positions, with minimal direct overlap of probe molecules. 142 
 
A.3 Pyrimidine atomic occupancy during the last 10 ns of the simulation is shown 
contoured at 100 σ for each of the ten simulations.  The observed acetonitrile 
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binding site (PDB: 2LYO) is shown in green.  In 9 out of 10 simulations, the 
acetonitrile binding site (active site) is the most occupied position.  Run 6 is the 
exception, which shows the highest occupancy site outside of the active-site 
region. 143 
 
A.4 Total occupancy for pyrimidine across all 10 simulations is shown for each portion 
of the trajectories.  For easier comparison, the occupancy shown is the fraction of 
the maximum occupancy.   For reference, the occupancy of the primary spurious 
site for the standard MixMD simulations is also shown for the “half-mass” 
simulations. 145 
 
A.5 Left) Pyrimidine atomic occupancy from the first 2.5 ns of all 10 standard MixMD 
trajectories ranks the spurious site (circled) higher than the active site (Acetonitrile 
from PDB:2LYO, green stick).  Right) Pyrimidine occupancy from the last 2.5 ns of 
the standard simulations identifies the active site as the top ranked site.  Bottom) 
The 2.5-5 ns time period of the “half-mass” simulations correctly identifies the 
active site.  All figures are contoured at 100 σ. 146 
 
A.6 The backbone RMSD relative to the crystal structure of the production portion of 
the 10 standard and 10 “half-mass” simulations is shown.  Both sets of simulations 
deviate from the starting structure to a similar extent.  RMSD values of 2 Å or less 
are typically indicative of normal conformational sampling within an MD 
simulation. 147 
 
B.1 In the accelerated molecular dynamics method of McCammon, a boost is added to 
the potential energy when the potential energy is below a specified energy cutoff, 
which effectively decreases the barrier between related conformations.  In regions 
below the energy cutoff, the system evolves according to the modified, “boosted” 




B.2 The highest occupied site identified using the MixMD Probeview tool is shown in 
dark blue for each of the simulations, with lower occupancy clusters shown in light 
blue. 155 
 
B.3 The graph shows the total occupancy for each cluster in the aMixMD and standard 
MixMD simulations.  The top-ranked site is shown in dark blue, while all other sites 
are shown in gray.  Relative to the standard MixMD simulations, the accelerated 
MixMD simulations identified fewer spurious sites.  As shown in the graph, the 
difference in total occupancy between the active site and other spurious sites is 
much larger in the aMixMD simulations, clearly identifying the active site as the 
top-ranked site. 156 
 
B.4 The top-3 ranked sites by occupancy for the standard MixMD and accelerated 
MixMD simulations are shown as colored surfaces.  Ubiquitin is shown in green for 
reference, but was not included in the simulations. 159 
 
B.5 Adapted from Meng et al.  The transition between DFG-in and DFG-out states can 
be assessed using dihedral angles measured from the preceding alanine to the 
aspartate of the DFG-motif and from the preceding alanine to the phenylalanine of 
the DFG-motif. 161 
 
B.6 A-D) The transition between the DFG-out and DFG-in states is characterized by the 
Ala-Phe and Ala-Asp dihedral angles.  Sampling during the respective trajectories is 
shown, colored according to the frequency of the observed angles.  The black star 
indicates the dihedral angles characteristic of the DFG-in conformation.  E) 
Pyrimidine occupancy from the frames falling within the frequently sampled 
region in the right lower quadrant of graph D, from point (-50,-60) to (30,-180).  
The DFG-out and DFG-in states are shown in green and cyan, respectively.  The 
xxi 
 
pyrimidine occupancy overlaps with the region that is occupied by phenylalanine 
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 Mixed-solvent molecular dynamics (MixMD) is a cosolvent mapping technique for 
structure-based drug design.  MixMD simulations are performed with a solvent mixture of small 
molecule probes and water, which directly compete for binding to the protein’s surface.  
MixMD has previously been shown to identify active and allosteric sites based on the time-
averaged occupancy of the probe molecules over the course of the simulation.  Sites with the 
highest maximal occupancy identified known biologically relevant sites for a wide range of 
targets.  This is consistent with previous experimental work identifying hotspots on protein 
surfaces based on the occupancy of multiple organic-solvent molecules.  However, previous 
MixMD analysis required extensive manual interpretation to identify and rank sites.  MixMD 
Probeview was introduced to automate this analysis, thereby facilitating the application of 
MixMD.  Implemented as a plugin for the freely available, open-source version of PyMOL, 
MixMD Probeview successfully identified binding sites for several test systems using three 
different cosolvent simulation procedures.  Following identification of binding sites, the 
occupancy maps from the MixMD simulations can be converted into pharmacophore models 
for prospective screening of inhibitors.  We have developed a pharmacophore generation 
procedure to convert MixMD occupancy maps into pharmacophore models.  Validation of this 
procedure on ABL kinase showed good performance.  Additionally, we have identified 
characteristic occupancy levels for non-displaceable water molecules so that these sites may be 
incorporated into structure-based drug design efforts.  Lastly, we have explored the potential 
for accelerated sampling methods to be used in tandem with MixMD to simultaneously capture 
conformational changes while mapping favorable interactions within binding sites.  These 




In addition, two exploratory studies were completed.  First, traditional MD simulations 
were performed to understand the dynamics of NSD1.  Crystal structures of NSD1 capture the 
post-SET loop in an autoinhibitory position.  MD simulations allow conformational sampling of 
this loop, yielding insight into its dynamic behavior in solution.  Second, an epidemiological 
study was conducted which was aimed at understanding the transmission and sequence 
variation of CTX-M-type β-lactamases, in fulfillment of the clinical research component of the 






Chapter 1. Introduction 
1.1 Protein Sequence, Structure, and Function 
 
Protein function requires a delicate balance of sequence and structural motifs with 
conformational dynamics.  Important sequence elements, such as catalytic residues, are 
generally conserved across protein families as these elements have evolved in concert with the 
protein’s function.  However, there may be a great deal of sequence variability even between 
highly related proteins, which can be important in regulating activity.  For example, the kinase 
class of enzymes is responsible for transferring phosphate groups from an adenosine 
triphosphate (ATP) cofactor to a specific residue on a target protein.  While there are a number 
of amino acids that are conserved between individual kinases, including the Aspartate-
Phenylalanine-Glycine (DFG) motif that coordinates binding of Magnesium ions and ATP, there 
exists a great deal of sequence and structural variation outside of this region1.  At first glance 
these differences may not seem important, as they are not necessarily involved in catalysis, but 
in fact are critical to allow proteins to function both specifically and efficiently within the 
context of the cell.  There are a vast number of pathways involved in cellular and organismal 
function, with individual proteins having a specific role within this network. Understanding the 
role of sequence and structural variations in garnering this specificity is essential to 
understanding disease processes and in identifying how small molecules could potentially 
inhibit these functions.   
 
The combination of genetic and epidemiological studies with biochemical research has 
generated a wealth of information about numerous proteins and cellular pathways, but there 
are still many unanswered questions.  We do not yet know all of the members of these 
pathways or all of the interactions taking place.  There is also heterogeneity within the protein 
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sequences carried between individuals.  These differences may have subtle effects, or may have 
very detrimental effects, and in some cases may emerge upon treatment with small molecule 
inhibitors.  This is especially relevant within the development of antiviral, antibacterial, or 
anticancer treatments, where resistance to the inhibitors is a significant factor limiting 
treatment of these diseases2, 3.  In the case of antibiotic development, bacteria have evolved a 
number of resistance mechanisms, including the production of enzymes which chemically alter 
drug molecules to prevent them from reaching their intended target.  The specificity of these 
enzymes for different classes of inhibitors is dependent on the enzyme’s sequence, and may 
evolve over time to yield increasing levels of resistance.  Traditionally, these differences in 
enzyme structure and function would be examined using a combination of structural and 
biochemical experiments.  For example, NMR or crystallography studies can be used to 
understand differences in protein structure, while biochemical assays can be used to measure 
differences in enzyme kinetics.  However, performing these experiments to characterize every 
protein variant is simply not feasible, due to time, financial, and experimental limitations.  
Alternatively, experimental data can be combined with computational simulations to examine 
the contribution of individual amino acids to protein dynamics and function, thereby allowing 
for the study of a much larger number of variants while bypassing the experimental limitations.   
 
1.2 Molecular Dynamics Simulations 
 
 Molecular dynamics (MD) simulations are a promising means to understand the role of 
individual amino acids in regulating protein structure and dynamics.  For example, many 
proteins have conformational changes which are important to their function4.  Molecular 
dynamics simulations can be used to simulate these conformational changes in atomic level 
detail, allowing researchers to study the contribution of individual amino acids to these 
processes5.   The results of these simulations can be utilized in many ways, depending on the 
goal of the study.  For instance, the resulting structures can be used to focus biochemical 
studies, such as mutagenesis, on regions or domains of interest to confirm the role that specific 
residues have been predicted to play.  These simulations may also be used to inform structure-
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based drug design efforts, by identifying conformational states that may be selectively targeted 
by inhibitors, or in combination with other techniques to identify potential binding sites on the 
protein’s surface. 
 
In order to perform a molecular dynamics simulation, structural data on the protein or 
biological system of interest is required.  Typically simulations are initiated from a crystal 
structure of the protein or system of interest, although models of the protein may be created 
from related proteins when structural data is unavailable.  Files containing descriptors of every 
atom within the protein are then created, which allow for interactions between protein atoms 
or between protein atoms and solvent to be calculated based on the bonded (bond lengths, 
angles and dihedral angles between atoms) and non-bonded interactions (Van der Waals and 
Coulomb interactions)  as determined from the starting structure.  The total potential energy is 
then given as the sum of each of these individual terms, as shown in Equation 1 for the AMBER 
suite of programs: 
 
𝑉𝑉(𝑟𝑟) =  � 𝐾𝐾𝑏𝑏 (𝑏𝑏 − 𝑏𝑏0)2
𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
+  � 𝐾𝐾𝜃𝜃(𝜃𝜃 − 𝜃𝜃0)2  
𝑎𝑎𝑏𝑏𝑎𝑎𝑎𝑎𝑎𝑎𝑏𝑏




/2)(1 + cos[𝑛𝑛𝑛𝑛 − 𝛿𝛿]) +  � (𝐴𝐴𝑑𝑑𝑖𝑖/
𝑏𝑏𝑏𝑏𝑏𝑏−𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑎𝑎𝑏𝑏
𝑟𝑟𝑑𝑑𝑖𝑖12)  − (𝐵𝐵𝑑𝑑𝑖𝑖/𝑟𝑟𝑑𝑑𝑖𝑖6) + (𝑞𝑞𝑑𝑑𝑞𝑞𝑖𝑖/𝑟𝑟𝑑𝑑𝑖𝑖) 
 
Using the relationship between force and potential energy, F = - 𝛻𝛻V = ma, allows for the 
positions and velocities of the atoms within the system to be calculated over time.  In order to 
solve for the velocity and position at each point in time, the equations of motion must be 
numerically integrated, as there is no exact solution.  The time step that can be used is limited 
by the fastest motions in the system, such as bonds containing hydrogens.  This requires time 
steps on the order of 1-2 fs, which limits the normally accessible simulation timescales.  A 
number of programs have been developed to carry out these simulations, including AMBER, 
CHARMM, and NAMD6-8.  Typically, many individual simulations are done and then average 
motions may be analyzed over time to understand the specific interactions of interest. 
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 Simulation times usually range from tens to hundreds of nanoseconds, depending on 
the size and potential conformations of the chosen system.  These timescales allow researchers 
to capture dynamic changes such as side chain rearrangements, loop motions, and helix 
bending.  Traditionally, these simulations are run across clusters of cpus (central processing 
unit), and/or gpus (graphics processing unit) to achieve simulations of this magnitude within a 
reasonable time period.  For simulations of biological processes that occur at longer timescales, 
specialized methodologies have been developed.  The Anton machine has been developed by 
D.E. Shaw Research to enable simulations of up to a millisecond, which allows researchers to 
capture longer timescale processes such as protein folding9.  For example, Anton was used to 
perform molecular dynamics simulations of the fast folding protein gpW in tandem with NMR 
experiments to understand the contributions of interacting residues to the folding process10.  
Distributed computing methods are also notable for being able to tackle long timescale 
processes by harnessing the power of huge numbers of cpus and gpus.  The Pande group has 
developed the Folding@home project which uses thousands of computers to parallelize 
molecular dynamics simulations11.  In the Folding@home project, individuals “volunteer” their 
computers to perform calculations for the Folding@home team when the computers would 
otherwise be idle.  The group has successfully applied this methodology to several systems, 
including Src Kinase.  In this study, they generated 500 µs of total simulation time from 
approximately 24,000 individual simulations.  The use of Markov state models allowed the 
group to analyze the extremely large trajectories in order to understand the dynamics and 
activation of Src, and resulted in the identification of a potentially druggable intermediate 
state12.   
 
Enhanced Sampling Techniques 
 As an alternative to running traditional molecular dynamics simulations on very long 
timescales, specialized sampling methods can be used to accelerate conformational sampling, 
or to focus sampling on a particular conformational transition of interest.  As shown in Figure 
1.1, the probability of transitioning between two states at different energy levels depends on 
5 
 
the energy barrier or “barrier height” between the two states.  The rate to cross this barrier is 
given by Equation 2: 
 
𝑘𝑘 ∝  𝑒𝑒−∆𝐺𝐺 𝑅𝑅𝑅𝑅�         (2)    
 
where ΔG is the change in energy between the starting state and the intermediate state (the 
barrier height), R is the gas constant, and T is the temperature13.  At the most basic level theory 
wise, sampling may be accelerated by increasing the temperature of the simulated system.  
Temperature-accelerated molecular dynamics was introduced by Sørensen and Voter in 200014.  
In this method, transitions between states are accelerated due to the increased temperature.  
As this method can potentially sample high energy states that wouldn’t normally be accessible, 
only transitions that would occur at the desired temperature are kept and others are filtered 
out14.  Initial applications of this method focused on simulations of atoms on a solid surface, but 
temperature-accelerated simulations have since been extended and applied to proteins15.  
Replica-exchange molecular dynamics, or REMD, similarly uses multiple temperatures to 
simulate the system of interest16.  In REMD, multiple replicas of the system are simulated at 
varying temperatures.  Replicas at neighboring temperatures may be exchanged, effectively 
allowing the system to bypass barriers that would exist in traditional molecular dynamics 
simulations.   
 
Figure 1.1: The probability of transition from one state (dark purple) to another (light 







 In cases where the region of conformational space to be sampled is known in advance, 
specialized methods can be used to focus sampling in this area.  In the umbrella sampling 
method, introduced by Torrie and Valleau in 1977, a bias is used to force the system to sample 
over energy barriers17.  In this method, the transition of interest is divided into a number of 
smaller changes, called “windows”.  For example, if one wishes to study the dihedral angles for 
a small peptide, the potential conformations may be separated into smaller increments, for 
instance every 10°, and each small conformational transition may be simulated simultaneously.  
During the simulations, restraints are used to ensure that the conformational sampling remains 
near the desired region.  The resulting trajectories can then be combined, such as with the 
weighted histogram analysis method or WHAM, to yield the unbiased energy over the entire 
reaction coordinate18.   
 
In cases where the desired end states are not known in advance, molecular dynamics 
simulations can be accelerated using a modified potential energy surface.  If a bias is added to 
the potential energy surface such that the depths of the wells are decreased, the effective 
barrier height separating different states is decreased.  In the hyperdynamics method, 
introduced by Voter in 1997, a bias potential is used to increase the potential energy within 
wells, while leaving the transition state regions at the original potential energy19.  This allows 
for the systems to increasingly sample transitions over the barrier regions.  In a similar manner, 
the McCammon group has introduced the accelerated molecules dynamics (aMD) method20, 21.  
In aMD, a potential energy boost (ΔV(r)) is added to the potential energy whenever the 
system’s energy drops below a predetermined cutoff value (E), given in equation 3.   
 
𝑉𝑉∗(𝑟𝑟) � 𝑉𝑉(𝑟𝑟),     𝑉𝑉(𝑟𝑟)  ≥ 𝐸𝐸𝑉𝑉(𝑟𝑟) +  ∆𝑉𝑉(𝑟𝑟),    𝑉𝑉(𝑟𝑟) < 𝐸𝐸         ∆𝑉𝑉(𝑟𝑟) =  
(𝐸𝐸 − 𝑉𝑉(𝑟𝑟))2
∝ +(𝐸𝐸 − 𝑉𝑉(𝑟𝑟))
       (3) 
 
As shown in Figure 1.2, the potential energy boost decreases the depth of the well, effectively 
decreasing the barrier height and promoting sampling between nearby states.  The level of 
boost in controlled by the tunable parameter, α.   As shown in Equation 3, the potential energy 
boost is inversely related to the value of α, with smaller levels of α yielding larger levels of 
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boost.  The level of boost can also be controlled by varying the energy cutoff E, although one 
must be careful not to set the cutoff value so high that the system is essentially exploring a flat 
energy landscape. 
 
Accelerated molecular dynamics provides two mechanisms of boosting the sampling 
during the simulation.  The boost may either be applied to the potential energy alone, as in 
Equation 3, or may be applied to both the dihedral energy and the potential energy22.  This 
“dual-boost” method was shown to sample conformational space of an alanine dipeptide more 
efficiently than either the potential or dihedral energy boosts alone while still maintaining the 
expected sampling distribution22.  One caveat with the application of aMD is that the resulting 
distributions must be reweighted to recapture the original potential energy surface.  
Reweighting algorithms have been developed that can effectively recapture the underlying 
potential energy surface for small systems, but are less accurate when applied to large 
systems23.     
 
 This method has been successfully applied to understand conformational sampling in a 
number of systems.  For example, Guo and Zhou applied accelerated molecular dynamics 









Figure 1.2: In the accelerated molecular dynamics method of McCammon, a boost is added 
to the potential energy when it is below a specified energy cutoff, which effectively 
decreases the barrier between related conformations.  In regions below the energy cutoff, 
the system evolves according to the modified, “boosted” potential energy surface, depicted 




communication in the regulatory subunit of protein kinase A (PKA)24.  PKA has two binding sites 
for cAMP that sequentially unbind to deactivate the enzyme, but the molecular mechanisms 
governing this ordered process were previously unknown.  Simulations of cAMP bound to either 
one or both of the binding sites in PKA in comparison with apo simulations of PKA allowed the 
authors to identify the pathway underlying the allosteric communication and implicated a role 
for essential interactions with a tryptophan residue that stacks with one of the cAMP 
molecules24.   aMD has also been applied to the study of thrombin and its interactions with 
individual domains of thrombomodulin25.  Previous studies had suggested the role of 
thrombomodulin binding in altering conformational loop dynamics in the active site region of 
thrombin.  Residue-residue correlation analysis from the resulting trajectories identified 
allosteric communication pathways which explained the observed anticoagulant activity 
differences between binding of thrombomodulin56 and thrombomodulin456 to thrombin.   
 
It is evident from these studies, as well as many others, that molecular dynamics 
simulations offer great insight into the function and dynamics of biological systems.  These 
simulations also give insight into the ways by which biological function and activity might be 
modified by small molecule inhibitors.  Once the dynamics and function of these enzymes are 
thoroughly understood, small molecule inhibitors that act to block or enhance this function may 
be designed.  For example, molecular dynamics simulations may give insight into inactive 
conformations that could potentially be stabilized by ligands to block enzymatic activity, or may 
help to identify important interactions within an active site region that could preferentially 
interact with an inhibitor over the natural ligand.   
 
1.3 Computational Drug Design 
 
 Since the rise of computational technologies in the 1970’s and 1980’s, computational 
methods for drug discovery have had widespread use in both commercial and academic studies 
towards the design and selection of potential small molecule inhibitors.  In the most general 
sense, computational techniques may be used to understand differences between small 
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molecules and to rationalize the patterns of activity seen within related series of compounds.  
QSAR (quantitative structure-activity relationship) methods are frequently used to understand 
trends in ligand activity seen between similar classes of ligands26.  QSAR combines both 
statistical and computational methodologies in order to examine hundreds to thousands, or 
even millions of compounds for potential activity.  For example, some of the earliest 
applications of QSAR were done by researchers wanting to understand how changing 
substituents on a common scaffold affected activity27, 28.  Using such descriptors as compound 
hydrophobicity (based on octanol-water partition coefficients, logP) and steric effects 
(calculated from a compound’s van der Waals radius), researchers were able to analyze trends 
in activity and suggest guidelines for the selection of compounds to synthesize.  QSAR 
techniques are also used in the clustering of molecules, to identify closely related compounds 
and to identify diverse sets of compounds for testing in order to efficiently cover chemical 
space.   
  
 Docking methods that attempt to predict the interactions between an individual ligand 
and a receptor are also being developed and are widely used29.  These methods can be applied 
in multiple ways, depending on the goal of the study.  In cases where a ligand is known to be 
active and a protein structure is available, but 3-D structural information of the protein-ligand 
complex doesn’t exist, docking can be used to predict the binding conformation of the ligand.  
Docking can also be applied as a virtual screening methodology to rank ligands for their 
potential to bind to a specific target.  The docking procedure consists of two main steps, pose 
generation followed by scoring and ranking of the generated poses.  In order to identify the 
poses, or orientations of the ligand within the receptor binding pocket, the potential 
configurations of the ligand must be identified.  In some methods, the potential ligand 
conformations are generated concurrently during the process of ligand placement.  Following 
ligand placement within the receptor binding site, the strength of the interactions for each 
conformation is assessed in a process known as scoring.  Several classes of scoring functions 
exist, which vary in complexity29.  Typically faster, less accurate scoring function are used for 
initial screening of compounds with more complex and computationally demanding scoring 
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functions reserved for secondary screening.  Many docking programs are available, both freely 
and through commercial licenses, including MOE, Glide from Schrödinger, DOCK, and 
AutoDock30-34.  Docking studies are frequently applied as intermediate steps in larger drug 
discovery efforts, but may sometimes be used as the primary technique.  For example, in a 
recent study by Chiem et al., the Glide docking program was used to virtually screen for 
inhibitors to AAC(6’)-Ib, an enzyme that confers resistance to aminoglycoside antibiotics35.  The 
authors initially docked 280,000 compounds from the ChemBridge database into a crystal 
structure of the enzyme using the standard precision method in Glide, followed by the extra 
precision method.  The authors chose 78 compounds for testing, which yielded one active 
compound35.   
 
 In a similar way, series of ligands that bind to a desired target may also be examined 
through the use of ligand-based pharmacophore models to identify common features that are 
responsible for a ligand’s activity36.  Such methods follow a general workflow where known 
ligands are selected, potential conformations are enumerated, their structures are aligned, and 
overlapping common features are identified.  In the absence of crystal structures that could 
indicate the exact interactions that a ligand is making with a receptor, such models are a good 
way to infer which interactions are crucial to a ligand’s activity.  The resulting consensus 
features may be used to rationalize ligand activity and for the screening of potential ligands for 
synthesis and experimental testing.  A number of software packages to perform ligand-based 
pharmacophore modeling are available, including commercial packages such as MOE and the 
PHASE utility from Schrödinger30, 37, 38.   For example, the PHASE program incorporates 
hydrogen bond donors and acceptors, hydrophobic, aromatic, and positively and negatively 
charged interactions37, 38.  Such methodologies are termed ligand-based drug design for their 
focus on the properties of ligands in mediating receptor-ligand interactions.  One of the caveats 
of using such ligand-based methods is the requirement for known active ligands.  Known 
ligands will not necessarily represent all of the interactions that a receptor is capable of making, 




 Alternatively, receptor-based pharmacophore models may be used.  Rather than 
examining consensus features solely between known ligands, receptor based methods look for 
potential interactions that the receptor may make, in order to identify all potential interactions 
that could be made with a hypothetical ligand.  The resulting pharmacophore models can then 
be applied in a very similar manner to those generated using ligand-based methods, but the 
process by which they are generated differs.  For example, Waltenberger et al. used an iterative 
procedure with LigandScout and Discovery Studio from Accelrys to generate both ligand-based 
and structure-based pharmacophore models of soluble epoxide hydrolase39, 40.  Starting with 9 
crystal structures and 68 active compounds identified from the literature, they were able to 
develop several pharmacophore hypotheses.  The resulting models were screened against the 
Specs database to identify potentially active compounds.  The compounds were ranked by their 
degree of fit to the pharmacophore model, and inspected for potential steric clashes with the 
receptor and the presence of non-desirable functional groups which led to the selection of 48 
compounds for experimental testing.  Of the tested compounds, 19 were active inhibitors40.  
The identification of active compounds relative to inactive compounds when screening ligands 
is termed the “hit-rate”.  In traditional high-throughput screening approaches, the hit rates are 
universally much lower than that observed in this study, showing the promise and utility of 
these structure-based drug design techniques.  Several programs exist that are able to directly 
create pharmacophore models using either receptor or receptor-ligand complexes, including 
Schrödinger, and the previously mentioned LigandScout and Accelrys 39, 41, 42.  In addition to 
these “all-in-one” programs, a number of complementary methods have been developed to 
identify potential interactions that a receptor may make.  These methods, which will be 
discussed in greater detail in the following section, do not generate pharmacophore models 
directly, but rather focus on identifying all of the potential interactions that a receptor may 
make.   
 
1.4 Mapping Binding Sites on Protein Surfaces 
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It has been shown that binding sites on a protein’s surface can be identified and 
characterized through their interactions with small molecules.  For example, the multiple 
solvent crystal structure (MSCS) technique uses crystallography in combination with various 
solvents, such as acetonitrile, ethanol, and isopropyl alcohol, to look for potential binding 
sites43, 44.  MSCS was first applied to the protein elastase with acetonitrile as the solvent45.  
Later studies by the same group solved structures of elastase with additional solvents43. As 
shown in Figure 1.3, some of the probe molecules bind in single sites, but many of them 
overlap within specific regions on the proteins surface.  Initial studies of this method showed 
that these molecules preferentially cluster within binding sites on the protein’s surface, 
indicating regions of the protein which favorably interact with multiple functional groups45.  
Such “hotspots”, i.e. regions that bind multiple probe molecules, are therefore indicative of 
binding sites and may be used to find easily desolvated regions which can potentially bind small 
molecule inhibitors.  Indeed, ligand bound structures of elastase show inhibitors binding at this 
site.   
Figure 1.3: Multiple solvent crystal structures of elastase are shown.  It can be seen that regions 
on the protein’s surface that have multiple overlapping probe molecules correspond to 
inhibitor binding sites.  Probe molecules are shown in gray, taken from nine different MSCS 
with the inhibitor JM102, (PDB: 4YM9, unpublished) shown for reference43. 
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NMR methods have similarly been developed to map binding sites of small molecule 
probes.  For example, in the SAR (structure-activity relationship) by NMR approach, compounds 
are screened via NMR for binding to a protein of interest46.  The first SAR by NMR study 
screened libraries of compounds for binding to FK506 binding protein (FKBP).  In the initial 
study, 10,000 compounds dissolved in perdeuterated DMSO were screened.  Compounds that 
bind to the 15N labeled protein induce a 15N or 1H-amide chemical shift change in the 2-D 15N–
HSQC spectra relative to the apo protein, and can therefore be identified.  Once an initial ligand 
is found that binds to the protein (a “hit”), derivatives of the initial ligand are screened and 
optimized in an iterative procedure that is repeated until a “lead” compound is found that has 
high affinity.  In the case of FKBP, this process was repeated to identify high-affinity binders for 
a nearby site.  These two high-affinity compounds which bind in adjacent regions on the protein 
surface were then linked, yielding a larger high-affinity (nanomolar) compound.  One of the 
advantages of this method is the ability to simultaneously determine the binding affinity of the 
molecules, so that compounds may be compared to identify the highest affinity binders. 
 
  Computational techniques have also been developed to identify favorable binding 
sites.  The GRID method, introduced in 1985 by Goodford, calculates the potential energy of a 
probe molecule interacting with a protein by considering the interactions at each xyz point on a 
0.5 Å gridded representation of the protein surface47.  Favorable binding sites on the protein 
surface can then be determined by examining the predicted affinity at each grid point location.  
As a test case, the GRID method was applied to several test systems, including E. coli 
dihydrofolate reductase (DHFR).  Regions with favorable interaction energy on the surface of 
DHFR determined with GRID correspond to the known binding site of trimethoprim.  Similar 
computational techniques have been developed which make use of multiple probe molecules.  
In the multiple-copy simultaneous search method (MCSS), many small molecule probes are 
distributed across a protein surface and minimized to identify the most favorable binding 
sites48.  The method was first applied to influenza hemagglutinin.  Acetate, methanol, methane, 
methyl ammonium, and water were selected as representative functional groups and 1,000 to 
5,000 copies of each probe were randomly distributed within the binding site of hemagglutinin.  
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Minimization of the probes yielded ~25-125 minima, depending on the probe type, and showed 
good agreement with the known sialic acid binding site.   
 
More recently, the FTMap computational method was introduced, which uses sixteen 
different probe types to identify binding hotspots on the protein surface49.  FTMap is utilized as 
a webserver where users upload their protein, DNA, or RNA target.  The receptor is then 
flooded with probe molecules, currently ethanol, isopropanol, isobutanol, acetone, 
acetaldehyde, dimethyl ether, cyclohexane, ethane, acetonitrile, urea, methylamine, phenol, 
benzaldehyde, benzene, acetamide and N,N-dimethylformamide.  The probe molecules sample 
different orientations through rotational and translational motion followed by minimization to 
identify the most energetically favorable binding sites.   The locations of the probe molecules 
are clustered to identify discrete binding sites on the receptor’s surface.  The resulting sites are 
then ranked by average energy and number of clusters that they contain to identify the top 
ranked site, as well as smaller secondary sites.  One of the main benefits of FTMap is its speed 
and ease of use, allowing for hot spot predictions within a manner of hours or days.  In one 
recent study of CXCL12, FTMap was used to identify the main hotspots mediating protein-
protein interactions between the chemokine CXCL12 and the CXCR4 peptide50.  FTMap 
identified several sites that corresponded to the binding sites of specific CXCR4 residues.  
Following the initial insight from the FTMap calculations, the authors utilized docking to screen 
the ZINC database for potential inhibitors capable of blocking the CXCL12-CXCR4 interaction.  
Experimental testing confirmed the ability of these ligands to bind to CXCL12 at the three main 
hot spots identified by FTMap, demonstrating the utility of this method.   
 
While these methods are very computationally efficient, they tend to neglect important 
determinants of ligand binding, namely the role of solvent and protein flexibility.  For example, 
it has been shown that FTMap is able to identify active sites, but may be unable to identify 
allosteric sites, likely because of the inability to fully capture the conformational states of the 
protein using static crystal structures as input51.  The use of static structures in computational 
drug design has been shown to result in the identification of false minima, therefore making it 
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difficult to identify the true binding sites on a protein’s surface52, 53.  Several methods have 
been used to incorporate protein flexibility into structure based drug design, including the use 
of ensembles of crystal structures or the use of side chain rotamers54.  For example, within the 
FTMap suite, FTFlex allows for side chain flexibility and FTDyn allows for ensembles of crystal 
structures49.  However, these methods are not always sufficient to capture the full 
conformational flexibility of the proteins. For example, crystal structures may not be available 
of all potential conformations, such as in cases where apo crystal structures (those containing 
no ligands) are unavailable.  There may be conformational rearrangements that occur upon 
ligand binding between the ligand-bound and apo protein structures which are not fully 
represented by available ligand bound structures.  Likewise, the role of competition between 
water and probes is typically neglected in these methods.  Prior to ligand binding, proteins are 
surrounded by solvent molecules.  In order for a ligand to bind, these water molecules must be 
displaced, or may be conserved and bridge interactions between the protein and ligand55-60.  It 
has been shown that structure-based drug design methods that explicitly consider the role of 
water molecules have better prediction rates than methods which neglect water molecules61.  
In order to overcome these limitations, molecular dynamics simulations incorporating multiple 
solvent probe molecules have been developed, which are able to explicitly account for protein 
flexibility and the role of solvation in mediating protein-ligand interactions. 
 
1.5 Cosolvent Molecular Dynamics Simulations 
 
 Cosolvent simulations have been developed as a promising means to capture protein 
flexibility while simultaneously accounting for the role of water.  In these simulations, the 
protein is immersed in a box containing water and small molecule probes, and then subjected 
to molecular dynamics simulations.  The small molecule probe types differ between methods, 
but are typically chosen to represent common functional groups found in drug-like molecules.  
Several methods have been developed, which differ in their experimental setup and analysis.  
The most relevant and well developed methods will be discussed in detail below; a 




The site-identification by ligand competitive saturation (SILCS) method by the MacKerell 
group is particularly notable, as the method has been extended for the development and 
screening of novel ligands.  The first SILCS study was published in 2009, and focused on the 
mapping of the SMRT and BCOR peptide interaction sites on the BCL-6 oncoprotein63.  In the 
initial SILCS methodology, the protein was solvated in a box containing propane and benzene 
molecules, each in a ~1M concentration with water.  Propane and benzene were chosen to 
identify hydrophobic and aromatic interactions, respectively, and water molecules identified 
potential hydrogen bonding interactions.  Ten simulations of 5ns production time each were 
completed, to yield 50ns of total simulation time.  In order to prevent aggregation of the 
solvents, an artificial repulsion term was applied when two fragments came within a set 
distance.  In the SILCS methodology, this is implemented by modifying the Lennard-Jones 
interactions to include an additional term for the center of each benzene and propane, such 
that the probe molecules will repel each other at short distances.  The resulting trajectories 
were analyzed at 2ps intervals to yield the occupancy of the probe molecules over the 
simulation at every point on a 1 Å cubic grid.  The resulting occupancy maps showed good 
agreement with many of the known residues in SMRT and BCOR that are known to be 
important determinants of binding63.  One of the main drawbacks of the initial SILCS 
methodology was the limited number of probe types used.  For example, using water as the 
probe for hydrogen bond donor and acceptor interactions prevents one from distinguishing 
which water interactions may be preferentially displaced by other functional groups capable of 
making similar interactions.   
 
The next subsequent updates to the SILCS methodology focused on the development of 




=  𝑒𝑒−𝛽𝛽(𝐸𝐸𝑖𝑖−𝐸𝐸𝑗𝑗)         (4)       
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where ki and kj are the number of molecules in states i and j, respectively, Ei and Ej are the 
associated energies, β is equal to 1/kBT where kB is Boltzmann’s constant and T is temperature, 
allows for the calculation of energetic differences between states based on the occupancy of 
the states.  In the SILCS methodology64, this is calculated on the basis of individual grid points: 
 
𝐺𝐺𝐺𝐺𝐸𝐸𝑥𝑥𝑥𝑥𝑥𝑥𝑅𝑅 = min �−𝑅𝑅𝑅𝑅 ln
𝑏𝑏𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑎𝑎𝑏𝑏𝑜𝑜𝑥𝑥𝑥𝑥,𝑦𝑦,𝑧𝑧𝑇𝑇
〈𝑏𝑏𝑜𝑜𝑎𝑎𝑘𝑘 𝑏𝑏𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑎𝑎𝑏𝑏𝑜𝑜𝑥𝑥〉
, 0�    (5)   
   
where the GFE, or grid based free energy for a specific grid point (x,y,z) and specific functional 
group/probe type T, is calculated from the occupancy of the probe type at that grid point 
relative to the occupancy in bulk solvent.  In the initial SILCS application of this equation, if the 
occupancy based free energy was greater than zero, meaning the occupancy at some (x,y,z) 
point was less than the expected bulk occupancy, the GFE was assigned to be zero64.  This 
equation was then used to predict the binding affinity of a ligand (Ligand Grid Free Energy, of 
LGFE) by summing over the GFE scores for each atom type in a ligand calculated, as shown in 
Figure 1.4.  To test this methodology, Raman et al. performed simulations of trypsin, α-
thrombin, HIV protease, FKBP12, Factor Xa, NadD, and ribonuclease A in the presence of a 1 M 
propane and benzene solvent mixtures64.  In the present method, 200 ns of production 
simulation were completed for each system.  The ability of the method to correctly rank the 
crystallographically observed binding mode was then tested by comparing the predicted LGFE 
of the crystal binding form of the ligand to decoy positions.  Overall, the method tended to 
predict the crystallographically observed binding mode of the ligands as energetically favorable, 
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Figure 1.4: The ligand grid free energy in the SILCS methodology is calculated by considering the 
positions of each of the atoms in a ligand of a specific type and the associated grid free energy 
values for each position (kcal/mol).  The grid free energy values are then summed, to give the 
overall ligand grid free energy value64. 
    
In order to increase the efficiency of solvent sampling within the SILCS methodology, a 
combined grand canonical-like Monte-Carlo/molecular dynamics (GCMC-MD) approach was 
introduced65.  In the SILCS GCMC-MD procedure, solvent probe molecules and water are 
inserted into the system from a reservoir for some number of GCMC steps, followed by 
molecular dynamics simulations to allow sampling of the solvent molecules with the protein.  
This cycle is repeated several times to allow for efficient sampling of the solvent molecules with 
the protein.  Initial validation studies of the SILCS GCMC-MD method focused on the occluded 
binding pocket of T4 lysozyme, with subsequent studies applying the methodology to 
successfully identify binding sites in androgen receptor, peroxisome proliferator-activated 
receptor gamma, metabotropic glutamate receptor, and beta-2 adrenergic receptor65, 66. 
 
In 2013, Raman et al. published an update to the SILCS methodology which addressed 
the deficiency of limited probe types, and extended the SILCS LGFE metrics to consider multiple 
conformations of a ligand67.  Methanol, formamide, acetaldehyde, methylammonium, and 
acetate were added to the original benzene and propane probes to form the SILCS tier II probe 
set.  To validate the additional probe molecules, their group selected Factor Xa, P38 Map 
Kinase, RNase A and HIV protease as test systems.  In the SILCS tier II method, the seven probes 
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are simulated together, at approximately 0.25 M each.  For each system, 10 simulations of 40ns 
were performed.  Following simulation, the trajectories are aligned and the occupancy of the 
probe molecules is determined as previously described.  In order to consider conformational 
sampling of the ligand, the authors included a Monte Carlo sampling step for the ligands within 
the resulting occupancy maps.  The LGFE is then calculated in the same way as previously 
described for each conformation, with the exception that the maximum GFE value was assigned 
to be 3 rather than 0, and that weighted LGFE values are calculated using a coefficient that 
varied depending on the probe type.  The authors rationalize the coefficients as accounting for 
the additive effect of including multiple atoms in the LGFE calculations, such that benzene LGFE 
values would be divided by 6 to account for the 6 non-hydrogen atoms in a benzene molecule. 
The LGFE values for each conformation k are then combined according to the following 
equation: 
 
𝐿𝐿𝐺𝐺𝐺𝐺𝐸𝐸 =  −𝑘𝑘𝐵𝐵𝑅𝑅 ln 〈𝑒𝑒𝑒𝑒𝑒𝑒 �−
𝐿𝐿𝐺𝐺𝐿𝐿𝐸𝐸(𝑘𝑘)
𝑘𝑘𝐵𝐵𝑅𝑅
�〉   (6)   
 
Depending on the input ligand conformations used, R2 values for the correlation between LGFE 
values and experimental binding affinities ranged from 0.02 to 0.79.  While the method had 
good performance in predicting binding affinities for some targets, others, such as Factor Xa (R2 
range 0.02-0.33), were not predicted well by the present methodology. Most recently, the SILCS 
methodology has been extended to compute relative binding affinities between related 
compounds, using either a single-step free energy perturbation (SSFEP) method or through a 
comparison of LGFE values68, 69.  A comparison of FEP, SSFEP, and the SILCS LGFE was performed 
on ACK1 and MAP kinase, and showed that SSFEP and SILCS LGFE gave comparable results with 
the more time-consuming FEP method, highlighting the potential of cosolvent simulations in 
facilitating fragment based drug discovery efforts by guiding the selection of suitable molecules 
for synthesis and testing.  
   
 Notably, the SILCS method has also been extended to develop pharmacophore models 
that can be used for virtual screening70, 71.  In the SILCS pharmacophore methodology, a grid 
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based occupancy is used as previously described, in which each grid point is given a grid free 
energy (GFE) value as shown in Equation 5.  The probe maps are then visualized using varying 
GFE cutoffs, to yield favorably occupied regions for each probe type.  Based on manual 
selection, regions are chosen for inclusion into the pharmacophore model.  Highly occupied 
sites within the region of the protein chosen for pharmacophore modeling are then converted 
into pharmacophore features.  This is done by clustering the grid points into distinct sites, with 
the center of the cluster becoming the center of the pharmacophore feature, and the radius of 
the pharmacophore feature set to include all grid points within the cluster.  In cases where an 
aromatic feature interacts with a hydrophobic feature by more than half, the features are 
combined to yield an aromatic-hydrophobic feature with the new center being the center of all 
grid points within the two features and the radius set to encompass all points within the two 
features.  The possible combinations of all pharmacophore features into a pharmacophore 
model are then compared, based on the sum of the GFE values for the individual 
pharmacophore features contained in the model.  The pharmacophore model can then be used 
for virtual screening.  The most recent version of the SILCS pharmacophore method applied to 8 
proteins showed equivalent or better performance in virtually screening potential ligands 
relative to DOCK 4.0, AutoDock 4, and AutoDock Vina70.    
 
MDmix 
Barril and coworkers have developed the related MDmix method of cosolvent 
simulations.  In the first development of their method, published in 2009, cosolvent simulations 
of isopropyl alcohol and water were used to identify potentially druggable sites on a protein’s 
surface72.  In their method, pre-equilibrated boxes of water and isopropyl alcohol at a 
concentration of 20% v/v are used to solvate the protein of interest.  Molecular dynamics 
simulations of at least 16ns are carried out for each protein, and then the resulting snapshots 
are overlaid with a grid in a similar manner to the SILCS protocol.  The resulting occupancies can 
then be counted and compared to the expected occupancy, to yield the theoretical binding 
affinity of the probe molecule for a specific site through the Boltzmann relationship.  They 
estimated the maximal affinity of a ligand for an identified site by clustering highly occupied 
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grid points and summing the predicted binding affinities within the region.  The MDmix method 
was initially applied to thermolysin, p53, elastase, MDM2, LSA1, protein tyrosine phosphatase 
1-b (PTP1B), P38 map kinase, and androgen receptor (AR).  The MDmix method correctly 
predicted the majority of known binding sites, with the exception of the phosphorylated-
tyrosine binding site on PTP1B.  While the method had good success in locating known binding 
sites, it suffers from some methodological limitations.  A later study by our group using the 
parameters for isopropyl alcohol from this initial MDmix study showed phase separation 
between isopropyl alcohol and water, which should not be seen if the parameters chosen are 
correct73.  Two additional studies using MDmix have been published, which focus on predicting 
water displacement and the role of conformational flexibility is the convergence of cosolvent 
simulations.  These contributions will be discussed in subsequent sections. 
 
1.6 The Mixed-Solvent Molecular Dynamics Method (MixMD) 
 
 The cosolvent simulation method that has been developed in our group is termed 
mixed-solvent molecular dynamics (MixMD).  Initial studies in the Carlson lab focused on 
methods to incorporated protein flexibility in computational drug design, which motivated the 
development of the multiple protein structure (MPS) method74-76.  In the initial MPS methods, 
ensembles of protein conformations, either from crystal structures or taken from MD 
simulations, were used to incorporated protein flexibility in pharmacophore modeling.  The 
initial studies used minimization of probes to map favorable interaction sites on the protein’s 
surface, allowing for the development of pharmacophore models.  As a natural extension of this 
method, the MixMD method has been developed to use molecular dynamics simulations for 
conformational sampling of the protein while simultaneously mapping favorable interaction 
sites with cosolvent probe molecules.  In 2011, Lexa and Carlson demonstrated the importance 
of including protein flexibility to accurately map binding sites on protein surfaces51.  Using hen 
egg-white lysozyme (HEWL) as a test system, 5 simulations of 10ns with HEWL solvated in a 
50% w/w acetonitrile and water mix were completed.  HEWL is a particularly good test system, 
as a crystal structure of HEWL solvated in acetonitrile and water is available, which allows for 
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experimental validation of the results77.  Three different restraint schemes were tested to 
determine the impact of protein flexibility on mapping results; 1) no restraints, 2) rigid 
restraints on the backbone, and 3) rigid restraints on every atom.  Interestingly, the study 
demonstrated that only the simulations without restraints successully identified the known 
acetonitrile binding site of HEWL without also identifying spurious sites51.  Alvarez-Garcia and 
Barril later studied the effect of using constraints on the observed mapping and binding afinities 
calculated from cosolvent simulations53.  Using HEWL in a 20%/80%  methanol, isopropyl 
alcohol, acetonitrile, or ethanol to water ratio, they tested constraints of 1, 0.1, and 0.01 
kcal/mol-Å2 relative to simulations performed without restraints.  Increasing levels of 
constraints on the heavy atoms resulted in more negative ΔG values relative to the 
unrestrained simulations.  The authors propose that weak restraints on heavy atoms will 
facilitate convergence of the simulations, as the ΔG values calculated from the 0.01 kcal/mol-Å2 
constraints were within error of the values calculated from unconstrained simulations.  
However, HEWL is known to be a very stable protein, so the generalizabilty of this observed 
effect is unknown. 
 
 The next developments to the MixMD method focused on the development of proper 
protocols for simulation setup, probe parameters, and analysis73, 78.  These studies were 
performed with the goal of identifying procedures that would allow consistent application of 
the MixMD methodology to proteins with potentially unknown binding sites.  Lexa and Carlson 
initially focused on the study of systems with published multiple-solvent crystal structures78.  
They selected elastase, HEWL, p53 core, RNase A, and thermolysin, all of which had crystal 
structures containing bound isopropyl alcohol.  5 to 10 50ns simulations of each protein were 
completed in a 50% w/w acetonitrile or isopropyl alcohol and water mix.  Comparing results 
taken from the first, middle, or end of the trajectories indicated that the first part of the 
trajectories tends to identify spurious sites.  Allowing time for sufficient sampling, and thus 
analyzing the end of the 50 ns trajectory correctly identified known probe binding sites.  
Furthermore, the experimentally known probe binding sites were mapped at very high 
occupancy, of at least 5 standard deviations above the mean occupancy with the 50%/50% w/w 
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probe to water ratio.  Importantly, Lexa and Carlson noted that some of the probe binding sites 
seen in crystal structures are due to interactions involved in the crystalline environment, and 
therefore should not necessarily be reproduced by simulations of inidividual proteins.  This 
finding highlighted the need to examine crystal packing contacts and crystallographic density of 
ligand-bound crystal structures when performing the analysis of cosolvent simulation results.     
 
 Lexa, Goh, and Carlson next focused on the development of experimentally consistent 
probe parameters73.  As noted previously, the initial MDmix studies by Seco and Barril exhibited 
unrealistic solvent behavior, specifically the separation of isopropyl alcohol and water into two 
layers72.  Lexa et al. tested the behavior of 11 solvents to identify those solvents that were 
water miscible within the context of an MD simulation with the TIP3P water model73.  Boxes of 
50%/50% w/w mixtures of water and isopropyl alcohol, acetonitrile, acetone, N-
methylacetamide, imidazole, pyridine, pyridazine, pyrimidine, pyrazine, benzene, or phenol 
were examined.  Parameters for the probes were taken from AMBER (for acetone, acetonitrile, 
and N-methylacetamide) or OPLS (all others), as described in the manuscript.   In order to 
quantitatively examine the behavior of the solvent during the simulation, radial distribution 
functions were calculated between the two solvent types.  Radial distribution functions, or 
RDFs, examine the probability of finding two molecules within a specified distance.  At long 
distances, the RDF should converge to a value of 1, indicating that there is no correlation in the 
location of the two types, and thus that the two solvent types are sufficiently mixing over the 
course of the simulation.  Using the RDF metric as indicative of proper solvent mixing, Lexa et 
al. identified isopropyl alcohol, acetonitrile, acetone, N-methylacetamide, imidazole, and 
pyrimidine as acceptable probe choices that showed water miscible behavior.  Notably, 
benzene, which is used as a solvent probe in the SILCS method, was found to be immiscible with 
water.   
  
 Following meticulous development of the MixMD method to ensure its experimental 
validity, studies by our group next turned to the application of MixMD in mapping protein 
surfaces.  Ung et al. applied the MixMD method to HIV-1 protease79.  Structures of both the 
24 
 
semi-open and closed conformations of HIV protease were used.  Simulations were performed 
using acetonitrile-, isopropyl alcohol-, or pyrimidine-water mixtures, at both 50%/50% w/w and 
5%/95% v/v ratios.  Pre-equilibrated solvent boxes were used for the 50% w/w solvent mixture, 
while simulations of the 5%/95% mixture used a layered setup.  In the layered solvent 
procedure, the system is first solvated with a layer of the desired probes, followed by a layer of 
water to yield the desired concentration.  The layered procedure was chosen in order to 
facilitate system setup, while also allowing for competition between probes and water for 
binding to the protein’s surface.  Since the 5%/95% ratio of probes to water results in a much 
lower number of probe molecules relative to the 50%/50% ratio, pre-equilibrated boxes would 
have necessitated longer simulation times for a sufficient number of probe molecules to sample 
the protein surface.  In the layered procedure, the probes are closer to the protein’s surface, 
facilitating sampling, while the large numbers of water molecules are expected to effectively 
compete with the probes for binding to the protein’s surface, thus yielding realistic results 
during the simulation.  It is important to note that the correct sites were still mapped with 
either setup procedure.  Five simulations of 20 ns were completed for each system, and the last 
10 ns were used for further analysis.  The resulting trajectories were aligned and the occupancy 
of probe molecules was determined for each point on the protein’s surface using a 0.5 Å cubic 
grid.  The resulting occupancies were normalized by subtracting the mean of the raw data and 
dividing by the standard deviation, to yield the occupancies in units of 1 standard deviation 
(equivalent to a Z-score).  Both simulation procedures identified known binding sites on the 
surface of HIV protease, including the eye, face, and exo sites in the open form, and clear 
mapping of the active site in the closed form.  The 5%/95% simulations, however, showed a 
much greater range between the occupancy of known binding sites compared with the 
occupancy of spurious minima which facilitated identification of true binding sites.  This 
difference is especially important in the prospective application of cosolvent simulations, as 
binding sites may not be previously known.  The lower probe to water ratio is also more 
consistent with experimental studies, which are typically performed at much lower 




 Most recently, MixMD was applied to identify allosteric binding sites.  Previously, 
cosolvent simulation methodologies have focused on the identification of the main binding 
sites of a protein.  However, targeting these sites with small molecule inhibitors may not always 
be feasible, or desirable, depending on the target.  In order to circumvent these limitations, 
inhibitors may target allosteric sites, which may potentially be more amenable to inhibitor 
development or may provide a greater level of specificity between related targets80.  Using a 
layered cosolvent approach at 5%/95% v/v ratio of probe to water, Ghanakota and Carlson 
applied MixMD to ABL kinase, androgen receptor, CHK1 kinase, glucokinase, PDK1 kinase, 
farnesyl pyrophosphate synthase, and protein tyrosine phosphatase 1B51.  All of the starting 
structures were taken from crystal structures without ligands bound in the allosteric site, to 
provide the most unbiased test of the MixMD procedure as none of the allosteric sites would 
be prearranged for ligand binding.  Ten independent simulations of 20 ns were completed for 
each protein, in the presence of acetonitrile, isopropyl alcohol, or pyrimidine and water.  As 
some of the systems bind charged ligands, two additional probe types were introduced: acetate 
and methylammonium, to identify these interactions.  The last 5 ns of each simulation was 
analyzed to determine the occupancy of each probe on a 0.5 Å cubic grid and normalized as 
previously described into standard deviation units.  Across all systems tested, the allosteric sites 
were consistently identified as being highly occupied by more than one probe type.  After 
analyzing all systems, Ghanakota and Carlson observed that the top four sites by probe 
occupancy ranking consistently identified both the active and allosteric sites.  Lower occupancy 
sites typically identified crystal packing interfaces and locations of buffer molecules.  For 
example, in ABL kinase, the myristate binding pocket is the highest ranked site by probe 
occupancy, followed by mapping of the active site, and later by mapping of the interface of the 
SH2-kinase domain51.  This consistent ranking suggests the ability of MixMD to be applied in a 
prospective manner, to identify other potential allosteric sites as well as active sites.      
 




 Given the ability of cosolvent simulations to correctly predict probe binding sites, it is 
likely that such simulations will also correctly predict the conservation or displacement of water 
molecules upon ligand binding.  This has been a long-standing problem in computational drug 
discovery, as the inclusion of essential water molecules improves predictions61, 81, but it is not 
always clear when water molecules should be included and when they may be neglected as 
likely being displaced upon ligand binding.  Initial methods that attempted to predict water 
displacement were based on statistical analysis of protein-ligand complexes, using various 
descriptors.  In more recent years, methods based on molecular dynamics or Monte Carlo 
simulations and using more in-depth energetic analysis have emerged. 
 
For example, the Consolv method was one of the first such methods to be introduced 
that attempted to predict water conservation or displacement upon ligand binding using a 
knowledge-based approach82.  Using 13 unrelated proteins that had both apo and ligand bound 
structures, Raymer et al. selected 157 active-site waters found in the apo structures to act as 
the test set for Consolv, and 1700 first solvation shell waters (i.e. those directly interacting with 
the protein, but not necessarily in the active site) for the training set.  The waters were then 
classified as conserved or displaced, depending on their presence in the corresponding ligand-
bound structures.  The environment surrounding each water molecule was determined, as 
characterized by the number of nearby protein atoms, the character of surrounding amino 
acids, the number of hydrogen bonds made between the water molecule and protein, and the 
crystallographic B-factor.  These descriptors were then compared to test water molecules, to 
identify water molecules having similar characteristics to the water of interest, and to classify 
the water molecule as conserved or displaced based on this similarity.  When applied to the test 
set, this yielded 77% accuracy in predicting whether a water molecule was displaced or 
conserved upon ligand binding.  Using similar descriptors, García-Sosa and coworkers 
introduced the WaterScore method, which examined B-factors, solvent-contact surface area, 
the hydrogen bond energy, and the number of protein-water contacts to differentiate between 
bound and displaceable water molecules83.  Using a regression model trained on 14 systems, 
the WaterScore method predicted the conservation or displacement of water molecules in 4 
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different test systems with 67.4% accuracy.  While these methods are very fast, they may not 
be able to accurately predict water molecules in all cases, and do not give detailed insight into 
the interactions that a specific water molecule is involved in. 
 
Alternatively, a number of methods for examining the role and potential displacement 
of an individual water molecule based on its hypothetical energy have been developed.  In 
order for a ligand to favorably displace a water molecule, the interactions that the displaced 
water molecule was making must be compensated for.  This has led to the development of 
methods that focus primarily on determining the detailed thermodynamic values for an 
individual water molecule.  For example, Barillari et al. compared the binding affinities of 
conserved and displaced water molecules using replica exchange thermodynamic integration, 
and found that displaced waters were bound less tightly than waters which are conserved upon 
ligand binding84.   They proposed that the likelihood of a water molecule being displaced or 
conserved could be calculated by comparing its binding affinity to that of known displaced or 
conserved waters.  Amadasi et al. introduced the HINT/RANK method for predicting water 
displacement85.  Using the HINT forcefield and their proposed RANK method, the authors 
predicted the conservation or displacement of a water molecule based on the number and 
strength of hydrogen bonding interactions made.  When applied to 50 water molecules from 4 
proteins, 76% were correctly predicted as displaced or conserved by the HINT/RANK method.  
The AcquaAlta method was developed to predict the positions of water molecules bridging 
interactions between proteins and ligands in docking86.  In this method, waters are placed to 
optimize hydrogen bonding between the protein and ligand via a bridging water molecule 
based on distance, interaction energy, and orientational constraints.  The AcquaAlta procedure 
correctly predicted the locations of 76% of waters in the training set, but when applied to 
docked ligands predicted only 53% of water positions.   
 
Monte Carlo simulations may also be used to analyze the energetics of water molecules.  
In the Just Add Water Molecules (JAWS) method, Monte Carlo simulations are used to calculate 
the binding affinity of water molecules87, 88.  In this method, water molecules are transferred 
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from bulk solvent to a binding site on the protein’s surface.  These waters are termed θ waters, 
where θ = 0 corresponds to a water molecule in the bulk solvent, and θ = 1 is a water molecule 
at a particular location in the binding site.  The probability that a water molecule occupies the 
binding site rather than the bulk solvent is controlled by the energy difference between the two 
states.  This relationship therefore allows for the binding affinity of a water site to be 
calculated: 
∆𝐺𝐺 =  −𝑘𝑘𝐵𝐵𝑅𝑅𝑇𝑇𝑛𝑛(
𝑃𝑃(𝜃𝜃𝑖𝑖=1)
𝑃𝑃(𝜃𝜃𝑖𝑖=0)
)    (7)   
 
based on the difference in sampling for a given site between bound (θ = 1 ) and bulk (θ = 0 )  
water.  This method was successfully applied to a series of ligands for scytalone dehydratase, 
p38-αMAP kinase, and EGFR kinase to explain differences in ligand binding affinity on the basis 
of energetics of individual water molecules88. 
 
Commercial software to predict water binding sites based on an individual water 
molecule’s interaction energy are also available.  OpenEye offers the SZMAP method to study 
the role of individual water molecules89  In the SZMAP method, an explicit water molecule is 
placed into a protein-ligand binding cavity, while the rest of the cavity is modeled using the 
Poisson-Boltzmann implicit solvent model.  The water is allowed to sample conformational 
space over a cubic grid, or may be altered to sample a desired position for comparison to a 
known potential water site.  The energy at each sampled point is then calculated, based on the 
sum of the van der Waals and electrostatic interactions between the protein, ligand, and water 
molecules, and a desolvation term for the protein and water.  Comparing the energy at a 
selected point with all other points via a partition function yields the probability of a water 
molecule being found at an individual point, as given in Equation 8. 
 














The developers of SZMAP also propose a means to calculate the enthalpic and entropic 
contributions for an individual water molecule’s binding affinity, by considering the number of 
favorable points for a water to occupy, and the strength of the interactions, as given by the 
numerator of Equation 889.  When applied to HIV protease, neuraminidase, trypsin, factor Xa, 
scytalone dehydratase, and oppA as test systems, SZMAP ΔΔG values calculated for the 
theoretical conversion of a neutral probe to a water molecule showed good correlation with 
the replica exchange thermodynamic integration calculated ΔG values.  Furthermore, they 
found the SZMAP calculated entropy of a water molecule to be the best predictor of 
conservation, with 93% accuracy in the test set. 
 
 The SPAM method, developed by GlaxoSmithKline, similarly considers the interaction 
energy of a water site to calculate a theoretical binding affinity90.  In the SPAM method, a 
molecular dynamics simulation is performed to allow for sampling of potential water positions 
around the protein.  Following this, the binding affinity is calculating by summing over the 
interaction energies of the water molecules during the simulations: 
 
𝑄𝑄𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆= ∑ [𝑃𝑃(𝐸𝐸𝑤𝑤𝑤𝑤𝑜𝑜𝑜𝑜𝑜𝑜) exp�−𝐸𝐸𝑤𝑤𝑤𝑤𝑜𝑜𝑜𝑜𝑜𝑜𝑅𝑅𝑇𝑇 �]𝐸𝐸𝑤𝑤𝑤𝑤𝑜𝑜𝑜𝑜𝑜𝑜
       
𝐺𝐺𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆 = −𝑅𝑅𝑅𝑅 ln𝑄𝑄𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆    (9)   
𝛥𝛥𝐺𝐺𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆 =  𝐺𝐺𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆,𝑏𝑏𝑏𝑏𝑜𝑜𝑏𝑏𝑏𝑏 −  𝐺𝐺𝑆𝑆𝑃𝑃𝑆𝑆𝑆𝑆,𝑏𝑏𝑜𝑜𝑎𝑎𝑘𝑘 
 
and comparing the resulting to those of bulk water.  The SPAM method was applied to study 
the water in HIV protease that bridges interactions between the “flaps” of the protein and the 
active-site ligand.  It was found that this water had a favorable interaction energy relative to 
bulk water, but was entropically unfavorable due to its constrained location, and therefore had 
a net unfavorable ΔGSPAM.  This finding is consistent with the ability of ligands to displace this 




The WaterMap method has been developed by Schrödinger, as an extension of the 
inhomogenous fluid solvation theory (IFST/IST) methods of Lazaridis91-95.  IFST based methods 
focus on the orientational correlation between a solvent molecule and the protein.  In the 
WaterMap method, conformational sampling of the water molecules is achieved via molecular 
dynamics simulations.  The entropy of a water molecule interacting with the protein is then 
determined by considering the correlations of the water molecule.  In combination with the 
interaction energy, the IFST-based entropy values yield a detailed thermodynamic view of an 
individual water molecule.  This can then be applied to understand potential affinity differences 
when comparing ligands.  For instance, WaterMap was applied to ligands of factor Xa that are 
known to displace water molecules.  WaterMap calculated ΔΔGbind values  correlated very well 
with experimentally known  ΔΔG  values, with an R2 of 0.8194.   
 
 IFST based methods have also been further developed academically.  Nguyen, Young, 
and Gilson have introduced a grid based implementation of the IFST method, termed GIST96.  In 
order to simplify evaluation of the original IFST equations, the GIST method discretizes the IFST 
integrals into sums over 3-D grid points.  The GIST method again uses MD simulations to 
generate appropriate sampling of water molecules across the protein surface.  Following the 
MD simulations, the GIST methodology can be applied to yield a detailed view of the energy 
and entropy of areas with high water density.  Of particular note is that the GIST methods have 
been implemented into the freely available AmberTools software, facilitating application of the 
methodology97. 
 
 While these methods are able to give a detailed thermodynamic view of water 
molecules, and may therefore hint at the ability for a water molecule to be displaced, none of 
these methods are capable of predicting the displacing group without additional calculations.  
For example, Haider and Huggins used IFST in combination with multiple-copy simultaneous 
search to identify favorably displaced waters of HSP90 and to predict which functional groups 
were likely to displace them98.  Cosolvent simulations are a promising means of predicting 
conserved or displaced waters, as they inherently account for the effects of solvation when 
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considering binding of probe molecules.  Alvarez-Garcia and Barril utilized the MDmix method 
to predict water displacement of HSP90 and HIV protease99.  Using a 20% concentration of 
either ethanol or acetamide in water, they performed 3 20ns MD simulations for each target.  
The predicted binding affinities of either probe or water molecules are then compared using 
the inverse of the Boltzmann equation, given in Equation 4.  In order to assess the predictive 
power of the MDmix method, the resulting probe occupancies were compared to the 
experimentally known preferred interaction types, taken from structures of ligand-bound 
HSP90 and HIV protease.  For the targets tested, Alvarez-Garcia and Barril found reasonable 
overlap between the MDmix probe occupancies and the functional groups of known ligands.  
For HSP90, 13 of 20 ligand interactions were replicated by MDmix, compared to 18 of 29 for HIV 
protease.  This inability to reproduce all known interaction types found in HIV protease and 
HSP90 inhibitors may be partially due to the limited set of probes used.  The authors then 
evaluated the ability of MDmix to predict water displacement by comparing the calculated 
binding affinities with the proportion of crystal structures containing a water molecule at a 
specific site.  While the authors observed a fairly good correlation between their predicted 
displacement score and the experimentally observed displacement (R2=0.72 for HSP90), this 
manner of comparison is fundamentally flawed.  Using the frequency of observing a water 
molecule in a crystal structure as a substitute measure of its ease of displacement is incorrect.  
Crystal structures are not solved with the intention of systematically testing if every water 
molecule is potentially displaceable.  Moreover, crystal structures are frequently solved 
containing a related series of ligands, which will bias the observed frequency of displacement 
for a given water molecule.  For example, if only one ligand places an R group at a particular site 
and displaces a water molecule, while all other ligands are focused around a central core, the 
metric used by the MDmix group would indicate that the water molecule at the edge site is 
difficult to displace while those at the center of the group of ligands are easily displaced.  It is 
possible though, that the binding affinity of the waters is exactly equal, or that those in the 
center of the ligands are actually more tightly bound and have a higher binding affinity.  The 
observed linear correlation between experimental displacement and predicted displacement is 
therefore just coincidence, and is highly variable depending on the available crystal structures. 
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1.8 Overview and Aims of Thesis 
 
 While several groups have been instrumental in the development of cosolvent MD 
techniques, there are still a number of limitations preventing their widespread application.  The 
primary aim of this thesis is to address these limitations, so that cosolvent MD simulations may 
be prospectively applied to identify binding sites and assist in structure-based drug design.  For 
example, existing analysis methods require a great deal of manual inspection to interpret the 
results of the simulations.  To address this, we have introduced MixMD Probeview, which 
automates the identification and ranking of potential binding sites from cosolvent simulations.  
Described in Chapter 6, MixMD Probeview is available as a plugin for the free, open-source 
version of PyMOL100.  MixMD Probeview shifts the analysis of MixMD occupancy maps from 
primarily qualitative ranking to a more quantitative analysis of overall occupancy.  This enables 
binding sites to be clearly distinguished from other easily desolvated sites.   
 
Furthermore, there are no freely available protocols for converting cosolvent simulation 
results into pharmacophore models for prospective use in screening ligands.  Using ABL kinase 
as a test system, we have developed a series of scripts, described in Chapter 5, which convert 
occupancy maps into pharmacophore features in the format required for virtual screening with 
the program MOE30.  This enables cosolvent simulation results to be utilized in a prospective 
manner.  Additionally, we have characterized occupancy levels during cosolvent simulations for 
non-displaceable water sites.  The incorrect treatment of binding-site water molecules is a 
major source of error in predicting protein-ligand interactions.  Using the analysis described in 
Chapter 4 allows for conserved water molecules to be identified and accounted for in 
subsequent structure-based drug design efforts.   
 
Lastly, we have examined the potential of accelerated molecule dynamics to enhance 
sampling in combination with MixMD.  Due to the time consuming nature of molecular 
dynamics simulations, the extent of conformational changes which may be studied are limited.  
As detailed in Appendix B, accelerated MixMD allows for faster convergence and promotes 
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greater conformational sampling, thereby extending the number of systems that MixMD can be 
applied to.  Altogether, these developments to MixMD enhance its predictive ability and 
facilitate application to a variety of structure-based drug design endeavors. 
As a secondary focus, we have carried out two additional studies.  These are described 
in Chapters 2 and 3, while the remainder of this thesis focuses on the development of MixMD.  
Chapter 2 details an epidemiological study that I contributed to in fulfillment of the clinical 
research component of the Translational Research Education Certificate through the Michigan 
Institute for Clinical & Health Research.  This study was aimed at understanding the 
transmission and sequence variation of CTX-M-type β-lactamases. Chapter 3 describes the use 
of traditional MD simulations to understand the dynamics of NSD1.  Existing crystal structures 
of NSD1 have the important post-SET loop in an autoinhibitory position.  MD simulations allow 
for the predicted motions of this loop to be analyzed, yielding insight into its conformational 
behavior in solution.   
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Chapter 2. Detection and Sequencing of CTX-M β-lactamases in Clinical E. coli 
Isolates 
 
This chapter has been adapted from the following publication: 
 
Graham, S.E., Zhang, L. Ali, I., Cho, Y.K., Ismail, M.D., Carlson, H.A., Foxman, B. Prevalence of 
CTX-M extended-spectrum beta-lactamases and sequence type 131 in Korean blood, urine, and 




A high proportion of extended-spectrum beta-lactamase (ESBL) producing Escherichia 
coli are of the ST131 lineage, but there are few estimates of ST131 prevalence among ESBL-
negative E. coli.  Without this information, it is difficult to evaluate the contribution of the 
ST131 lineage to the emergence and spread of ESBL E. coli. A total of 1,658 E. coli isolates were 
collected at Gachon University Gil Medical Center in Korea from 2006 to 2008.  The antibiotic 
resistance profile was determined for all isolates, and ESBL-positive isolates were screened for 
the presence of CTX-M-type ESBLs.  All ESBL-positive (n=84) and a representative sample of 
ESBL-negative (n=100) isolates were screened for O25b-ST131 using a PCR-based assay.  The 
isolates were further classified on the basis of fumC and fimH types, which allowed for a 
comparison of the two typing methods.  5.7% of isolates were ESBL-positive, 87% of which 
contained CTX-M-type ESBLs.  There was no significant difference in the prevalence of ST131 
between ESBL-positive and –negative groups; 14% of ESBL-positive isolates and 9% of tested 
ESBL-negative isolates were ST131 by CH-typing.  ST131-positive isolates harbored CTX-M-1-
group ESBLs (including CTX-M-15) more frequently than other CTX-M types, and exhibited 
greater levels of antibiotic resistance than non-ST131 isolates.  Furthermore, a number of 
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isolates identified as O25b-ST131 by PCR corresponded to non-ST131 sequence types by CH-
typing, emphasizing the need to consider the testing method when comparing reported 




Escherichia coli is the most common cause of urinary tract infections (UTI) and a 
frequent cause of bloodstream infections. UTI treatment is increasingly complicated due to the 
spread of antibiotic resistant organisms.  Of particular concern are the extended-spectrum 
beta-lactamases (ESBL), which are resistant to penicillins and oxyimino-cephalosporins 101.  The 
CTX-M group of ESBLs is currently the dominant type of ESBL observed in E. coli 102.   CTX-M-
containing isolates are often multidrug-resistant, especially to the UTI treatments of choice: 
fluoroquinolones and trimethoprim-sulfamethoxazole 103-106. 
 
The increasing prevalence of CTX-M type ESBLs among E. coli isolates, specifically type 
CTX-M-15, is attributed to the spread of sequence type 131 (ST131) 107-109.  Due to the initial 
association with ESBLs, the majority of ST131 studies have described isolates that have ESBL 
resistance, or compare matched sets of resistant and susceptible isolates 110.  In order to 
understand the role that ST131 has played in the spread of ESBLs, it is necessary to better 
estimate the prevalence of ST131 among ESBL-negative isolates. 
 
As sequence type assignment using multi-locus sequence typing (MLST) is time-
consuming and expensive, several techniques have been developed which aim to identify ST131 
isolates using PCR and/or sequencing of selected genes110.  For example, Clermont et al. 
developed a PCR-based assay for an O25b-ST131-specific polymorphism in the pabB gene 111.  
Weissman and coworkers proposed the use of CH-typing, determined by sequencing of internal 
fragments of fimH and fumC, to identify sequence types and partition them into subgroups 112.  
While a comparison of the three MLST schemes and the corresponding CH-types is available, 
most studies make use of a single typing method for reasons of practicality 113.  In order to 
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understand the effect of different typing methods on the observed prevalence of ST131 among 
clinical isolates, we used both a PCR-based assay for O25b-ST131 and CH-typing.     
 
 Herein, we present the prevalence of ST131 among all ESBL-positive, and a random 
sample of ESBL-negative blood, urine, and rectal E. coli isolates obtained from the Gil Medical 
Center in Korea between 2006 and 2008. Further, we compare the antibiotic resistance profiles 




 Bacterial Strains 
The entire 2006-2008 collection from Gachon University Gil Medical Center in Korea 
consisted of 94 ESBL-positive isolates (76 urinary, 17 blood, and 1 rectal) and 1564 ESBL-
negative isolates (707 urinary, 373 blood, and 484 rectal) as described previously  114.   For the 
current study, we included all viable ESBL-positive isolates (66 urinary, 17 blood, and 1 rectal) 
and a random sample of ESBL-negative isolates (using the RAND function in Excel) to represent 
the source distribution in the original collection; 24 blood isolates, 45 urinary isolates, and 31 
rectal isolates.  
 
The collection includes four categories of E. coli isolates: 1) All E. coli positive blood 
cultures from inpatients with bacteremia during January 2006 to December 2008.  2) All E. coli 
positive urinary cultures from patients with urinary tract infections (UTIs), defined as the 
presence of greater than 105 CFUs/mL bacterial growth collected from a midstream specimen 
between December 2006 and December 2008. 3) E. coli urinary cultures from asymptomatic 
UTI patients, using the same definition and dates as in (2).  4) E. coli rectal isolates from healthy 
individuals who attended the Health Promotion Center of Gil Medical Center between 
September and December 2007.   Isolates were frozen at -80°C in Glycerol/Luria Broth (1:1) 




 Susceptibility Testing  
Rectal isolates were initially screened for E. coli with UriSelect media (Bio-Rad). Species 
were identified using the VITEK system (bioMérieux), and all 1,658 isolates were screened for 
susceptibility to amikacin, ampicillin, cefotaxime, ciprofloxacin, gentamicin, imipenem, and 
trimethoprim-sulfamethoxazole using the disk diffusion method.  ESBL producing isolates were 
identified using the microdilution method.  Results were classified according to the CLSI criteria 
(2010).   
 
PCR Detection of CTX-M ESBL 
 Primers designed to amplify all known CTX-M variants were used 115.  PCR was carried 
out in 25 µL volumes using 12.5 µL GoTaq DNA polymerase (Promega), 9.5 µL  water, 2.5 µL 
template DNA (extracted by boiling lysis), and CTX-M forward and reverse primers to a final 
concentration of 200 nM using the published conditions115. The PCR products were run on 
agarose gel, the resulting bands were purified (QIAquick gel extraction kit, QIAGEN), and 
sequenced (University of Michigan DNA Sequencing Core) using forward primers to determine 
the CTX-M group present.  CTX-M types were determined using NCBI BLAST to compare known 
types with the sequencing results116.  Statistical analysis was done using SPSS (IBM, version 22) 
and OpenEpi.  Significance was determined using the Chi-square test. 
PCR Detection of O25b-ST131 
  Isolates were screened for the presence of O25b-ST131 E. coli using primers identified 
by Clermont et al.111.  PCR was carried out in 25 µL volumes, with 12.5 µL GoTaq DNA 
polymerase (Promega), 5 µL water, 2.5 µL template DNA (extracted using QIAcube, QIAGEN), 
and 2.5 µL each of 10 µM pabB and trpA.  The PCR reaction was performed under the following 
conditions: initial denaturation at 94°C for 4 minutes, 30 cycles of 5 seconds at 94°C, 10 seconds 
at 65°C, 1 minute at 72°C, followed by a final extension at 72°C for 5 minutes.  Results were 
visualized on agarose gels.  Known O25b-ST131 and K-12 E. coli were used as positive and 
negative controls, respectively. A subset of the samples were previously typed by MLST and 





CH-typing was performed using the published conditions112.  PCR reactions were carried 
out with 12.5 µL GoTaq DNA polymerase (Promega), 2.5 µL forward and reverse primers, 2.5 µL 
template DNA (extracted using QIAcube, QIAGEN), and 2.5 µL water.  The PCR products were 
run on agarose gels to confirm a band of the expected size.  Subsequently, the products were 
purified (QIAquick PCR purification kit, QIAGEN) and sequenced with forward and reverse 
primers (University of Michigan DNA Sequencing Core).  The resulting sequences were trimmed 
and aligned using CodonCode.  fumC and fimH types were assigned using the available web-
services (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli and 
https://cge.cbs.dtu.dk/services/FimTyper-1.0/) and NCBI BLAST, and compared to published 
CH-types 112, 117.  Significance was determined using the Chi-square test or Fisher’s exact test as 
appropriate. 
 
2.4 Results and Discussion 
 
Prevalence of ESBL and ST131 among Tested Isolates 
Overall, 5.7 % of the collection’s isolates had the ESBL phenotype.  The ESBL phenotype 
was significantly more common among urinary isolates than blood isolates (9.7% versus 4.4%, 
p=0.0014) and least common among rectal isolates (0.2%).  These results are consistent with a 
previous report from Korea 118.  Based on CH-types, there was no significant difference in the 
prevalence of ST131 by ESBL-phenotype or isolate source. The prevalence of ST131 was 14.3% 
(12/84) among ESBL-positive isolates, and 9% (9/100) among ESBL-negative isolates (p=0.26).  
These values are near the range reported in previous Korean studies of ESBL-positive E. coli 
(19.7% to 36.2%, by MLST) 108, 119-121. 
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Within the ESBL-positive isolates, 15.2% (10/66) of urine isolates and 11.8% (2/17) of 
blood isolates were ST131 by CH-typing (p=1.0).  Within the ESBL-negative isolates, 15.6% 
(7/45) of urine isolates and 4.2% (1/24) blood isolates were ST131 (p=0.31). Only 1 rectal isolate 
in the tested subset was ST131 Figure 2.1.  With regard to CH-types, 9/12 ESBL-positive isolates 
had CH-type 40-30, 1 was type 40-41, 1 was type 40-29, and 1 was fumC type 40 and fimH null. 
To the best of our knowledge, CH-type 40-29 has not been previously described as ST131, 
however fimH type 27 has been found in ST131 isolates 122.  fimH type 29 differs from fimH type 
27 by only 1 base pair within the CH-typing region; therefore the isolate was assumed to be 
ST131.  Within the ESBL-negative isolates, 5/9 were CH-type 40-30 and 4 were type 40-41.  
Figure 2.1: Prevalence of ST131 by source and ESBL phenotype within Escherichia coli isolates 
positive for ESBL (n=84) and representative sample of non-ESBL (n=100) from the 2006-2008 
collection of Gachon University Gil Medical Center in Korea120 
 
Association between ST131 and CTX-M 
Almost all of the ESBL-positive isolates carried CTX-M (87%); there was no significant 
difference in prevalence by source – although the one ESBL positive rectal isolate did not carry 
CTX-M.  ST131 positive isolates contained CTX-M-1 group enzymes (including CTX-M-15) more 
frequently than other ESBL isolates (6/9 or 67% versus 32/64 or 50%).  This was not true for 
CTX-M-9 group enzymes which were less frequent among ST131 isolates (3/9 or 33% vs 33/64 




 CTX-M Positive 
Source (n) Percentage n 
ESBL positive (84) 86.9% 73 
Blood (17) 94.1% 16 
Rectal (1) 0.0% 0 
Urinary (66) 86.4% 57 
   Source (n) CTX-M-1 group CTX-M-9 group 
CTX-M positive 52.1% 49.3% 
Blood+ (16) 15 2 
Urinary (57) 23 34 
ST131 
  Positive (9) 66.7% 33.3% 
Negative+ (64)  50.0% 51.6% 
      
+1 isolate had both CTX-M-1 and CTX-M-9 group ESBLs 
 
Table 2.1: Presence of CTX-M by source and sequence type among extended-spectrum beta-
lactamase (ESBL) positive Escherichia coli isolates from the 2006-2008 collection of Gachon 
University Gil Medical Center in Korea120. 
 
 
Association between ST131 and Antibiotic Resistance 
 In general, ST131 blood and urine isolates had higher levels of resistance to most 
antibiotics than non-ST131 isolates, as shown in Figure 2..  ST131 isolates were less frequently 
resistant than non-ST131 isolates to trimethoprim-sulfamethoxazole (7/20 vs. 65/132, p=0.24). 
Previous studies have shown conflicting results in regards to ST131’s resistance to 
trimethoprim-sulfamethoxazole123, 124. Similar to previous studies, ST131 isolates in the present 
study were more resistant to amikacin than non-ST131 isolates123.  Whole genome sequencing 
of 104 E. coli ST131 identified from a collection of 1,908 consecutive single-patient E. coli from 
the United States and Germany suggests that fluoroquinolone resistance is primarily confined 
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to the H30-R subclone of ST131 125.  This was also true in a 2012-2013 Korean study of 268 
consecutive E. coli urinary and blood isolates from 21 Korean hospitals where 21% were ST131: 
all of the ST131 of the H30 subclone were resistant to ciprofloxacin (48/48) compared to 50% of 
the non-H30 (4/8) 126.  In the current study, 13/14 CH-type 40-30 isolates were resistant to 
ciprofloxacin compared to 1/5 CH-type 40-41.  
 
Figure 2.2: Antibiotic resistance by the ST131 phenotype among blood and urine Escherichia 
coli isolates positive for ESBL (n=83) and representative sample of non-ESBL (n=69) from the 
2006-2008 collection of Gachon University Gil Medical Center in Korea120. 
 
 Comparison between ST131 Assignment Methods 
   Isolates in this study were initially screened for the presence of O25b-ST131 using the 
method of Clermont et al.  Although the prevalence of ST131 among ESBL-positive isolates 
(18/84, 21%) was seemingly in line with previous studies, the majority of ESBL-negative isolates 
(83/100, 83%) were classified as O25b-ST131.  Testing was repeated multiple times by different 
individuals using fresh reagents and MLST-typed controls.  Comparison with CH-types using the 
method of Weissman et al. revealed that only 9/100 of the ESBL-negative isolates were ST131.  
Within the ESBL-positive isolates, 38.9% (7/18) of isolates identified by PCR-based typing as 
O25b-ST131 were assigned CH-types corresponding to sequence types other than ST131.   For 
example, 4 ESBL-positive isolates were positive by PCR for O25b-ST131 but corresponded to 
ST95 by CH-typing.  This was also seen in a previous study using the PCR-based assay, in which 
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ST95 isolates were misclassified as ST131 127.  A comparison of the results of the two-typing 
methods for all isolates combined is shown in Table 2.2.  
 
  fumC/fimH Type 















O25b-ST131 13 2 1 1 7 33 44 
Non-O25b-ST131 1 3 0 0 0 45 34 
*ST131 complex was defined as isolates with fumC types included in the ST131 complex by Achtman 
MLST, not including ST131 itself  
Table 2.2: ST131 assignment using pabB compared with assignment using fumC/fimH. 
Extended-spectrum beta lactamase (ESBL) positive Escherichia coli (n=84) and a sample of 100 
ESBL negative E. coli from the 2006-2008 collection of Gachon University Gil Medical Center in 
Korea120. 
 
The potential for false-positives using ST131 classification methods based on individual 
genes has been previously recognized113.  In the present study, we found the results of CH-
typing to align more closely with previously reported values and antibiotic resistance 
phenotypes of ST131 isolates than the PCR-based method of Clermont et al.  CH-typing is also 
advantageous as it is able to identify alternative sequence types by linking CH-types with 
sequence types.   For these reasons, we suggest the use of the CH-typing method rather than 




Previous studies of ST131 E. coli have primarily focused on resistant isolates, making it 
difficult to determine the role of the ST131 lineage itself in the dissemination of ESBLs.  In the 
present study, we observed a similar prevalence of ST131 in both ESBL-positive and –negative 
isolates, particularly among urinary isolates.  Further partitioning by CH-typing allowed for a 
comparison of resistance within the ST131 group, and found CH-type 40-30 isolates to be more 
frequently resistant to ciprofloxacin and slightly more frequent among ESBL-positive isolates 




We characterized isolates collected during a period in which ST131 is thought to have 
been rapidly expanding.  These data are especially pertinent, as they offer insight into the 
spread and evolution of ST131 over time; information essential for predicting future expansion 
of ST131 and understanding ST131’s potential role in the spread of additional antibiotic 
resistance genes.  However, there are a few limitations.  Isolates were collected at only one 
study site, which limits the generalizability of our data.  Data on antibiotic usage among 
participants is not available, and so differences in antibiotic exposure and selection for resistant 
E. coli cannot be accounted for.  Nevertheless, our results indicate that the difference in 
prevalence of ST131 E. coli between ESBL-positive and ESBL-negative isolates during this time 
period was not significant, and that variation in the resistance phenotype within the ST131 







Chapter 3. Dynamic Behavior of the Post-SET Loop Region of NSD1 
 
This chapter has been adapted from the following publication: 
Graham, S.E., Tweedy, S.E., Carlson, H.A. Dynamic behavior of the post-SET loop region of 
NSD1: Implications for histone binding and drug development.  Protein Science. 2016, 
25(5):1021-1029.
 
 3.1 Abstract 
 
NSD1 is a SET-domain histone methyltransferase that methylates lysine 36 of histone 3.  
In the crystal structure of NSD1, the post-SET loop is in an autoinhibitory position that blocks 
binding of the histone peptide as well as the entrance to the lysine-binding channel.  The 
conformational dynamics preceding histone binding and the mechanism by which the post-SET 
loop moves to accommodate the target lysine is currently unknown, although potential models 
have been proposed.  Using molecular dynamics simulations, we have identified potential 
conformations of the post-SET loop differing from those of previous studies, as well as 
proposed a model of peptide-bound NSD1.  Our simulations illustrate the dynamic behavior of 
the post-SET loop and the presence of a few distinct conformations.  In every case, the post-SET 
loop remains in an autoinhibitory position blocking the peptide-binding cleft, suggesting that 
another interaction is required to optimally position NSD1 in an active conformation.  This 









Histone methylation is an important genetic regulatory element, among other post-
translational modifications.  Methylation occurs at a number of different sites, including 
arginine, lysine, and histidine residues, and is catalyzed by the methyltransferase group of 
enzymes128. The histone lysine methyltransferase enzymes are responsible for catalyzing the 
transfer of a methyl group from s-adenosylmethionine (AdoMet) to the target lysine.  
Depending on the target residue and specific enzyme, the lysine may be mono-, di-, or tri-
methylated.  These enzymes feature a conserved SET domain composed of approximately 130 
residues, and they often have similar pre- and post-SET motifs129. 
 
The NSD family of histone methyltransferases are responsible for mono- and 
dimethylation of lysine 36 on histone 3 (H3K36), and other targets have also been reported130.  
The NSD family of proteins have been implicated in several types of cancer, including acute 
myeloid leukemia, breast cancer, glioma, neuroblastoma, and multiple myeloma131-134.  In the 
case of acute myeloid leukemia, methylation of H3K36 by NSD1 was shown to be essential to 
gene activation and leukemogenesis through the presence of NUP98-NSD1 fusion 
proteinswhich alter transcriptional regulation131.  Histone methyltransferases are therefore a 
promising drug target for the treatment of these diseases, although development efforts are 
hampered by the difficulty in achieving specificity among a protein family characterized by their 
conserved catalytic domain.  
 
One way to achieve ligand selectivity is to capitalize on differences in flexibility between 
potential binding targets135.  The post-SET loop of SET-domain histone methyltransferases 
exhibits great conformational diversity.  For example, NSD1, ASH1L, and SETD2 have all been 
crystallized with the post-SET loop in an autoinhibitory position (the protein’s conformation is 
such that the entrance to the active site is physically blocked), the structures of DIM-5, NSD3 
(PDB: 4YZ8, unpublished data), and MLL show a disordered loop, while the structure of G9a has 
the loop in an alpha-helical conformation 136-141.  Recent structural studies of the catalytic 
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domain of NSD1 and the homologous protein ASH1L indicate two potential autoinhibitory 
mechanisms observed in the post-SET loop, as shown in Figure 3.1137, 138.  A similar 
autoinhibitory loop position is also observed in the structure of SETD2139.  In either case, a 
conformational change must occur in this loop region in order for the lysine to enter the 
substrate-binding channel.  Previous studies have primarily focused on the structure of NSD1 
after manual insertion of a peptide rather than free-dynamics of the loop.  The dynamics of the 
post-SET loop are significant, as the loop must move prior to peptide binding or its movement 
must be induced upon interaction with the substrate.  In addition, mutagenesis studies on the 
corresponding region of ASH1L have suggested that this loop region is not merely a blockade to 
peptide binding, but rather plays a more complex role in enzymatic activity142.  As ligands 
targeting this region of NSD1 would have to bind prior to the peptide binding in order to be 









Few studies thus far have analyzed the dynamic behavior of NSD1, so it is unclear what 
conformations exist prior to histone binding.  Qiao and coworkers performed a 2 ns MD 
(Molecular Dynamics) simulation in order to examine the conformational variability of the post-
SET loop region137.  Although they were able to see “modest conformational changes”, the 
length of their simulation was relatively short and so they may not have captured other 









Figure 3.1: Crystal structures of NSD1 and ASH1L  
A) The structure of the catalytic domain of NSD1 is shown (PDB: 3OOI).  The SET domain is 
shown in blue, the post-SET loop is shown in magenta, and the post-SET domain is shown in 
green.  The Zinc ions are shown as gray spheres. B) The post-SET loop region of ASH1L is 
shown in cyan in comparison with the post-SET loop region of NSD1 in magenta.  For clarity, 
only the loop region of ASH1L is shown. C) Surface representation of the post-SET loop of 
NSD1 which shows the lysine-binding channel to AdoMet obstructed by the post-SET loop. D) 
Surface representation of the post-SET loop of ASH1L, showing a cavity not found in the 
crystal structure of NSD1 
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nucleosome against NSD1 to position H3K36 into the substrate binding channel.  In their 
procedure, the majority of the nucleosome was held rigid while the histone tail was allowed to 
move.  In the resulting model, the nucleosomal DNA contacts the post-SET loop, which may play 
a role in stabilizing the active conformation137.  Work by the di Luccio group also utilized MD 
simulations to analyze a peptide-bound model of the post-SET loop143, 144.  However, their 
computational work has serious technical flaws; namely the use of a 1-ps time step.  Typical 
time steps for molecular dynamics simulations are on the order of 1-2 fs.  The 1-ps time step is 
orders of magnitude too large, which leads to instabilities in the forces and poor sampling in the 
calculated motion of the protein145.  Additionally, they minimized their structures after 
simulation, so it is unclear what conformations were observed during the simulations 
themselves.   
 
While the previous studies give some insight into the conformational diversity observed 
in the post-SET loop, they have not sufficiently examined the potential conformations of NSD1 
without the peptide bound which may be an important state for developing inhibitors of methyl 
transfer nor in the presence of the H3 peptide to better understand the substrate-bound state 
of NSD1.   In order to determine which conformations this loop may adopt, we have performed 
MD simulations of NSD1 with the post-SET loop as observed in the crystal structure as well as 




In the present study, we utilized Molecular Dynamics simulations to examine three 
possible starting conformations of the NSD1 post-SET loop: 1) a peptide-bound model, 2) the 
position observed in the crystal structure (“closed-inactive”), and 3) the position observed in 
the homologous protein ASH1L (“open-inactive”).  In the closed-inactive structure, the post-SET 
loop folds more compactly towards the AdoMet cofactor in contrast to the more-relaxed 





No peptide-bound crystal structures of NSD1 were available, so we first created the 
model of the histone H3 peptide (residues 33-37) bound to NSD1-AdoMet based on the 
structurally homologous SET domain of the H3K9 methyltransferase GLP (PDB: 3SW9)146.  This 
was done using the program MOE to manually adjust the post-SET loop of NSD1 to mirror the 
positioning observed in the structure of GLP and to insert the corresponding peptide30.  Due to 
the large number of rotatable bonds in a peptide, modelling the peptide-bound conformation 
using a homologous structure produces a more reliable model than docking the peptide into 
the structure.  While previous studies have shown that a post-SET extension of NSD1 is required 
for nucleosome binding, no crystal structures containing the both SET domain and this region 
exist. Although hypothetical models have been proposed, modeling this region in our 
simulations would introduce another level of uncertainty; therefore we have chosen to use the 
construct of NSD1 found in the crystal structure (PDB: 3OOI)137, 147. 
 
Inactive Conformations 
Second, we sought to enumerate potential conformations of the post-SET loop that may 
exist prior to binding of the nucleosome.  To do so, we carried out two sets of simulations 
based on binary NSD1-AdoMet.  The first, which we have termed the closed-inactive position, 
started from the crystal structure of NSD1 (PDB: 3OOI)137.  During our simulations, we observed 
a subset of the closed-inactive models transitioning to a more relaxed conformation resembling 
the autoinhibitory loop position seen in ASH1L.  In order to determine if this is a stable 
conformation, we also modeled the post-SET loop to match the position seen in the crystal 
structure of ASH1L, termed the open-inactive position(PDB: 3OPE)138.  This was done using the 
secondary structure matching utility within the program Coot to align the corresponding post-
SET loop residues of NSD1 to those of ASH1L148.  
 
Computational Setup 
Parameter files for the simulations were prepared using the tleap utility in AmberTools 
with the AMBER FF99SB force field149.  The parameters for the AdoMet cofactor were created 
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using the antechamber utility in AmberTools with GAFF atom types and the AM1-BCC charge 
model150, 151.  Protonation states were assigned using PROPKA152, 153.  In the case of the peptide-
bound model, the target lysine was modeled as neutral in order to more closely mimic the 
transition state preceding methylation.  This choice was based on the computational study by 
Zhang and Bruice which indicated the presence of a neutral lysine that is deprotonated through 
a water channel prior to methylation in related SET-domain lysine methyltransferases154.  The 
systems were solvated with TIP3P water and sodium or chloride ions were added as necessary 
to achieve a net-neutral charge155.  The systems were initially minimized for 7500 steps, 
followed by heating to 300 K over 80 ps with a 2-fs time step and restraints on the protein.  The 
systems were then equilibrated at 300 K for 1.75 ns while the restraints were gradually 
released.  The SHAKE algorithm was used to constrain bonds with hydrogens and the 
temperature was controlled with the Berendsen thermostat156.  Ten separate production runs 
of 50 ns were completed for each of the three setups.  All simulations were carried out using 
the sander and pmemd utilities in AMBER11149.  The trajectories were analyzed using the ptraj 
and cpptraj utilities157.  Visualization of trajectories was done using VMD and PyMOL100, 158. 
 
Movement Metric 
In order to quantify the movements of the post-SET loop during the simulations of the 
inactive conformations, we selected two metrics that captured the observed rotation and 
translation of the loop.  This allowed us to assess the extent of conformational variation in each 
trajectory.  The first metric calculated was the average of two dihedrals, Gly213N-Gly213Cα-
Gly213C-Asn214N and Gly104C-Asn214C-Asn214Cα-Asn214Cγ, which measured the rotation of 
the post-SET loop away from AdoMet.  The second metric measured the distance between Cγ 
of Asn214 and the O3’ atom of AdoMet.  For ease of comparison, both metrics were normalized 










 Over the course of our simulations, the post-SET loop relaxed into a stable conformation 
with minimal changes to the rest of the protein.  RMSD measurements confirm this 
observation; the initial homology model deviated from the sampled trajectories with a minimal 
RMSD for the post-set loop region of approximately 3 Å.  In comparison to the minimized and 
equilibrated homology model, RMSD values over the course of the simulation oscillated around 
2 Å for both the post-SET loop and the entire protein.  Each of the simulations of peptide-bound 
NSD1 exhibited similar behavior.  In every case, the post-SET loop maintained a helical 
conformation for residues 208-215 (PDB: 3OOI numbering), as shown in Figure 3.2.  This 
conformation allows the lysine of the peptide to remain adjacent to AdoMet in preparation for 
methyl transfer.  Based on our simulations, this structure represents a potential model of NSD1 




Figure 3.2: Model of Peptide-bound NSD1  
A) Representative structure of peptide-bound NSD1.  The H3 peptide is shown in salmon.  
This structure was chosen from a clustering of the final 10 ns of all peptide-bound runs, and 
is the representative structure from the highest occupancy cluster. B) Representative 
backbone RMSD plot calculated relative to the equilibrated peptide-bound model.  As shown 
in magenta, the loop relaxed into a stable conformation with a relatively small RMSD to the 






In contrast with the peptide-bound simulations, the post-SET loop region exhibited 
greater conformational variability during our simulations of NSD1-AdoMet.  In the simulations 
starting from the closed-inactive structure, two of the runs adopted a conformation resembling 
the open-inactive structure, five of the runs sampled about the closed-inactive conformation, 
and three runs transitioned into a third autoinhibitory conformation.   
 
The transition from the closed-inactive to the open-inactive structure was characterized 
by an outward movement of Asn214 (PDB: 3OOI numbering) and the simultaneous rotation of 
the adjacent post-SET loop region.  The degree of conformational variation was assessed using 
the dihedral and distance metrics described in the methods section.  The transition from 
closed-inactive to open-inactive can be seen in the first and second closed simulations, as 
shown in Figure 3.3A and B respectively, in which both the dihedral metric and distance metric 
increase.  This corresponds to a movement of the post-SET loop away from the AdoMet 
cofactor and towards the nearby α-helix.  This conformational change is confined to the region 
directly surrounding Asn214, with very little conformational change in the rest of the post-SET 
loop region. This outward movement of the Asn214 residue is not observed in the remainder of 
the closed-inactive simulations.  
 
In three of the simulations (Figure 3.3F, I, J), we see a third conformational state, 
characterized by an increase in the distance metric without a corresponding increase in the 
dihedral metric.  In these cases, Asn214 rotates in the opposite direction, away from both 
AdoMet and the alpha helix.  In one case, this results in an enlargement of the upper portion of 
the peptide-binding cleft, although the lysine binding channel is still blocked.  Interestingly, the 
cleft makes a flexing motion over time, initially forming a wider intermediate state, which then 
narrows somewhat at the end of the simulation.  This is depicted in Figure 3.3K.  This simulation 
was run for an additional 80 ns (for a total of 130ns) to determine if the loop would further 
transition into a conformation with the lysine binding channel exposed, however, the loop 




In the remainder of the simulations, shown in Figure 3.3C-E, G, and H, the loop remains 
in the closed-inactive position.  In these cases, the post-SET loop primarily samples around the 
starting position and does not rotate outward.   
 
Open-Inactive Simulations 
 There is much less conformational variation observed in the simulations that were 
initialized with the post-SET loop positioned like that of ASH1L.  Using the same metric as the 
closed-inactive simulations, as shown in Figure 3.4, the loop maintains the initial structure 
while sampling around this position. The backbone RMSD fluctuates around 2 Å, while the 
backbone RMSD of the post-SET loop region relative to the homology model is approximately 
2.5-3 Å over the course of the simulations.  The open-inactive simulations were initiated with 
Asn214 pointing outwards towards the α-helix and away from AdoMet.  In contrast to the 
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Figure 3.3: Closed-Inactive Metrics  
A-J) The metrics describing the movement of the post-SET loop in the closed-inactive 
simulations are shown.  The average dihedrals are shown on the Y axis while the distance is 
shown in the X axis.  All values shown are normalized for easier comparison.  In five of the 
simulations, the post-SET loop samples around the starting position.  In the remaining 
simulations, we observed a transition to two other distinct conformations. K) Initial, 
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Figure 3.4: Open-Inactive Metrics 
A-J) The metrics describing the movement of the post-SET loop in the open-inactive simulations 
are shown.  The average dihedrals are shown on the Y axis while the distance is shown in the X 
axis.  All values shown are normalized for easier comparison.  In all cases, the post-SET loop 
primarily samples about the starting conformation. K) Comparison between final structures 
from the “open-inactive” simulations (purple) and crystal structures of the homologous protein 










 In our simulations of NSD1, we witnessed several conformational changes.  In the case 
of the NSD1-AdoMet simulations, we observe three conformations in total.  The first is that 
found in the NSD1 crystal structure, PDB: 3OOI, which has the post-SET loop in an 
autoinhibitory position (“closed-inactive”).  Second, we observed another autoinhibitory 
position resembling that of ASH1L, PDB: 3OPE (“open-inactive”).  This conformation was 
observed in both the simulations beginning from the closed-inactive structure and in those 
starting from the open-inactive homology model.  While we do not know how frequently this 
open conformation occurs in solution relative to the closed position, it was observed to be 
stable over the entire length of our simulations. Recent structural studies of the corresponding 
autoinhibitory loop of ASH1L showed similar conformational sampling within the loop region142.  
Interestingly, we observed a third conformation in which the post-SET loop moves upward, 
widening the peptide binding cleft.  In previous studies by Qiao and coworkers, their docking 
simulations positioned the nucleosomal DNA against the portion of the loop blocking the lysine 
binding channel137.  It is possible that the motion observed in our simulations is a precursor to 
histone binding, with the remainder of the post-SET loop moving upon contact with the 
nucleosomal DNA.  While a shortened construct of NSD1 has been shown to methylate the 
H3K36 peptide in vitro, NSD1’s preferred substrate is nucleosomal H3K36130, 159.  We speculate 
that the necessary conformational change in the post-SET loop that opens the lysine binding 
channel and peptide binding cleft occurs spontaneously on occasion, thereby allowing for the 
methylation of peptide substrates, but is typically induced by the presence of the nucleosome 
via an induced-fit mechanism, thus explaining the preference for nucleosomal H3K36.  Our 
study is limited by the fact that full-length crystal structures of NSD1 are unavailable, and so it is 
possible that there is another determinant of NSD1’s specificity in vivo.  Nevertheless, our 
simulations yield insight on the dynamics of the post-SET loop region. 
 
The observed conformations may also be useful in the design of NSD1-specific small 
molecules.   Currently known inhibitors of SET-domain histone methyltransferases function as 
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either competitive inhibitors of the substrate peptides or inhibitors of the cofactor AdoMet.  
For example, compounds such as BIX01294, E72, and UNC0321 have been found to block 
binding of the target peptide of H3 to the histone methyltransferase G9a, and Sinefungin 
derivatives have been developed that bind in place of AdoMet139, 160-163.  Targeting histone 
methyltransferases via these mechanisms may be potentially difficult because of the need to 
develop specific inhibitors.  Indeed, Nguyen et al. have studied the binding site similarity of SET-
domain methyltransferases and found scaffolds that may bind to subsets of these164.  They 
suggest that the substituents on these scaffolds may be changed to garner specificity.  As an 
alternative to this, it may be possible to capitalize on the differing conformational changes 
between SET-domain methyltransferases, including those seen in our simulations of NSD1.  As 
mentioned previously, the structure of the post-SET loop region varies within the histone 
methyltransferase family.  By designing small molecules that stabilize the autoinhibitory loop 
rather than the cofactor or lysine binding site, researchers may be able to develop ligands with 
greater specificity for NSD1 over other SET-domain methyltransferases.  The results presented 
here provide conformations that can be used for structure-based drug-design efforts to inhibit 









Water molecules are an important factor in protein-ligand binding.  Upon binding of a 
ligand with a protein’s surface, waters can either be displaced by the ligand or may be 
conserved and possibly bridge interactions between the protein and ligand.  Depending on the 
specific interactions made by the ligand, displacing waters can yield a gain in binding affinity.  
The extent to which binding affinity may increase is difficult to predict, as the favorable 
displacement of a water molecule is dependent on the site-specific interactions made by the 
water and the potential ligand.  Several methods have been developed to predict the location 
of water sites on a protein’s surface, but the majority of methods are not able to take into 
account both protein dynamics and the interactions made by specific functional groups.  Mixed-
solvent molecular dynamics (MixMD) is a cosolvent simulation technique that explicitly 
accounts for the interaction of both water and small molecule probes with a protein’s surface, 
allowing for their direct competition.  This method has previously been shown to identify both 
active and allosteric sites on a protein’s surface.  Using a test set of ten systems, we have 
developed a method using MixMD to identify conserved and displaceable water sites.  
Conserved sites can be determined by an occupancy-based metric to identify sites which are 
consistently occupied by water even in the presence of probe molecules.  Conversely, 
displaceable water sites can be found by considering the sites which preferentially bind probe 
molecules.  Furthermore, the inclusion of six probe types allows the MixMD method to predict 
which functional groups are capable of displacing which water sites. The MixMD method 
consistently identifies sites which are known to be conserved and predicts the favorable 





Water molecules play an important role in protein-ligand interactions.  The specific 
conservation or displacement of water molecules is a significant factor in molecular 
recognition165, drug selectivity166, and a ligand’s binding affinity88.  Upon ligand binding, waters 
at the binding interface must be displaced or participate in interactions between the protein 
and ligand.  Waters at the binding interface fall into one of three categories: 1) waters which 
are always conserved, 2) waters which may be displaced by some ligands but not others, and 3) 
waters which are always displaced.   
 
In the strategic design of ligands, scientists frequently try to increase a ligand’s affinity 
by selectively displacing waters.  It would be advantageous for researchers attempting this to 
have a means to predict whether a water site could be displaced, and whether this would lead 
to an increase in a ligand’s affinity.  To this end, a number of computational methods have been 
developed which attempt to predict the relative ease of displacement of a water site.  For 
example, statistical methods such as AcquaAlta86, Consolv82, HINT/RANK85, and Waterscore83 
utilize varying molecular descriptors such as crystallographic B-factors, number of hydrogen 
bonds, and descriptors of surrounding residues to analyze a hydration site.  While these 
methods are relatively fast, they give predictive rates in the range of 50-70% depending on the 
method and test set used.  Water prediction methods have also been incorporated into docking 
software.  For example, the WaterDock methodology used with AutoDock Vina reported 
successful prediction of a water molecule’s displacement in 75% of cases167.  Alternatively, 
Monte Carlo simulations of water molecules may be performed to predict their locations and 
binding affinity, such as in the Just Add Water Molecules (JAWS) method87, 88.   
 
Since the specific interactions that determine whether a water molecule can be 
displaced or not are inherently site dependent, methods based on static structures may not 
accurately capture the variability among binding sites of different systems.  Molecular 
dynamics-based methods are a promising alternative, as they are able to account for dynamics 
and interactions specific to each protein.  For example, inhomogeneous fluid solvation theory 
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(IFST) provides a means of calculating binding energies, including enthalpic and entropic 
components, from molecular dynamics (MD) simulations91, 92.  This method has been 
implemented into the WaterMap tool and successfully applied to a number of targets93, 94, 168-
171.  The SPAM method also utilizes molecular dynamics simulations to calculate the affinity of a 
water site by considering the probability distribution of the interaction energies of each water 
site with its surroundings90.  
 
While these methods are useful to analyze the energetics of individual water sites and 
predict their potential for displacement, they do not test the ability of specific functional groups 
to displace each site.  In recent years, several cosolvent simulation techniques have been 
developed to map favorable interactions within a protein’s binding site, including the MixMD, 
SILCS, and MDmix methods52, 53, 63, 64, 67, 72, 73, 78, 79, 99.  In cosolvent MD simulations, a protein is 
initially immersed in a solution of small molecule probes and water.  Following MD simulations 
during which the probes and water compete for binding to the protein’s surface, the solvent 
occupancy can be calculated to identify locations on the protein’s surface which preferentially 
interact with either the solvent probes or water.  Furthermore, post-processing of the 
trajectories allows the binding affinity of each water site to be calculated99.  While these 
methods are similar in their use of mixed solvents, each has methodological differences, such as 
the use of different probe molecules, whether individual probe molecules are run alone or in 
combination, and the use of restraints on protein and solvent atoms.  The Mixed-Solvent 
Molecular Dynamics (MixMD) method has been developed by our group and previously shown 
to identify both active and allosteric sites51.  In the present manuscript, we validate and extend 





Ten systems were selected for the present test: Aldose Reductase (PDB:1ADS)172, TEM-1 
β-Lactamase (PDB:1ZG4)173, β-Secretase (BACE, PDB:1W50)174, Bromodomain Containing 
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Protein 4 (BRD4, PDB:2OSS)175, Dihydrofolate Reductase (DHFR, PDB:1DG8)176, Heat Shock 
Protein 90 (HSP90, PDB:1AH6)177, Neuraminidase (PDB:4HZV)178, Penicillin Binding Protein 4 
(PBP-4, PDB:2EX2)179, Penicillopepsin (PDB:3APP)180, and Thrombin (PDB:3U69)181.  These 
proteins were selected based on the criteria that they had apo crystal structures with better 
than 2 Å resolution and that each had multiple comparable ligand-bound structures in which 
water molecules were conserved, displaced, or selectively displaced relative to the apo 
structure.  All crystallographic waters were removed prior to system setup.  Hydrogens were 
added and side-chain positions were optimized using MolProbity182.  Using a layered cosolvent 
approach, each protein was surrounded with a layer of probes (acetonitrile, isopropyl alcohol, 
N-methylacetamide, pyrimidine, or a methylammonium/acetate mix) followed by a layer of 
TIP3P water in a 5%/95% v/v ratio73.  Simulations of the proteins in pure water were also done 
for comparison.  Input files were prepared with tleap using the AMBER FF99SB force field and 
parameters developed by Ryde for NADP and NADPH183-185.  Sodium or chloride ions were used 
to neutralize the systems, and ACE/NME caps were added to protein chains when appropriate.  
The systems were initially minimized with restraints on the protein for 5000 steps, followed by 
2500 steps of minimization on the entire system.  The systems were gradually heated at 
constant volume over 40,000 steps with a 2 fs timestep and restraints of 10 kcal/mol-Å2 on the 
protein.  After the systems had reached 300K, they were equilibrated at constant pressure for 
1.75 ns as the restraints were gradually removed.  Production runs were carried out for each 
system for 20 ns with the Andersen thermostat186.  In total, 50 simulations were performed in 
AMBER12 for each protein; ten runs of 20 ns each per probe type185.  Five simulations of 20 ns 
were completed for each of the systems in pure water.  This provided a total of over 1 µs of 
total MD production for each protein. 
 
Probe and Water Occupancy Calculation 
The resulting trajectories were aligned using the AmberTools ptraj utility, and the 
occupancy of the probes and water during the last 10 ns of each simulation were calculated 
using a 0.5 Å grid over the entire solvent box185.  To simplify further analysis, the resulting 





      (1)   
where xi is the raw count at grid point i, µ is the mean occupancy over all grid points, and σ is 
the standard deviation across all grid occupancies.  The occupancies can then be visualized in σ 
units, corresponding to the number of standard deviations above the mean occupancy (much 
like viewing electron density from crystal structures).  Water and probe occupancy was 
visualized in PyMOL100. 
 
SPAM Binding Affinity 
In order to compare the relative affinity of water for a specific site, we calculated the 
theoretical binding affinity for all water molecules using SPAM as implemented in AMBER1490, 
187.  The trajectories from the last 10 ns of each simulation (100 ns total per probe/system) 
were aligned and an in-house script was used to identify all water sites occupied at a level 
greater than the expected occupancy of bulk water.  The interaction energies over every frame 
for each water site were then calculated with a cutoff of 10 Å using the SPAM routine in 
cpptraj157.  An in-house script was used to convert the interaction energies into ∆GSPAM 




To assess the ability of the MixMD method to find conserved water sites on a system-
wide scale, we compared the water sites identified in the simulation with those found in 
comparable crystal structures.  Comparable structures were identified using the Sequence 
Clusters from the Protein Data Bank at 95% sequence identity.  This returns a list of crystal 
structures in the PDB at the specified similarity ranked by quality factor (based on resolution 
and R-value).  The entries from this list (up to the top 99) with resolution better than 2.5 Å were 
selected for comparison.  To identify hydration sites in each crystal structure, the structures 
were aligned using the wRMSD tool188 and clusters of waters were identified using WatCH189.  
WatCH clusters water molecules using a 2.4 Å threshold to identify water molecules occupying 
the same region.  Each cluster was considered to be a water site.  The experimental 
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conservation of each water site was then calculated as the percentage of structures which had 
a water molecule within the cluster relative to the total number of structures.  All reported 
percent conservation values in this manuscript refer to the percent conservation calculated 
from this analysis.  It is important to note that observed experimental conservation will not 
necessarily be correlated with the displaceability of a water site.  For example, multiple 
structures of a protein are frequently solved containing a series of related ligands, which may 
displace the same water molecule in every case.  In addition, water molecules may be capable 
of being displaced, but ligands targeting that site may not yet have been developed (eg. waters 
on the edge of a binding site may be displaceable but current ligands do not extend that far).  
Nevertheless, this analysis gives some insight into the relative “ease of displacement” for each 
water site.   
 
4.4 Results and Discussion 
 
Predicting Water Displaceability 
A method to predict water displacement would be most useful if it could definitively 
predict displacement using a clear-cut procedure.  Therefore, we sought to create a set of 
guidelines with which to classify waters on the basis of MixMD results.  The majority of current 
methods use predicted binding affinities to classify a water site as displaceable or conserved.  
Using the SPAM methodology, the theoretical affinity (∆GSPAM) for each water site was 
determined in the presence of water alone or with probes and water, which were then plotted 
as a histogram as shown in Figure 4.1.  The simulations of water alone serve to identify the 
maximum number of water sites, as both conserved and displaceable sites will be identified.  In 
simulations of water and probe, a decrease in the number of identified sites is expected, as 
water sites will be displaced by the probe molecules.  As predicted, there is a large decrease in 
the number of waters with positive ∆GSPAM, indicating their favorable displacement.  However, 
a small decrease in the number of sites having weakly favorable (negative) ∆GSPAM values is also 
seen, indicating that these sites were displaced by the probe molecules or their free energies 
became less favorable in the presence of the probes.  While the SPAM-generated ∆G values 
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give insight into the energetics of each individual site, they do not provide an unambiguous way 
to classify sites as displaceable or not.   
 Figure 4.1: Histogram of SPAM-calculated binding affinities for water sites in each solvent type.  
∆GSPAM is binned in 1 kcal/mol increments.  A decrease in the number of water-occupied sites is 
observed between the water-only (red) and water with probe simulations (colored lines), 
indicating the displacement of these sites by the probe molecules. Notably, there is a sharp 
decrease for water with positive ∆GSPAM, but some waters with weakly favorable ∆GSPAM are 
also displaced. 
 
As an alternative to using a specific energy-based cutoff, the MixMD water occupancy 
can be visualized directly to identify sites which may be displaced.  Since the MixMD 
simulations are performed with both small molecule probes and water, sites that would more 
favorably bind water over probe molecules (conserved sites) would have greater levels of water 
occupancy than sites which more favorably bind probes (displaceable sites).  In order to 
determine what level of water occupancy throughout the simulations is characteristic of non-
displaceable sites, each system was visualized in PyMol to identify water density within 10 Å of 
the MixMD identified binding hotspot of known ligands, as previously defined51.  Local maxima 
were identified and their σ values (occupancies) binned to generate a histogram, as shown in 
Figure 4.2.  When water occupancy is visualized at high σ values, only a few sites are observed.  
These sites are locations that are very frequently occupied by water despite the presence of 
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probe molecules, and are therefore considered to be non-displaceable.  As σ values are 
decreased, sites that are less frequently occupied by water molecules are identified.  Since 
these sites are not as frequently occupied by water when probe molecules are present, they are 
considered to be potentially displaceable.  A cutoff of 20 σ was chosen to classify water sites as 
conserved or displaceable.  In raw occupancy, this equates to a water molecule being at the 
same grid point in at least ~3% of all snapshots (note that a water site contains several grid 
points and the total occupancy of a water site is the sum over all of the associated grid points).  
The 20 σ value was found to be an ideal balance between identifying water sites which are 
conserved, while also not misclassifying sites which may be displaced.  Contouring the 
occupancy at lower σ levels identifies sites which are known to be displaced; higher σ values 
miss sites that are known to be conserved.  As distinct water sites will inherently have higher 
levels of expected occupancy than bulk water, we sought to describe the distribution of 
occupancies for only the local maxima within the active-site region.  We have also included the 
cumulative probability distribution in Figure 4.2.  The chosen 20 σ cutoff corresponds to a 
cumulative probability of ~0.84, and is therefore approximately 1 standard deviation above the 
mean occupancy for waters within the active site. In the sections that follow, results of this 
method for 10 systems are shown in order to demonstrate its ability to correctly predict water 
displacement, with examples of the method’s ability to predict conserved and displaced waters 





40σ 30σ 20σ 
10σ 5σ 
Figure 4.2:  Above) Colored mesh depicts 
water occupancy from simulations of 
each probe and water mixture.  At high 
occupancy levels, few water sites are 
identified. These are sites which are 
repeatedly occupied by water molecules 
even in the presence of probe molecules.  
Water sites that first appear at lower 
sigma values are less frequently occupied 
by water when probe molecules are 
present.  Left) The distribution of 
normalized occupancies for water sites 
(local maxima) within the active-site 
region.  Data is taken from water 
occupancy in the presence of all probe 
types and across all systems.  
Highly Occupied Water Sites 




Comparing Site-Specific Binding Preferences 
 
Aldose Reductase 
Aldose reductase contains a cluster of buried water molecules which are conserved in 
99% of all crystal structures, located at site A in Figure 4.3.  Other water molecules in the 
binding pocket are displaced by ligands, including sites B and E, and are only conserved in 1-
20% of crystal structures.  Using the 20 σ cutoff, we correctly predict the cluster of conserved 
water sites and predict the displacement of water sites which are experimentally known to be 
displaceable.  In Figure 4.3, the crystallographic water locations in the apo structure are shown 
as red spheres while the water density from the simulations is shown in colored mesh.  Non-
displaceable water sites can be easily identified by visualizing the water occupancy from the 
simulations, such as in the case of site A, where the water occupancy directly overlaps with the 
three observed crystallographic water positions.  ΔGSPAM values from the water-only simulations 
classify only one of these three sites to be favorable (having a negative ΔGSPAM), while the other 
two sites are unfavorable.  However, none of the probes tested were capable of displacing 
these sites, which is consistent with their high experimental conservation.   
 
Water sites displaced by one or more probes can also be easily identified by the lack of 
observed water density, indicated by the absence of colored mesh.  For example, water site B is 
predicted to be displaced by isopropyl alcohol, N-methylacetamide, pyrimidine, and the 
acetate/methylammonium mix, but not by acetonitrile as water density in the presence of this 
probe molecule is observed.  The MixMD predictions are consistent with experimentally 
observed displacement of this site by a carboxyl group in most ligands, as seen with the 
representative ligand in Figure 4.3190.  This site is also known to be displaced by phosphate as in 
the structure of aldose reductase bound to glucose-6-phosphate (PDB:2ACQ), pyrrolidine of 
minalrestat (PDB:1PWL), and pyridazinone when bound to sulfonyl-pyridazinone inhibitors 
(PDB:1Z89)191-193.  In some ligand-bound structures, the carboxyl group occupying site B is 
shifted to the right, and an additional water site C is observed194.  This water site is found in the 
MixMD simulations of water and acetate/methylammonium, as shown in Figure 4.3.  Site E is 
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predicted to be displaced by all of the tested probes, and is observed to be displaced by several 
functional groups, including thiazole derivatives (PDB:2NVC), chlorine of dicholorophenyl 
(PDB:2IPW), and by the sulfur substituent in epalrestat (PDB:4JIR)190, 195, 196.  This is consistent 
with the MixMD predictions in which multiple functional groups are able to displace these 
water sites.  In addition to known sites, MixMD identifies two hydration sites (D) which are not 
found in crystal structures of aldose reductase.  These two sites are found within the water-only 
simulations to have positive (unfavorable) ΔGSPAM values.  This is consistent with the ligand-
bound structures placing a carboxyl group at this site, but this interaction is not replicated by 
the acetate occupancy during the simulations.  However, it is very possible that these sites are 
at least partially occupied by water molecules in solution, as crystallographic conditions such as 
temperature and resolution influence the number of identified water sites.  For example, 
crystal structures solved at 2 Å resolution have ~1 water molecule per residue, while structures 
solved at 1 Å have ~1.6 waters per residue197.  Therefore, it is likely that additional sites found 
in MixMD simulations represent hydration sites found in solution that are not identified in 




Figure 4.3: Aldose Reductase  
Water density is shown at the 20 σ level, colored according to the probe type included in the 
simulation.  ΔGSPAM values from the water-only simulations are given in kcal/mol.  ΔGSPAM values 
for all waters within the active-site region ranged from -1.79 to 5.76 kcal/mol.  Crystallographic 
waters (PDB:1ADS172, 3U2C:WAT1338194) are shown for reference.  Selected sites are labeled.  
The ligands epalrestat (PDB:4JIR,EPR190) and sulindac (PDB:3U2C,SUZ194) are shown for 
comparison.  A) Cluster of water sites which are predicted by the MixMD simulations to be 
always conserved.  B) Water site which is displaced by all probes except for acetonitrile.  In 
some apo and ligand bound structures, a water molecule is found at site C, 
(PDB:3Q67:WAT710198, 3U2C:WAT1338194 transparent red sphere).  When bound in this 
conformation, the oxygen of the ligand is positioned at site D.  D) Water occupancy maxima not 





In the structure of β-secretase, the MixMD method correctly predicts several conserved 
water sites which are found in greater than 95% of crystal structures.  The method also predicts 
the displacement of several water molecules known to be displaced in the majority of crystal 
structures.  Interestingly, MixMD is able to predict the presence of a water molecule which 
bridges interactions between the ligand and protein in some cases, but is displaced by a ligand 
in others.  In the apo-structure of BACE, this water molecule interacts with the two catalytic 
aspartates.  As shown in Figure 4.4A, the amino group of inhibitors can displace this water site 
















between the protein and ligand, as shown in Figure 4.4B.  The MixMD simulations predict that 
this water site can be displaced by the acetate/methylammonium, N-methylacetamide, and 
pyrimidine probes (as evidenced by the lack of water occupancy from these simulations).  This 
is consistent with known ligands that use an amino group (PDB:4RCD, 3LL) to displace the water 
site by interacting with both aspartates199.  Our simulations modeled the two aspartates as 
deprotonated, which has been shown to be the preferred protonation states for a subset of 
BACE inhibitors200.  Other inhibitors, including those which place a hydroxy group at this site, 
preferentially interact with BACE when one of the aspartates is protonated200, 201.  The MixMD 
results generated from the simulations with doubly deprotonated aspartates are consistent 
with this, which predicted this site to be favorably conserved in the presence of isopropyl 
alcohol.  Using SPAM, the ΔG for this site is calculated to be -4.69 kcal/mol, which indicates that 
the site can be favorably occupied by a water molecule.  This is consistent with the selective 
conservation of this site within ligand-bound structures.  However, this site can also be 
displaced by some ligands, which is not apparent from the SPAM calculations alone.  This water 
site has also been previously analyzed with the WaterMap method to guide synthesis efforts202.  
One of the goals of that study was to develop BACE inhibitors that did not displace the catalytic 
water in order to reduce the number of hydrogen bonds present in the inhibitor, in order to 
yield a ligand with more desirable drug-like properties. While the WaterMap method was 
successfully applied to explain SAR results, complementary structure-based drug design efforts 
were required.  Alternatively, the MixMD method can be used, which allows users to predict 
the ease of displacement of a water site, while simultaneously predicting the location of 
favorable interactions of the probe molecules within the binding site.  This information can 
then be used to identify favorable interactions that may be targeted with future ligands.  Thus, 





Figure 4.4: β-Secretase 
Crystallographic waters from the apo structure of BACE (PDB: 1W50174) and the bridging water 
in the ligand bound structure (PDB:4FM7, WAT909202) are shown for reference. ΔGSPAM for the 
circled water site is -4.69 kcal/mol in the water-only simulations.  ΔGSPAM values in the active 
site region ranged from -4.69 to 6.68 kcal/mol.  A) MixMD correctly predicts the displacement 
of the circled water site by acetate/methylammonium, N-methylacetamide, and pyrimidine 
probes.  The ligand from PDB:4RCD199(3LL) is shown for comparison.  Water density is shown at 
the 20 σ level, colored according to the probe type included in the simulation. The inset figure 
shows the Methylammonium density at 150 σ. B) This site may also be conserved and bridge 
interactions between the ligand and protein, as predicted by the simulations with acetonitrile 
and isopropyl alcohol.  The ligand from PDB:4FM7202(OUP) is shown for comparison. 
 
β-lactamase  
Apo β-lactamase contains a number of water sites which are experimentally known to 
be displaced in ligand-bound structures.  These sites are correctly predicted by MixMD to be 
displaced by probes.  In addition to the displaceable water sites in β-lactamase, the MixMD 
simulations also predict the location of conserved waters, including the cluster of water 
molecules known to be important in stabilizing the Ω-loop203.  However, there are two 
exceptions, as shown in Figure 4.5.  Classic inhibitors of β-lactamase form a covalent 
attachment to the enzyme following nucleophilic attack of the β-lactam ring by a deprotonated 
serine.  The carbonyl oxygen of the β-lactam ring displaces a water molecule, while a nearby 








sites are known to be displaced by boronic acid inhibitors205.  SPAM calculations for the water-
only simulations predict one of the sites to be very favorably occupied (ΔGSPAM=-5.58) and the 
other to be unfavorable (ΔGSPAM = 1.17).  In contrast, MixMD simulations predict both of these 
sites to be conserved.  This discrepancy is likely due to two reasons.  First, simulations were 
performed with the serine protonated, which therefore mimics the apo structure in which the 
serine is free to coordinate with the water molecule rather than being covalently attached to 
the inhibitor.  Second, the boronic acid inhibitors were designed as analogues of the transition 
state, and they are able to uniquely emulate the interactions of the hydration sites allowing for 
their displacement.  These specific interactions are not replicated by the current probes in our 
methodology, and so these sites were predicted to be conserved.  As the current set of probes 
is limited, future introduction of additional probes is expected to eliminate this shortcoming.  
 
Figure 4.5: β-lactamase 
Water density is shown at the 20 σ level, colored according to the probe type included in the 
simulation.  Crystallographic waters from the apo structure (PDB:1ZG4173) are shown for 
reference.  ΔGSPAM values from the water-only simulations are shown in units of kcal/mol.  
ΔGSPAM values for the active-site region ranged from -5.58 to 3.62 kcal/mol.  While MixMD 
correctly predicts many of the waters in the active site of β-lactamase as being displaced, there 
are two known discrepancies.  These are attributed to the limited set of probe types used and 











Apo BRD4 contains several water molecules which are displaced upon interaction with 
ligands.  For example, site A in Figure 4.6 is predicted to be displaced by all of the probe types 
tested.  This is consistent with crystal structures of bound ligands, in which many functional 
groups displace this site, including triazole (PDB:2YEL, WSH), the carbonyl of acetylated histone 
proteins (PDB:3JVK, peptide), and the oxygen of isoxazole (PDB:3SVF, WDR)206-208. Within the 
binding pocket, there are a number of water molecules which are found in the majority of 
crystal structures.  For example, site B in Figure 4.6 is found in 97% of all comparable crystal 
structures.  Interestingly, MixMD predicts that several of these sites can be selectively 
displaced.  SPAM ΔG values for these sites are also positive, indicating their potential for 
displacement.  A recent crystal structure has been solved verifying this, in which an inhibitor 
extends deeper into the binding pocket and displaces these sites (PDB:4O7F, 2RQ209), as shown 
in Figure 4.6.  This emphasizes the utility of and need for water prediction methods.  Based on 
conservation alone, it would appear that these sites are not easily displaced.  However, MixMD 





Figure 4.6: BRD4 
Water density is shown at the 20 σ level, colored according to the probe type included in the 
simulation.  Crystallographic waters from the apo structure (PDB:2OSS175) are shown for 
reference.  ΔGSPAM values from the water-only simulations are shown in units of kcal/mol.  
ΔGSPAM values for the active site region ranged from -0.73 to 3.61 kcal/mol.  A) Site predicted by 
MixMD to be displaced, shown with an example ligand (PDB:3UVW, peptide175) displacing the 
site.  B) Water site found in 97% of comparable structures, predicted by MixMD to be 
displaceable is shown with an inhibitor displacing this site (PDB:4O7F, 2RQ209). 
 
DHFR 
The results for DHFR provide another good example of MixMD’s ability to discriminate 
between waters that are always conserved, always displaced, and those that are selectively 
displaced.  In DHFR, 100% of homologous structures contain a water at site A (Figure 4.7) which 
is predicted by MixMD to be always conserved.  On the other hand, SPAM calculations predict 
this site to be unfavorable, with a ΔGSPAM of 5.13 kcal/mol.  Site B is often displaced, with only 
18% of structures containing a water molecule at this location.  This is consistent with SPAM 
calculations, which also identify this site as unfavorable (ΔGSPAM of 5.13 kcal/mol).  For example, 
the amino group of methotrexate (PDB:1DF7, MTX) displaces this site, which in agreement with 
the MixMD prediction that this site will be displaced by N-methylacetamide176. The inability of 
other groups to displace this site is illustrated in the binding mode of folic acid to DHFR.  Folic 










but binds with a different orientation210.  In methotrexate, a nitrogen (which occupies site B on 
the crystal structure) substitutes for an oxygen in folic acid.  However, folic acid binds to DHFR 
with the pteridine ring flipped 180°, which results in the oxygen pointing in the opposite 
direction. This specificity is captured by the behavior of the probes in the simulations.  
Visualizing the N-methylacetamide occupancy by atom shows that the nitrogen is oriented in 
the direction known to be preferred from ligand-bound structures with the oxygen always 
positioned away from this site.   Site C is another example of nitrogen displacing a water 
molecule.  In this case, MixMD predicts that this site can also be displaced by N-
methylacetamide, as well as acetate/methylammonium and isopropyl alcohol.   Thus, not only 
can MixMD identify displaceable water sites, but can also identify specific functional groups 
capable of displacing a site.     
Figure 4.7: Dihydrofolate Reductase 
Water density is shown at the 20 σ level, colored according to the probe type included in the 
simulation. Crystallographic waters from the apo structure (PDB:1DG8176) are shown for 
reference.  ΔGSPAM values from the water-only simulations are shown in kcal/mol.  ΔGSPAM 
values within the active-site region ranged from -1.42 to 5.13 kcal/mol.  A) Water that is found 
in 100% of comparable crystal structures, predicted to be conserved by MixMD.  B) Water site 
known to be displaced by nitrogen, predicted by MixMD to be displaced by N-methylacetamide.  
C) Water site known to be displaced by nitrogen, predicted by MixMD to be displaced by N-















HSP90 has been well studied, and many potent inhibitors exist211.  Site A, as shown in Figure 
4.8, is found in 100% of homologous structures and is predicted by MixMD simulations to be 
favorably conserved.  SPAM calculations identify this site as being only weakly favorable 
(ΔGSPAM of -0.34 kcal/mol).  Studies focused on the structure-activity relationship of HSP90 have 
noted the tightly coordinated nature of this water molecule, leading researchers to avoid 
displacing this site212.  Site B, on the other hand, is displaced by ligands containing either a 
hydroxyl group or a carbonyl group, as shown with geldanamycin bound to HSP90 in Figure 
4.8213.  This is consistent with the MixMD prediction that this site is displaceable by N-methyl 
acetamide, with the hydrogen-bond donor and acceptor regions of N-methylacetamide 
occupying similar orientations to those found in ligand bound structures177, 214.  HSP90 has 
previously been studied by Alvarez-Garcia and Barril using their cosolvent simulation method 
MDmix99, and by Haider and Huggins using IFST with MCSS98.  IFST with MCSS incorrectly 
predicted site B to be conserved based on predicted ∆G values.  SPAM calculations also identify 
this site as being weakly favorable (ΔGSPAM of -1.04 kcal/mol), whereas MDmix correctly 
predicts site B as displaceable (1AH6:393, 1YER:336).  In Barril’s MDmix, a water site is classified 
as displaceable if one of the tested probe molecules binds to the site with higher affinity.  
However, in MDmix only ethanol and acetamide solvent mixtures were used, which limits the 
applicability of the data.  For example, water 391 (PDB:1AH6) in the crystal structure of HSP90 
is displaced by the phosphate groups of ATP (PDB:1BYQ)215.  Barril’s MDmix predicts this water 
to be conserved (water site 325 in 1YER numbering), as none of their probes are capable of 
displacing this site, while our method correctly predicts this site as displaceable.  Thus, the use 
of multiple probe molecules in MixMD offers a greater predictive power over alternative 












Figure 4.8: Heat Shock Protein 90 
Water density is shown at the 20 σ level, colored according to the probe type included in the 
simulation. Crystallographic waters (PDB: 1AH6177) are shown for reference.  ΔGSPAM values 
from the water-only simulations are shown in kcal/mol.  ΔGSPAM values within the active-site 
region ranged from -1.65 to 5.70.  Geldanamycin (PDB:2YGA,GDM213) is shown for reference A) 
Water site found in 100% of homologous structures, predicted to be conserved by MixMD.  B) 




Upon ligand binding to neuraminidase, several water sites are conserved.  For example, 
a cluster of water molecules, shown in Figure 4.9A, are found in 100% of homologous crystal 
structures.  SPAM calculations predict that these sites are unfavorable, with ΔGSPAM values 
ranging from 0.48 to 8.56 kcal/mol.  However, MixMD simulations predict the conservation of 
these sites in the presence of all probes tested, consistent with their high experimental 
conservation.  On the other hand, a number of waters are displaced upon ligand binding, for 
instance by the carboxyl group of the ligand, as shown in Figure 4.9B178.  MixMD correctly 
predicts the displacement of these sites, as indicated by the lack of water density at this 
location and the presence of acetate density.  Although other methods have been applied to 








example, neuraminidase has been previously studied by the JAWS method87.  While the JAWS 
method was able to identify favorable and unfavorable hydration sites in the active site, the 
method requires the use of ligand-bound structures to identify water sites that would be 
displaced upon ligand binding.  Our MixMD method does not require ligand-bound structures, 
and all of these simulations were initiated from apo structures.  MixMD simulations could be 
easily extended to study sequence level changes.  For example, neuraminidase variants are 
common, and show differing susceptibilities to inhibitors216.  Interestingly, the number of water 
sites contained in the active site has been shown to vary depending on the mutant studied, and 
it has been suggested as one factor influencing the observed variations in binding affinity of 
inhibitors217.  MixMD could potentially be used for further study of neuraminidase variants, to 
yield insight into the specific factors that mediate the observed water occupancy and variable 
binding affinities of inhibitors.   
Figure 4.9: Neuraminidase 
Crystallographic waters (PDB:4HZV178) within 10 Å of the MixMD-identified hotspot are shown, 
along with water density from the MixMD simulations shown at the 20 σ level, colored 
according to the probe type included in the simulation. ΔGSPAM values from the water-only 
simulations are shown in kcal/mol.  ΔGSPAM values within the active-site region ranged 
from -3.35 to 8.56 kcal/mol.  A) Cluster of conserved water sites found in 100% of homologous 
structures, predicted by MixMD to be conserved. B) Water sites displaced by carboxyl of ligand 
(Zanamivir shown, PDB:4I00, ZMR178) are correctly predicted by MixMD to be displaced.  The 















Penicillin Binding Protein 
The MixMD results for PBP-4 provide another example of the method’s ability to predict 
conserved and displaceable sites, as well as to discriminate between related systems.  As shown 
in Figure 4.10, the MixMD results correctly predict the conservation of the water at site A, 
which is found in all related structures.  The results also correctly predict the displacement of 
water at site B, which is displaced by the carbonyl oxygen of the β-lactam ring of penicillin 
derivatives179.  SPAM calculations identify site B as weakly favorable (ΔGSPAM of -0.86 kcal/mol) 
while site A is identified as unfavorable (ΔGSPAM  of 9.55 kcal/mol).  Interestingly, TEM-1 β-
lactamase has an equivalent water molecule to site B which was predicted to be conserved.  In 
TEM-1, this water molecule interacts with the nearby hydrolytic water molecule, the backbone 
carbonyl of Ala237, and the backbone nitrogens of Ser70 and Ala237173.  The surrounding 
environment of PBP-4 is similar, although the potential interactions with the neighboring water 
molecule are lost since PBP-4 does not contain an analogous water molecule at this site179.  The 
difference in observed occupancy values can therefore be rationalized as being due to differing 
coordination of the two water molecules, consistent with the apo crystal structures of TEM-1 
and PBP-4.  While TEM-1 and PBP-4 both interact with β-lactam rings, they have evolved to 
have different functions218.  The fact that the MixMD results for these two enzymes are not 




Figure 4.10: Penicillin Binding Protein 
Crystallographic waters (PDB:2EX2179) within 10 Å of the MixMD identified hotspot are shown, 
along with water density from the MixMD simulations shown at the 20 σ level, colored 
according to the probe type included in the simulation. ΔGSPAM values from the water-only 
simulations are shown in kcal/mol.  ΔGSPAM values within the active-site region ranged 
from -1.09 to 9.55 kcal/mol.  A) Water site found in 100% of related crystal structures, 
predicted to be conserved in the presence of all probe types tested.  B) Water site displaced by 




Ligands of penicillopepsin displace a number of water sites, as shown in Figure 4.11.  
Within the active-site region, only two water sites are predicted as being conserved, while all 
other sites are predicted to be potentially displaceable.  Aspartic proteases, such as 
penicillopepsin, unvaryingly have a water molecule that interacts with the two active aspartates 
and is involved in catalysis219.  This location is shown at site A in Figure 4.11.  However, this 
water may be displaced by inhibitors that interact with these aspartates.  For instance, this 
water is displaced by the phosphonate portion of the ligand shown in Figure 4.11220.  This is 
consistent with the MixMD predictions that this site will be displaced.  As MixMD incorporates 








of water sites that commonly bind charged ligands, as shown in the case of site A.  Additionally, 
MixMD predicts the displacement of several other water sites, consistent with ligand-bound 
crystal structures which show the majority of water sites in this region to be displaced upon 
binding.  MixMD also predicts the location of water sites which are known to be conserved, 
including the water located at site B.  On the other hand, SPAM calculations predict this site to 
be unfavorable, with a ΔGSPAM of 7.71 kcal/mol.  This water molecule is buried and participates 
in a network of interactions that are essential to stabilize the active site219.  It is conserved in 
100% of related structures of penicillopepsin as well as in structures of related aspartic 
proteases.  Furthermore, disruption of this stabilizing network of interactions has been show to 
disrupt the active-site geometry in related enzymes219, illustrating the biological importance in 
conserving this water site.   
 
Figure 4.11: Penicillopepsin 
Crystallographic waters (PDB:3APP180) within the active site are shown, along with the water 
density from the MixMD simulations at the 20 σ level, colored according to the probe type 
included in the simulation. ΔGSPAM values from the water-only simulations are shown in 
kcal/mol.  ΔGSPAM values within the active-site region ranged from -1.17 to 7.71 kcal/mol.  A) 
Water site displaced by phosphonate-containing ligand (PDB:1BXO, PP7220) is correctly 
predicted as displaceable by the MixMD simulations.  B) Important water site found in 100% of 
related structures which participates in a network of stabilizing interactions is predicted as 









Upon ligand binding to thrombin, several water sites are displaced, as shown in Figure 
4.12181.  The majority of water sites within this region have positive ΔGSPAM values, consistent 
with their favorable displacement.  Interestingly, a number of water sites are observed in the 
MixMD simulations which are known to be involved in thrombin’s activity.  Thrombin is 
allosterically regulated by a Sodium ion, whose binding site is connected to the active site via a 
water channel221, 222.   Site B is located within this region, and it is identified by the MixMD 
simulations to be conserved, although SPAM calculations classify this site as unfavorable 
(ΔGSPAM of 1.92 kcal/mol).  One of the benefits of the MixMD methodology is the ability to 
contour occupancy at different levels, corresponding to a range of very high to moderate to low 
occupancy.  While high σ levels in the presence of probe molecules were used as a cutoff for 
classifying water conservation, lower σ values still identify discrete water sites with occupancy 
greater than that of bulk water.  When the water occupancy is visualized at lower occupancy 
levels, such as 10 σ, several additional sites within the water channel of thrombin are identified, 
pointing to MixMD’s ability to identify not only absolutely conserved sites, but also water sites 




Figure 4.12: Thrombin 
Crystallographic waters within the active site (PDB:3U69181) are shown, along with the water 
density from the MixMD simulations at the 20 σ level, colored according to the probe type 
included in the simulation.  ΔGSPAM values from the water-only simulations are shown in 
kcal/mol.  ΔGSPAM values within the active-site region ranged from -0.33 to 5.63 kcal/mol.  A) 
Water site that is found in 74% of comparable crystal structures and is predicted to be 
selectively displaced by acetonitrile and isopropyl alcohol.  B) Water site is predicted to be 
always conserved, found in 100% of comparable crystal structures.  C) Water site that is 




As shown in the examples above, the MixMD method correctly predicts the 
conservation and displacement of the water sites in each system tested.   We have also shown 
that the SPAM method applied to water-only simulations yields affinities inconsistent with 
experimental data.  This shows that a water molecule’s binding affinity alone cannot account 
for the ability of a particular functional group to replicate the specific interactions coordinating 
each water molecule.  Although ligands may be designed to displace a water site, this is not 
necessarily accompanied by a corresponding increase in binding affinity if the ligand does not 
adequately mimic the specific contacts previously made by the water molecule.  Using the 










functional groups.  This in turn allows for the prediction of conserved and displaceable water 
sites, while simultaneously determining which groups can successfully displace them.  MixMD is 
able to identify specific groups that can displace a site, identify conserved water sites that play 
important roles and are involved in protein function, and discriminate between closely related 
proteins, including β-lactamase and penicillin binding protein.  In addition, MixMD correctly 
predicts the displaceability of water sites that are incorrectly predicted by other methods as 
being conserved, as shown in the results of HSP90.  MixMD had only one shortcoming in the β-
lactamase case.  Boronic acid inhibitors displace two water sites in β-lactamase which were 
predicted as conserved in the MixMD simulations.  None of the probes in the current set 
contain diols, and so the displacement of this site was not predicted.   Efforts are currently 
underway to expand the available probe set to include additional groups, which is expected to 
extend MixMD’s predictive power.  Overall, the MixMD method successfully classifies the 
displacement of water sites by common functional groups.  These results may be used in the 
strategic design of ligands to determine which water sites should be conserved and which sites 
can be favorably displaced.  Furthermore, MixMD results can also give insight into pockets that 










 Receptor-based pharmacophore models describe the location and extent of favorable 
interaction sites on a protein’s surface.  Pharmacophore models are generated by examining 
the interactions made by individual functional groups, either from mapping methods based on 
static structures or using molecular dynamics simulations in the presence of small molecule 
probes.  Our group has developed the mixed-solvent molecular dynamics (MixMD) method for 
identifying specific favorable interactions and binding-site regions on a protein’s surface.  
MixMD and related cosolvent methods are an especially promising means of mapping binding 
sites, as they explicitly account for the role that protein dynamics and solvent play in mediating 
protein-ligand interactions.  We have developed a framework for converting the occupancies of 
specific functional groups on the cosolvents into pharmacophore features.  These 
pharmacophore features are then consolidated into pharmacophore models for use with the 
program MOE.  The pharmacophore models can then be screened against libraries of 
compounds to identify potential new inhibitors that replicate the desired interactions.  Using 
ABL kinase as a test system, we show a good ability to discriminate between active and inactive 
compounds based on MixMD generated pharmacophore models.  In every pharmacophore 
model tested, a larger proportion of active compounds satisfied the model than did inactive 
compounds.  Prospective application of this method to develop allosteric ligands for Src kinase 








 Pharmacophore models map the important features responsible for the interaction 
between a ligand and its target.  Pharmacophore models can be generated from related 
ligands, termed ligand-based pharmacophores, to describe conserved features within the series 
of ligands.  Models can also be generated in relation to the protein’s surface, which are known 
as receptor-based pharmacophore models.   
 
Several methods have been proposed to identify important interactions on a protein 
target.  The earliest methods focused on the interaction between small molecule fragments 
(“probes”) and a protein’s surface.  The aptly named GRID method utilizes a 3-dimensional grid 
to describe the space surrounding the protein surface.  At each grid point, the potential energy 
of the probe molecule is calculated, thereby identifying favorable interaction sites47.  Similarly, 
MCSS (Multiple Copy Simultaneous Search) performs minimization of a few thousand small 
molecule probes which are initially scattered across the active site.  The resulting minima have 
been shown to overlap with functional groups of known ligands48.  More recently, FTMap has 
been introduced, which also focuses on the identification of minima of small molecule probes49, 
223.  FTMap is implemented as a webserver where users upload their target of interest.  
Potential interactions with the target are sampled via rigid body docking of 16 probe molecule 
types.  The resulting locations are then ranked based on their calculated energy.  While these 
methods are very fast, they are not able to identify all known ligand binding sites, likely because 
of insufficiently accounting for protein flexibility51. 
 
Cosolvent molecular dynamics (MD) simulations are a promising means of generating 
receptor-based pharmacophore models, as they explicitly account for the effects of solvation 
and protein flexibility.  Cosolvent MD methods use a mix of small molecule probes and water to 
solvate the protein of interest.  MD simulations allow for sampling of potential probe and water 
positions while simultaneously accounting for conformational flexibility of the protein.  
Following molecular dynamics, the occupancy of probe molecules over the course of the 
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simulation is determined.  Sites on the protein’s surface that are frequently occupied by 
multiple probe molecules correspond to regions making important interactions, and therefore 
identify biologically relevant sites.  Although several cosolvent methods have been introduced, 
as recently reviewed by Ghanakota and Carlson62, few have actually been developed enough for 
successful pharmacophore modeling.   
 
The SILCS method by Mackerell and coworkers has had the most comprehensive 
development.  SILCS uses fairly high concentrations of small molecule probes to map protein 
surfaces.  Using either traditional MD or a combined Monte-Carlo/MD approach, benzene, 
propane, methanol, formamide, acetaldehyde, methyl-ammonium and acetate probes at a 
concentration of ~0.25 M each are allowed to sample potential binding sites on the protein’s 
surface65, 67.  The resulting trajectories are aligned and overlaid with a 1 Å cubic grid, and the 
occupancy of the probe molecules at each grid point is determined.  In the SILCS method, 
occupancies are converted into free energy values at each grid point based on the Boltzmann 
distribution64.  Grid points having favorable (negative) energy values within the region of 
interest are selected for construction of the pharmacophore model71.  The selected grid points 
are then clustered using a distance-based algorithm, to define distinct interaction sites.  
Pharmacophore features are created from these sites using a sphere centered on the average 
of the grid point locations, with a radius set to contain all of the grid points within the cluster up 
to a maximum value.  This upper limit for pharmacophore radii prevents excessively large 
pharmacophore features, which would hinder specificity of the resulting model.  Following 
pharmacophore feature generation, potential pharmacophore models are created by joining 
the pharmacophore features into several groups.  These models are ranked by the number of 
pharmacophore features they contain and by the sum of the grid free energies of each of the 
pharmacophore features.  The SILCS pharmacophore method was initially validated on HIV 
protease, Factor Xa, and dihydrofolate reductase.  For the three systems, known ligands were 
preferentially selected over decoy ligands, with AUCs ranging from 0.56 to 0.8871.  Subsequent 
SILCS pharmacophore validation studies using additional systems and a larger number of 
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solvents showed similar performance70.  While the SILCS pharmacophore method showed 
reasonably good performance, it is a commercial service and not freely available.   
 
We have focused on the extension of the MixMD method developed by our group for 
the generation of receptor-based pharmacophore models.  The MixMD method has been 
carefully developed to map known binding sites on a protein’s surface while accounting for 
protein flexibility51, 52.  One of the important differences in the MixMD method relative to 
others is the use of fairly low (5% by volume) concentrations of water-miscible, organic solvent 
probe molecules.  Using low concentrations of probe molecules has been shown to accurately 
reproduce known binding sites, while decreasing the number of false-positive sites identified79.  
Importantly, using low concentrations of organic solvents also allows for experimental 
validation, as most crystallographic studies would not be feasible at higher concentrations.  
Previous MixMD studies have introduced several potential solvents, including imidazole, 
pyrimidine, acetonitrile, isopropyl alcohol, n-methylacetamide, methyl-ammonium, and 
acetate51, 73.  These solvents give insight into a wide range of potential interactions taking place 
on the protein’s surface, including hydrogen-bonding, hydrophobic, aromatic, and charged 
interactions.  In order to validate the MixMD pharmacophore method, ABL kinase was selected 
as a test system.  Successful validation of the method ensures that virtual screening performed 
using MixMD generated pharmacophore models will be capable of distinguishing true ligands 
from inactive compounds.  Following validation, the MixMD method was prospectively applied 
to Src kinase towards the development of novel allosteric inhibitors.  
 
ABL and Src share a similar overall structure, containing kinase, Src homology 2 (SH-2) 
and Src homology 3 (SH-3) domains.  Most ligands bind within the active-site region of the 
kinase domain, although a few allosteric ligands have been developed.  For example, in the 
inactive form of ABL the c-terminus of the kinase domain adopts a helical structure and folds 
back against a myristate bound pocket nearby.  This conformation allows the SH-2 and SH-3 
domains to close against the kinase domain.  Ligands designed to replicate this interaction 
stabilize the closed form, thereby acting as allosteric inhibitors224.  This interaction is absent in 
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Src, which instead has a phosphorylated tyrosine that serves as a “latch” for the SH-2 domain 
(Figure 5.1).  With the goal of identifying similar acting sites in Src that would also promote the 
closed form, this form of Src was used as input for MixMD simulations.  
 
Figure 5.1: The closed form structure of Src Kinase (PDB:2SRC)225 is shown.  In the closed 
conformation, a phosphorylated tyrosine (circled) at the very c-terminus of the kinase domain 
binds to the SH-2 domain.  In the open form, this interaction is absent and the SH-2 and SH-3 
domains rotate away from the kinase domain. Most kinase inhibitors target the ATP-binding 




Simulations of ABL kinase have been previously completed by our group using 
pyrimidine, isopropyl alcohol, and acetonitrile51.  For completeness, additional simulations 
using imidazole, n-methylacetamide, and a methylammonium/acetate mixture were completed 
for ABL to incorporate all MixMD solvent types into the MixMD pharmacophore method.  






crystal structure of the closed form containing the SH2, SH3, and kinase domains (PDB:2SRC)225.  
In the closed form, tyrosine-527 near the c-terminus is phosphorylated and binds to the SH2 
domain.  This residue was phosphorylated in the simulations.  The crystal structure contained 
an ATP analog, AMP-PNP, which was removed.  Hydrogens were added and side chain positions 
were optimized using MolProbity182.  Simulations were prepared using four solvent mixtures: 
pyrimidine, acetonitrile, isopropyl alcohol, and an acetate/methylammonium mixture73.  These 
five solvent types were chosen to identify aromatic, hydrophobic, hydrogen-bonding, and 
charged interactions.  Each solvent mixture was run individually, and was initiated as a layer of 
solvent probe molecules surrounding the protein followed by a box of TIP3P water in a 5%/95% 
ratio of solvent to water.  Sodium ions were added to yield a net neutral charge.  Structures 
were prepared in the AMBER utility tleap, using the ff99SB force field185.  For each solvent 
mixture, ten individual simulations were performed.  Minimization was done for 5000 steps 
with restraints on the protein, followed by 2500 steps of minimization on the entire system.  
Following minimization, the systems were heated to 300K at constant volume over 40,000 steps 
with a 2 fs timestep and restraints of 10 kcal/mol-Å2 on the protein.  The systems were then 
equilibrated at constant pressure for 1.75 ns as the restraints were gradually removed.  Ten 
production runs for each probe mixture were performed for 20ns using the GPU enabled 
version of AMBER11/12 PMEMD185, 226-228.   
 
Identifying Binding Sites 
 MixMD simulations have previously been shown to identify biologically relevant sites as 
those having high levels of probe occupancy from multiple probe types51.  Active and allosteric 
sites typically fall within the top few (~5) ranked sites.  In order to determine the probe 
occupancy, the last 10 ns of each trajectory were aligned with the cpptraj utility in AMBER157.  
Using a 0.5 Å x 0.5 Å x 0.5 Å grid, the occupancies of each probe molecule at every point on the 
protein’s surface were counted.  The results were then normalized into units of standard 
deviations away from the mean occupancy (termed σ units).  Occupancy maps were visualized 
in PyMOL100 to identify regions on the protein’s surface having high occupancy arising from 





Once potential binding sites are identified, the interactions within each binding site 
region can be converted into pharmacophore models for use in virtual screening.  To do so, the 
resulting trajectories are aligned, the protein is overlaid with a 0.5 Å cubic grid, and the 
occupancies for each grid point are determined (Figure 5.2).  Because pharmacophore models 
require specific interaction types rather than overall probe locations, the occupancy for 
pharmacophore models was calculated for individual functional groups rather than total probe 
occupancy.  For pyrimidine, imidazole, and acetonitrile, the occupancy was determined from 
the center of mass of each of the molecules.  Counting the occupancy in this manner yields the 
center of the aromatic or hydrophobic interaction site.  The oxygen and methyl groups of 
isopropyl alcohol and oxygen and nitrogen of N-methylacetamide were each counted 
separately to account for the presence of multiple functional groups within each probe.  
Acetate and methylammonium probe occupancy was determined based on the location of all 
atoms, to identify regions favoring charged interactions.  Highly charged ligands are typically 
undesirable, so these features were not included in the final pharmacophore models used for 
virtual screening.  However, they were incorporated in the MixMD pharmacophore generation 
protocol, and so may be incorporated into pharmacophore models when desired.   
 
Prior to converting the grid points into pharmacophore features, low occupancy grid 
points were removed.  This facilitates identification of high affinity interactions, corresponding 
to high occupancy regions.  Including the low occupancy points would result in extremely large 
pharmacophore features that encompass the majority of the protein’s surface.  The cutoff for 
each set of grid points (in the range of 10-20% of the maximum value) was chosen based on 
visual inspection, so that discrete sites were obtained rather than large patches of density.  For 
ABL kinase, a cutoff of 10% was used for all maps except for acetate, methylammonium, and 
the n-methylacetamide carbonyl maps which used points having greater than 15% occupancy.  
For Src Kinase, acetonitrile, pyrimidine, and isopropyl alcohol maps were cutoff at 15% of the 
maximum value while 20% was chosen as the cutoff for acetate and methylammonium 
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occupancy.  An in-house R script was created to group grid points into clusters using the 
DBSCAN algorithm229.  DBSCAN is a density based clustering algorithm that identifies connected 
regions of density within a set distance parameter, eps.  This was set to 1 Å in the current 
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Figure 5.2: A) Individual trajectories are aligned and overlaid with a 0.5 Å cubic grid.  B) At each 
grid point, the occupancy of probe molecules is counted for each frame in the trajectory.  For 
example, the occupancy of the center of aromatic probes is counted at each grid point.  C) This 
yields a time-averaged occupancy value at each grid point.  D) Low occupancy grid points are 
removed (eg. those less than 10% of the max occupancy).  The remaining points are clustered 
with the DBSCAN algorithm to identify discrete interaction sites.  This process is repeated for 
each individual probe or interaction type. 
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  Following clustering of individual interaction types, clusters within the binding site of 
interest are selected for pharmacophore modeling.  Due to the multiple potential interactions 
of isopropyl alcohol and n-methylacetamide, hydrogen-bond donor and acceptor clusters are 
manually selected for inclusion in the pharmacophore model by visualizing the surrounding 
protein structure and nearby high occupancy water molecules.  The selected clusters are then 
consolidated, so that overlapping clusters are converted into a single pharmacophore feature.  
For example, aromatic and hydrophobic clusters occupying the same site would be assigned to 
a joint “aromatic|hydrophobic” interaction type.  Overlapping clusters were defined as clusters 
having centers (local maxima) within 2.5 Å (for hydrophobic and aromatic clusters) or 1.5 Å (for 
hydrogen-bond donors or acceptors).  The values of 2.5 Å and 1.5 Å are the approximate width 
of a pyrimidine probe and approximate Van der Waals radius of oxygen or nitrogen atoms, 
respectively.  The larger value for aromatic and hydrophobic interactions accounts for the fact 
that these occupancies were determined based on center of mass rather than individual atom 
positions like hydroxyl groups.  Local maxima separated by less than these distances would thus 
be considered to be occupying the same site.  Pharmacophore features arising from only one 
probe type are represented using the highest occupied point as the center, with a radius given 
by the RMSD of all other points within the cluster to the center.  Features that contain multiple 
probe types are represented as joint features using the average of all points as the center, with 
the radius given by the RMSD of all other points to this center.  This process is shown in Figure 




   
Virtual Screening Procedure 
Pharmacophore features are joined into a pharmacophore model and converted into 
the proper format for use with the program MOE and the PCH pharmacophore scheme30.  
Pharmacophore models of ABL Kinase were screened against all co-crystallized ligands of ABL 
(n=13)230-240 and the DUD-E ABL1 Kinase final decoys set (n=10,750)241.  Pharmacophore models 
of the putative allosteric sites in Src Kinase were screened against the ChemBridge CORE and 
EXPRESS libraries (Accessed July 2016: ChemBridge Corp., San Diego, CA), the Maybridge 
Figure 5.3: The DBSCAN algorithm is used to identify clusters of highly occupied grid points.  
Top) For each cluster of probe density, the highest occupied point is selected as the center 
and the RMSD of every other point to the center is calculated, to yield the radius of the 
pharmacophore feature.    Middle) When multiple probes overlap within the specified 
cutoff, the average of all grid points within the cluster is used to define the center of the 
pharmacophore feature, and the radius is determined from the RMSD of all points to this 
center. Bottom) Maxima separated by a greater distance than the cutoff have minimal 
overlap, and are more appropriately represented as separate features. 
Distance < 2.5 (Hyd|Aro) 
     









Fragment and Hit finder libraries (Accessed July 2016: Maybridge, Thermo Fisher Scientific), 
Leicestershire, UK), and the ZINC Leads Now and Frags Now libraries9, 242.  MOE allows for the 
stringency of pharmacophore models to be adjusted by using a multiplicative factor to increase 
the pharmacophore feature radii or to allow for partial matches.  For ABL kinase, 1x to 2x radii 
were tested, for partial matches of 6-13 (of 13 total) possible pharmacophore features.  
Following previous work by our group75, 243, partial matches were allowed to hit any of the 
possible features.  Screening in this manner allows for the greatest number of potential 
compounds to be identified.  As the occupancy cutoff used for clustering of Src was higher than 
that of ABL, pharmacophore features were smaller on average than those of ABL.  To account 
for this, larger multiplicative factors were tested when screening the pharmacophore models.  
For Src kinase, 1, 1.33, 1.67, 2, and 2.33x radii were tested along with partial matches of 6-7 (of 
7 total) possible pharmacophore features for the SH2-kinase interface site and 7-8 (of 8 total) 
possible pharmacophore features for the SH3-kinase interface.  The coordinates and 1x radii of 
all pharmacophore models are given in the supplementary information. 
 
5.4 Results and Discussion 
  
Validation of Pharmacophore Protocol 
 In order to validate the MixMD pharmacophore creation protocol, pharmacophore 
models for the active site of ABL kinase were created.  As shown in Figure 5.4, MixMD 
simulations correctly identify the active and allosteric sites of ABL kinase, as previously noted51.  
The grid points falling within this region were selected for conversion into a pharmacophore 
model, as shown in Figure 5.5.  The observed occupancy in the ABL kinase active site spans a 
wide area and includes a number of potential interactions, resulting in 13 total pharmacophore 
features.  However, it is unlikely that a single ligand could make all of these interactions at 
once.  Indeed, virtual screening in MOE against known actives and the DUD-E ABL kinase decoy 
set requiring matches of 10-13 pharmacophore features yielded no hits.  Requiring 6-9 
pharmacophore features yielded a number of ligands that satisfied the requirements, shown in 
Table 5.1.  As expected, increasing the pharmacophore radii by a multiplicative factor yielded a 
98 
 
greater number of matching ligands.  A larger proportion of known active compounds satisfied 
the pharmacophore models than did inactive compounds, as shown in Figure 5.6.  Models were 
further compared by calculating each model’s deviation from a perfect model (ie. distance from 
the model data point to the ideal model having perfect sensitivity and specificity at 100% of 
actives, 0% of inactives)243.  Based on this metric, pharmacophore models based on eight 
pharmacophore features had the best performance.  Requiring eight pharmacophore features 
with 1.5x radii found 76.9% of active compounds and 19.1% of inactives.  Using seven 
pharmacophore features with 1.1x radii performed similarly, finding 69.2% of known active 
compounds and only 11.4% of inactives.  Increasing the radii to 1.3x and requiring a match to 
seven pharmacophore features identified 92.3% of active compounds, but had worse 
specificity, with 39.1% of inactive compounds satisfying the pharmacophore model.  In order to 
perform the most unbiased test of the MixMD pharmacophore method, models were allowed 
to match any of the pharmacophore elements, as long as the required number was met.  
Including domain-specific knowledge to set a subset of required elements (such as the 
aromatic|hydrophobic regions on either side of the activation loop, or specific hydrogen-
bonding interactions) would likely have improved the models’ performance, but would bias the 
results.  Regardless, the MixMD pharmacophore method successfully identified known active 




Figure 5.4: MixMD occupancy for acetonitrile (orange), imidazole (purple), isopropyl alcohol 
(blue), n-methylacetamide (yellow), and pyrimidine (magenta).  The active and allosteric sites 
can be identified by the surrounding probe density, initially seen at very high occupancies (left).  
Visualizing the probe density at medium occupancy levels shows the extent of the binding site 
and full range of potential interactions (right).  Ligands are shown in green for reference (PDB: 
3KFA235, 3MS9236), but were not included in the simulations. 
  
50σ 20σ 
Figure 5.5: A) The region of ABL kinase 
mapped with the highest occupancy of 
MixMD density was selected for 
pharmacophore modeling.  B) The 
occupancy for each interaction type was 
counted for each grid point.  C) Grid points 
are clustered into pharmacophore features.  










Table 5.1: Percentage of tested compounds satisfying the pharmacophore model.  Actives were 
taken from co-crystal structures of ABL in the protein databank (n=13) 230-240 and inactives were 
taken from the DUD-E ABL-1 kinase final decoy set (n=10,750) 241. 
 
Pharmacophore Model Performance for ABL Kinase Active Site 
Num. Features 9 8 7 6 
Radii Actives Inactives Actives Inactives Actives Inactives Actives Inactives 
1x 0.0% 0.0% 0.0% 0.1% 53.8% 4.5% 92.3% 45.5% 
1.1x 0.0% 0.0% 7.7% 0.5% 69.2% 11.4% 92.3% 64.5% 
1.2x 0.0% 0.0% 7.7% 1.7% 69.2% 23.4% 100.0% 78.3% 
1.3x 7.7% 0.1% 38.5% 4.6% 92.3% 39.1% 100.0% 86.7% 
1.4x 15.4% 0.6% 53.8% 10.8% - - - - 
1.5x 23.1% 1.9% 76.9% 19.1% - - - - 
1.6x 30.8% 4.2% - - - - - - 
1.7x 38.5% 8.1% - - - - - - 
1.8x 46.2% 12.9% - - - - - - 
1.9x 46.2% 19.1% - - - - - - 
2x 61.5% 25.7% - - - - - - 
Figure 5.6: Percent of active compounds (n=13) satisfying the pharmacophore model of 
the ABL kinase active site relative to the percentage of inactive compounds (n=10,750).  
Pharmacophore models requiring 6-9 matches with 1-2x radii were tested. 
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Prospective Screening of Src Kinase 
 MixMD simulations of Src Kinase identified two pockets of density at the SH-2 and SH-3 
kinase interfaces, as shown in Figure 5.7.  Both sites were among the top ranked sites by 
maximal occupancy of probe molecules.  Based on this ranking and their presence along the site 
of an important stabilizing interaction, we hypothesized that ligands targeting these sites may 
be able to stabilize the closed conformation of Src Kinase.  To our knowledge, there are no 
known inhibitors targeting these sites.  Pharmacophore models were created for the SH-2 and 
SH-3 sites separately, following the same clustering procedure used for ABL kinase.  Screening 
the models against the ChemBridge and Maybridge libraries yielded a number of hits, as shown 
in Table 5.2.  The hit rates for each pharmacophore model were compared in order to select a 
tractable number of compounds for purchase and experimental testing.  As the stringency of 
the pharmacophore model is adjusted by incrementally increasing the radii, an increasing 
number of hits are obtained.  Likewise, decreasing the number of required pharmacophore 
elements also increases the number of hits.  As seen in the validation studies of ABL kinase, the 
appropriate pharmacophore models have a moderate level of stringency to successfully identify 
active compounds, without matching an overly large number of inactive compounds.  Based on 
this, we selected the pharmacophore model requiring a match to all of the pharmacophore 
elements at 1.67x radii for the SH-2 kinase interface (87 hits) and 2x radii for the SH-3 kinase 
interface (45 hits) for subsequent testing.  The selected pharmacophore models were then 
screened against the ZINC Leads Now and Frags Now subsets.  This resulted in an additional 132 
matching compounds for the SH2-kinase site and 35 for the SH3-kinase site.  A subset of these 
compounds is currently being experimentally tested, using a protease accessibility assay, to 
determine each compound’s effect on the global conformation of Src.  This was developed by 
Matthew Soellner and coworkers at the University of Michigan, and is based on the exposure of 
the region linking the kinase and SH domains244.  Compounds that do not induce the closed 
state allow for cleavage of this region by thermolysin.  The ratio of open to closed states can 
then be measured over time from the band intensity of each product on an SDS gel.  All 















Table 5.2: Matching compounds from screening the ChemBridge and Maybridge libraries 
against the pharmacophore models.  Compounds were required to hit either all or all but one of 
the possible pharmacophore features.  Bolded numbers indicate the pharmacophore models 
selected for further testing.  
Src Kinase Virtual Screening Results 
 SH-2 Kinase Interface SH-3 Kinase Interface 
Num. 




1x 1 1035 0 0 
1.33x 7 - 0 29 
1.67x 87 - 2 1065 
2x 430 - 45 - 
2.33x 2354 - 466 - 
Figure 5.7: Left) MixMD density is shown for acetonitrile (orange), isopropyl alcohol (blue), 
and pyrimidine (magenta) contoured at 20 σ.  The SH-2 and SH-3 domains form two pockets 
with the kinase interface, which ranked among the top sites (circled) by MixMD probe 
occupancy.  Right) Pharmacophore models for the SH-2 and SH-3 kinase interfaces of Src.  
Spheres are colored according to the pharmacophore feature type.  Coordinates and radii of 
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 Using the procedures described herein, MixMD occupancy maps can be converted to 
pharmacophore models for virtual screening with MOE.  Validation on ABL kinase showed a 
good ability of our models to correctly identify known active compounds from sets of inactive 
compounds.  For ABL kinase, the extensive mapping by the probe molecules within the active 
site yielded a large number of pharmacophore features that were impossible to satisfy 
simultaneously.  Screening using a reduced subset of the total features successfully identified 
known inhibitors, but also matched some of the inactive compounds.  Increased specificity 
could potentially be achieved by manually selecting pharmacophore features for inclusion 
based on knowledge of known active compounds and their interactions with the binding site.  
Since the goal of this study was to validate the pharmacophore generation protocol rather than 
to screen for new inhibitors of ABL, this was not tested.  Similarly, pharmacophore features 
could be selected based on the observed occupancy at each site during the simulation, so that 
high affinity sites are required features in the final pharmacophore model.  This would likely 
help to bias the hit compounds towards those with higher potential affinities.  Specificity may 
also be increased by incorporating additional shape information from the occupancy maps of 
the MixMD simulations.  Pharmacophore models are typically represented using spheres 
centered at some point, but it is compelling to think that screening into the occupancy maps 
directly would incorporate more specific interaction preferences and lead to better 
distinguishing active and inactive compounds. 
  
 As screening of the compounds satisfying the pharmacophore models of the SH-2 and 
SH-3 kinase interfaces in Src are not complete, it is not known if any active compounds will be 
identified.  Admittedly, this is a difficult task, as no ligands targeting these sites have been 
previously discovered and so it is unknown if ligands binding to this site are even capable of 
stabilizing the closed conformation.  Nevertheless, we have developed a framework for 
conversion of MixMD results into pharmacophore models, which enables future prospective 
applications of the method. 
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5.6 Supplementary Information 
 
ABL Kinase Active-Site Pharmacophore Model 
Feature Type x y z r 
Aromatic|Hydrophobic 5.3272 -5.0214 -1.1163 1.3145 
Aromatic|Hydrophobic -0.1101 -1.9205 9.8228 2.5990 
Aromatic|Hydrophobic 7.8438 -2.8039 -0.9048 2.3757 
Aromatic|Hydrophobic 1.8230 -3.1502 12.8002 0.8922 
Aromatic|Hydrophobic 5.6607 -6.3754 5.6796 2.0000 
Aromatic|Hydrophobic 7.2642 -4.2688 -6.0361 0.7080 
Acceptor 1.6400 -3.6080 7.9810 1.5700 
Donor 5.6980 -5.6720 -4.4910 1.1900 
Donor 4.6580 -6.0810 5.5090 0.7700 
Acceptor 3.8690 -5.9630 -0.8630 0.9200 
Donor 4.3920 -6.4490 3.6360 0.8900 
Donor 4.1758 -5.3850 7.4456 1.0892 
Donor|Acceptor 5.8791 -4.7948 9.3955 0.5605 
Table 5.3: Feature type, coordinates, and radius for all potential features in the pharmacophore 
model of the ABL kinase active-site.  
 
Src Kinase SH2-Kinase Interface Pharmacophore Model 
Feature Type x y z r 
Anion 5.5230 -5.6350 16.7550 0.9500 
Anion 6.0370 -5.6670 19.2520 0.8700 
Cation 9.0930 -2.7200 17.7590 1.0000 
Cation 8.6420 -0.7180 18.7790 0.6100 
Aromatic 8.2500 -6.7500 15.7500 0.6700 
Hydrophobic 10.7840 -6.9740 10.4210 0.7100 
Aromatic|Hydrophobic 8.0313 -4.2384 13.5361 1.8173 
Aromatic|Hydrophobic 3.0393 -4.6260 16.5623 1.4948 
Acceptor 8.3230 -3.9700 14.9010 0.7100 
Donor 1.8200 -4.8830 17.9230 0.8500 
Donor|Acceptor 5.9943 -4.1058 14.3220 0.7301 
Table 5.4: Feature type, coordinates, and radius for all potential features in the pharmacophore 




Src Kinase SH3-Kinase Interface Pharmacophore Model 
Feature Type x y z r 
Anion 5.8340 -6.9120 -10.7590 1.2300 
Anion 7.8500 -6.4640 -9.7670 0.5000 
Anion 9.3950 -6.5650 -1.7760 1.9000 
Cation 5.9760 -1.4480 -6.7140 0.7100 
Aromatic 5.7500 -5.2500 -10.2500 0.8800 
Aromatic 8.7500 -8.2500 -7.2500 0.5900 
Hydrophobic 6.0140 1.3820 -9.7700 0.5000 
Aromatic|Hydrophobic 5.4768 -1.8869 -12.6331 1.5279 
Aromatic|Hydrophobic 7.6836 -7.8453 -11.6304 1.0508 
Acceptor 6.7650 -0.2800 -12.5710 0.9200 
Acceptor 4.7170 -3.7590 -10.5830 0.6500 
Donor|Acceptor 4.0605 -5.2698 -12.3397 0.6608 
Table 5.5: Feature type, coordinates, and radius for all potential features in the pharmacophore 









 Mixed-solvent molecular dynamics (MixMD) is a cosolvent simulation technique for 
identifying binding hotspots and specific favorable interactions on a protein’s surface.  MixMD 
studies have the ability to identify these biologically relevant sites by examining the occupancy 
of the cosolvent over the course of the simulation.  However, previous MixMD analysis required 
a great deal of manual inspection to identify relevant sites.  To address this limitation, we have 
developed MixMD Probeview as a plugin for the freely available, open-source version of the 
molecular visualization program PyMOL.  MixMD Probeview incorporates two analysis 
procedures: 1) to identify and rank whole binding sites and 2) to identify and rank local maxima 
for each probe type.  These functionalities were validated using four common benchmark 
proteins, including two with both active and allosteric sites.  In addition, three different 
cosolvent procedures were compared to examine the impact of including more than one 
cosolvent in the simulations.  For all systems tested, MixMD Probeview successfully identified 
known active and allosteric sites based on the total occupancy of neutral probe molecules.  As 
an easy-to-use PyMOL plugin, we expect that MixMD Probeview will facilitate identification and 




 First introduced in 200972, hotspot mapping with molecular dynamics (MD) simulations 
of small molecule probes and water is being increasingly applied towards the development of 
small molecule inhibitors.  These cosolvent simulations provide two types of information.  First, 
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when many probes map a location, it identifies binding sites on the protein’s surface, including 
ligand binding sites, protein-protein interaction sites, and other biologically relevant 
interactions.  Secondly, the functional groups on the individual probes identify functional sites 
on the protein’s surface that favor specific interactions, which can be used to inform structure-
based drug design efforts.  Several cosolvent simulation methods have been introduced, as 
recently reviewed by Ghanakota and Carlson62.    While these methods all utilize mixtures of 
small molecule probes and water, they have a number of differences regarding the specific 
probes used, the protocol for simulation, and the method of identifying and ranking the results.  
For example, some cosolvent methods have focused on the use of a single probe molecule per 
simulation while others have multiple probes run simultaneously.  The MixMD method 
developed by our group previously utilized a layered setup of a single probe type and water in a 
5%/95% v/v probe to water ratio79.  Introducing charged probes required a transition to ternary 
solvent mixtures to balance the number of positive and negative charges within the system51.  
Other simulation methods, including the SILCS method67 from the MacKerell group and 
cosolvent simulations by Bakan et al.245, have utilized 4-7 different types of probe molecules 
within the same simulation.  Simulations containing multiple probe types clearly require fewer 
simulations than comparable methods that simulate each probe separately, but the extent to 
which this influences the predicted binding sites is unclear.   
 
Traditionally, hotspots have been identified by overlapping density from multiple probe 
molecules43, 49, 51.  In our MixMD method, the occupancy of probe molecules is determined by 
overlaying the protein and solvent system with a grid and counting the number of times a 
probe molecule occupies each region.  The occupancy is then converted into “σ units”, 
expressed as the number of standard deviations away from the mean occupancy.  This allows 
for the maps to be viewed at different occupancy contour levels, in an analogous way to 
crystallographic electron density.  The resulting maps are visualized in PyMOL to identify the 
highest occupied sites comprised of multiple probe types.  These regions, or hotspots, are then 
ranked by maximal occupancy51.  When applied to seven test systems, this method successfully 
identified known biologically relevant sites on the basis of maximal occupancy51.  However, 
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manually inspecting every probe map at multiple occupancy contour levels for every system is 
tedious and time-consuming, thereby limiting the number of systems that can be studied. 
 
Other approaches have identified binding sites by converting the probe occupancies into 
theoretical binding affinities.  In the SILCS method67 and the method by Bakan et al.245, the 
binding affinity at a specific grid point is calculated from the Boltzmann relationship: 
 
∆𝐺𝐺𝑑𝑑 =  −𝑅𝑅𝑅𝑅 ln(
𝑂𝑂𝑖𝑖
𝑂𝑂𝑏𝑏𝑏𝑏𝑏𝑏𝑘𝑘
)    (1)   
 
where Oi is the occupancy at grid point i, Obulk is the expected occupancy in bulk solvent, and T is 
the temperature.  In the SILCS method, these energies are referred to as grid free energies, and 
they can be used to visualize predicted affinities on the surface of the protein or may be used to 
determine the theoretical binding affinity of a ligand having atoms at point i67.  In the approach 
used by Bakan et al., distinct interaction sites are identified, and the lowest energy point, 
calculated from Equation 1, is selected to represent the site245.  Nearby sites are merged and 
the energies are summed to yield theoretical affinities for each region.  The affinities are then 
used to rank the “druggability” of each site.  This approach was used successfully to identify 
known binding sites for five systems, and to rank potential binding sites within each system by 
the maximum predicted affinity245.   
 
While Equation 1 is straightforward to use, there are some inherent limitations in the 
calculation of binding affinities at the level of sub-atomic grid points using data from 
simulations of whole probe molecules.  The binding affinity of a probe molecule is dependent 
on the contributions of every atom within the probe.  For example, in the case of isopropyl 
alcohol, the hydroxyl group may be making hydrogen bonding interactions, while the methyl 
groups are making hydrophobic interactions.  Partitioning the binding affinities calculated from 
the entire probe molecule’s occupancy down to the grid point level neglects to consider these 
effects.  Instead, we have focused on the analysis of overall occupancy of the probe molecules 
as a whole.  Using a clustering method to identify separate regions on the protein’s surface, we 
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calculate the total occupancy of probe molecules for each site across all simulations.  This 
identifies the regions that are highly occupied by multiple probe types across multiple 
simulations.  
 
To facilitate application of our MixMD method, we have developed a plugin, which we 
call MixMD Probeview, for use with the freely available open-source version of PyMOL100.  
Requiring only a PDB-formatted file containing grid points and associated occupancies from a 
set of cosolvent simulations (easily obtained by post-processing of trajectories with 
AmberTools187), MixMD Probeview identifies binding sites composed of multiple probes as well 
as local maxima for individual probes.  We have validated this method on four systems 
(including two with allosteric sites), using data taken from more than 2 µs of simulation time 
per system.  Simulations were performed for multiple solvent setup procedures, including both 
solvents alone (ie. a single probe and water) and in several combinations (ie. 2 or more probe 
types and water).  This allowed us to verify the ability of MixMD Probeview to identify binding 
sites for a range of systems and cosolvent procedures.  Additionally, since simulations were 
completed for both individual probes and probes run in several different mixtures, we were 
able to compare the resulting probe occupancy and binding site prediction for different 
simulation methods.  For each system and solvent mixture, the simulations were analyzed at 
two levels.  The first being the ability to correctly predict and identify biologically relevant 
regions as highly ranked hotspots, and the second being the agreement in functional group 




 ABL kinase (PDB:3KFA)235, Androgen receptor (AR, PDB:2AM9)246, β-secretase (BACE, 
PDB:1W50)174, and dihydrofolate reductase (DHFR, PDB:1DG8)176 were selected as test systems.   
These proteins are commonly used benchmark systems and include systems with allosteric sites 
to provide a thorough test of MixMD Probeview’s ability to predict binding sites.  All ligands and 
water molecules in the crystal structures were removed, with the exception of the NADPH 
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cofactor in DHFR which was retained and modeled using the parameters developed by Ryde183, 
184.  Hydrogens were added and asparagine, glutamine, and histidine positions were optimized 
using MolProbity and the Protonate 3D tool in MOE30, 182.  For each system, probes were run 
individually (“solo”) or in one of two combined sets, given in Table 6.1.  Portions of these 
simulations were completed previously by our group51.  Solvent mixtures were chosen to 
minimize the need for two probes to compete for mapping the same type of interaction with 
the protein surface.  For example, pyrimidine and imidazole are both aromatic probes and 
would be expected to occupy many of the same sites.  For this reason, none of the probe 
mixtures include both pyrimidine and imidazole.  In each case, a 5%/95% v/v ratio of probe 
molecules to TIP3P155 water was maintained, with the 5% of probe molecules split evenly 
between probe types.   
 
Solo Combination A Combination B 
Acetonitrile (ACN) Acetonitrile Acetonitrile 
Isopropyl Alcohol (IPA) + Isopropyl Alcohol + Isopropyl Alcohol 
Imidazole (IMI) Imidazole + Imidazole 
N-methylacetamide (NMA) + N-methylacetamide N-methylacetamide 
Pyrimidine (PYR) Pyrimidine + Pyrimidine 
Methylammonium (MAI) + Methylammonium + Methylammonium 
+ Acetate (ACT) + Acetate + Acetate 
Table 6.1: The boxes indicate the probe mixtures used for each set of simulations.  The solo 
probes were all run as a single probe in combination with water, except for methyalmmonium 
and acetate, which must be run together to achieve an overall neutral charge.   
 
The simulations were initiated using a layered setup, with probe molecules placed 
around the protein, followed by a box of water to achieve the desired concentration.  This 
setup was chosen to facilitate probe sampling at lower concentrations, consistent with previous 
development of the MixMD method79.  The tleap module of AmberTools12 or 14185, 187 was 
used for system setup, with the FF99SB247 force field and previously developed solvent 
parameters51, 73.  The systems were initially minimized, followed by heating to 300 K with 
restraints on the protein.  The restraints were then gradually removed as the systems were 
equilibrated.  For each system and solvent type, 10 simulations of 20 ns production time with a 
2 fs timestep were completed with AMBER12 or 14149, 185, 187, 226, 227.  Proper solvent behavior 
111 
 
over the course of the simulation was verified using radial distribution functions calculated 
using the cpptraj module in AmberTools14187. Following simulation, the last 10 ns of each 
trajectory were aligned, and the occupancy of the center of mass of each probe molecule was 
calculated on a 0.5 x 0.5 x 0.5 Å grid using an in-house modified version of the cpptraj module in 
AmberTools14157, 187.  The modification to cpptraj was necessary to allow for center-of-mass 
based occupancies to be calculated. 
 
Our PyMOL plugin, MixMD Probeview, was used for the analysis of the occupancy grids.  
The plugin consists of two analysis procedures: 1) to identify and rank whole binding sites and 
2) to identify and rank maxima of each probe type.  MixMD Probeview is written in Python and 
uses the scikit-learn package for clustering248.  In order to identify whole binding sites on the 
protein’s surface, the DBSCAN clustering algorithm was used.  This algorithm is capable of 
identifying density connected regions of any shape or size and does not require a predefined 
cluster size or number of clusters229.  DBSCAN clustering relies on three parameters: 1) a cutoff 
to determine which grid points to cluster, 2) epsilon (ε), the maximum distance by which two 
points can be separated and still be considered within the same cluster, and 3) the minimum 
number of points that must be contained in a cluster to consider it a valid cluster.  Clusters are 
created by grouping all points that are reachable within the epsilon distance, and containing at 
least the minimum number of points.  An example of the DBSCAN clustering process is shown in 
Figure 6.1.  In practice, this allows for the automated identification of clusters of probe 
occupancy from either overlapping or adjacent grid points.  The DBSCAN algorithm is 
particularly useful for identifying ligand binding sites because of its requirement for connected 
regions of density, thereby identifying sites that could be connected within the span of a few 
bond lengths.  In the present study, grid points having greater than 10% of the maximum 
occupancy were used for clustering with a distance parameter of 3 Å.  This is approximately the 
width of pyrimidine or twice the length of a carbon-carbon bond in ethane, and so would 
identify regions that could be connected within 1-2 bond lengths.  The minimum number of 
points was set to 10 to remove small clusters from further analysis.  Following clustering of the 
occupancy grid points, the resulting clusters can be ranked by either the maximum occupancy 
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found in the cluster or the total sum of occupancy within the cluster.   
 
  While the DBSCAN clustering algorithm is suitable for identifying binding sites, it is not 
capable of differentiating groups of points whose edges are adjoining, as frequently happens in 
regions adjacent to local maxima.  In order to identify and rank favorable probe binding sites for 
individual probe molecules, the Mean Shift clustering algorithm was used249.  The Mean Shift 
algorithm was chosen as it is capable of identifying arbitrary shapes and sizes of clusters from 
data points with varying density in 3-D space, making it ideally suited to finding clusters 
corresponding to local maxima from cosolvent simulations.  In the Mean Shift clustering 
procedure, the distribution of data is represented by a kernel density estimate with bandwidth 
parameter h.  An iterative process is then applied to the data to identify a local density gradient 
followed by a shift of the center of the kernel until the gradient of the density is zero, and the 
peak in the data is identified249.  As depicted in Figure 6.2, this clustering process identifies the 
highest occupied region as the center, with lesser occupied regions surround this point grouped 
into the cluster based on the observed spatial distribution.  Larger bandwidth values will 
generate fewer, larger clusters while a smaller bandwidth value will give a greater number of 
small clusters.  The clusters can then be ranked by the maximum occupancy within the cluster. 
Figure 6.1:  The DBSCAN clustering procedure identifies connected regions of probe density 
arising from multiple probe types (represented by different colors). Grid points within the 
distance parameter ε are grouped into the same cluster.  The resulting clusters can then be 
ranked based on the probe occupancy within the cluster. 
Distance > ε 
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Figure 6.2: The mean shift clustering algorithm groups points based on their distribution in 
space.  Densely occupied regions correspond to the center of a cluster (dark blue), while 
sparsely occupied regions indicate cluster edges (light blue). 
6.4 Results and Discussion 
 
Validating Parameters for Combined Solvent Mixtures 
 Previous work by our group has highlighted the importance of validating solvent 
parameters prior to their use in cosolvent simulations73.  Improper sampling of solvent 
positions would invalidate the underlying assumptions used when considering the ranking of 
observed probe occupancies.  MixMD solvent parameters were previously shown to yield 
proper solvent behavior for runs of a single probe mixed with water, but could potentially have 
different behavior when used with combinations of solvents.  As shown in Figure 6.3, all solvent 
mixtures showed proper mixing, with all g(r) values at 8 Å close to 1.  Example values shown 
were taken from the production simulations of DHFR.  This indicates that the solvent molecules 
were evenly mixed with no condensation into a separate phase from the water. 
  
DBSCAN Clustering to Identify Binding Sites 
 Previous studies by our group established that biologically relevant sites could be 
identified based on maximum solvent occupancy in cosolvent simulations51.  These simulations 
correctly identified the active and allosteric sites as being among the top ranked sites by 
occupancy.  However, when solvent mixtures are used rather than single cosolvents some sites 
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that would normally be ranked as having maximal occupancy may have intermediate occupancy 
values because of multiple, exchanging solvent molecules.  Ranking by maximal occupancy in 
these cases would favor sites that bind a single probe type tightly rather than those sites which 
bind multiple probe types tightly.  To account for this, we have moved to ranking based on total 
occupancy within a region.  Occupancies were generated based on the center of mass of each 
probe molecule so that each probe would contribute equally when the total (summed) 
occupancies were calculated.  The rankings shown in the following sections were generated 
using our PyMOL plugin with the occupancies of all neutral probe molecules.  Previous MixMD 
studies have shown the ability to identify most active sites using the occupancies of neutral 
probe molecules51.  Charged probe molecules were included in each set of simulations, and 





































Probe-Probe RDF for Solvent Mixtures 
 g(r) at 8 Å    
 Combination A Combination B    
ACN-ACN 1.02 0.99    
IPA-IPA 1.08 1.08    
NMA-NMA 1.21 1.18    
PYR-PYR 1.09 1.17    
IMI-IMI 1.10 1.07    
ACT-ACT 0.99 0.94    
MAI-MAI 0.93 0.87    
PYR + NMA + MAI + ACT ACN + IMI + IPA 
IMI + NMA 
ACN + IPA PYR + ACT + MAI 
O-O RDF for TIP3P Water in Solvent Mixtures 
Figure 6.3: Radial distribution functions of the oxygen in water show expected behavior in all 
cases.  Probe-probe radial distribution functions deviate slightly from 1, but are within the 
acceptable ranges previously established by our group.  All values shown were taken from 




 Both active and allosteric ligands bind to ABL kinase, with varying specificity depending 
on ABL’s conformational state.  As shown in Figure 6.4, MixMD simulations identify both the 
active and allosteric sites as the top ranked sites for every solvent combination tested, though 
the ordering differed depending on the solvent set.  Ligands that bind to the active site of the 
inactive, DFG-out form of ABL kinase (used to initiate the MixMD simulations) form interactions 
at the ATP binding site as well as the site that is occupied by phenylalanine in the DFG-in 
conformation237, 250.  These two sites are encompassed by the MixMD identified binding site, 
which shows two areas of density connecting over the activation loop. As shown in Figure 6.4, 
there is a patch of highly occupied probe density at both the left and right sides of the active-
site ligand, corresponding to the ATP and phenylalanine positions, respectively.  Summing over 
the clustered grid points identifies the active site as having the highest total occupancy for both 
the individual probe and solvent combination B simulations.  In the case of the simulations of 
solvent combination A, the left and right portions of the active site are broken up into two 
clusters, as they are separated by slightly more than 3 Å.  This results in the active site being 
ranked second, behind the allosteric site.  Including the second cluster at the left side of the 
active site would have ranked the active site as the highest occupied cluster.  Regardless, the 
top two sites clearly have a greater degree of occupancy than other sites, as seen in the boxplot 
in Figure 6.4. 
 
The second site identified by the MixMD occupancy corresponds to the allosteric site of 
ABL kinase.  Allosteric ligands bind in the myristate pocket, near the C-terminus.  In the 
autoinhibited form of ABL kinase, the C-terminus adopts a bent conformation, allowing the SH-
2 and SH-3 domains to close against the adjacent kinase face250.  Ligands binding to this site can 
act to stabilize the autoinhibited form of ABL (eg. GNF-2, PDB:3K5V)251, or may block bending of 
the helix to stabilize the active conformation (eg. DPH, PDB:3PYY)252.  Both allosteric activators 
and inhibitors occupy the myristate binding site, shown in dark blue in Figure 6.4.  Activators 
form additional interactions to the left of this site, which effectively blocks helix bending.  These 
additional interactions are replicated in the MixMD simulations, and correspond to the small, 




Figure 6.4: Cluster ranking by total occupancy for ABL kinase.  The active site ligand B91 
(PDB:3KFA)235 and allosteric ligand (myristate, PDB:1OPJ)250 are shown for reference.  The top 
two sites for each solvent set are shown as dark blue clusters, with the total occupancy within 
these clusters given in bold.  In every case, ranking by total occupancy identifies the active and 
allosteric sites as the highest ranked sites.  The boxplot shows the distribution of total 
occupancies for each cluster and solvent set.  The top two sites (corresponding to the active 
and allosteric sites) are noticeably higher in occupancy than the remaining clusters (light blue). 
Solo Combo A Combo B 











Androgen Receptor (AR)  
Androgen receptor (AR) is a soluble steroid-type protein that acts as an intracellular 
transcription factor253.  AR is stimulated by androgens (e.g., testosterone and 5α-
dihydrotestosterone) which bind to the active site and regulate gene expression for male sexual 
characteristics.  Both agonists and antagonists of AR have been developed to treat conditions 
such as hypogonadism and prostate cancer253.  As shown in Figure 6.5, ranking by total 
occupancy from MixMD simulations successfully identifies the active site as the top ranked site 
in all three solvent sets.   
 
AR also contains two allosteric sites, as shown in Figure 6.5.  Ligands binding to these 
sites alter the receptor’s conformation, and subsequently, its ability to bind to steroid receptor 
coactivator 2-3(SRC2-3)254.  The inability to bind to SRC2-3 hinders the receptor’s functionality, 
which ultimately diminishes the androgen response. These allosteric sites were identified in all 
three sets of simulations, but the ranking differed depending on the solvent set used.  In the 
solo and solvent combination A simulations, the active site and two allosteric sites were the top 
three ranked sites.  In the simulations of solvent combination B, the active site was ranked as 
number 1, but the two allosteric sites were ranked lower than one site that is a crystal packing 
interface.  Comparing the distribution of occupancies among clusters, this discrepancy might be 
due to the smaller number of individual simulations for solvent combination B relative to the 
other solvent combinations.  For each solvent set, 10 independent simulations of 20 ns are 
performed per solvent mixture.  This results in 50 simulations (not including charged probes) 
for the solo simulations, 30 for solvent combination A, and 20 for solvent combination B.  
Averaging over a larger number of simulations might better distinguish functional binding sites 




Figure 6.5: Cluster ranking by total occupancy for androgen receptor.  The top ranked sites by 
occupancy are shown in dark blue, with the total occupancies for these clusters in bold.  All 
other clusters are shown in light blue.  Active (PDB:3V4A, PK1)255 and allosteric (PDB:2PIU,4HY 
and PDB:2PIX, FLF)254 ligands are shown for reference.   The SRC-2 coactivator peptide is shown 
in magenta (PDB:2QPY)254.  The active site is the top ranked site in all cases.  In the solo and 
solvent combination A simulations, the two allosteric sites are the next highest ranked sites.  
However, in solvent combination B the total occupancies for the remaining sites are close 
together, making it difficult to discern the allosteric sites from ranking alone.   
 
 




















 BACE is responsible for cleavage of β-amyloid precursor protein256.  The active site of 
BACE is a large cleft, containing a number of known subsites involved in ligand recognition257-
259.  Ligands do not have to make all of these interactions however, and effective ligands have 
been developed that bind within only a small region of the overall active site.  For example, 
LY2811376 binds BACE with nanomolar affinity by engaging the catalytic aspartates and S1 and 
S3 subsites, and leads to decreased levels of Aβ  in animals and humans260.  MixMD simulations 
correctly identify these subsites, showing the highest levels of probe occupancy within the 
region occupied by LY2811376.  As shown in Figure 6.6, MixMD identifies the active site cleft as 
the highest ranked site for every solvent set tested, though the spread of the clusters differs.  
The cluster from the solo simulations spans the largest area, with probe occupancy extending 
across the binding cleft.  In the solvent combination A and B simulations, a smaller region is 
mapped, but this smaller region corresponds to the portion of the active-site known to be 
targetable by small, high-affinity inhibitors.   
 
Dihydrofolate Reductase 
Dihydrofolate reductase (DHFR) is an enzyme that catalyzes the transformation of 
dihydrofolate to tetrahydrofolate, which is utilized for purine and thymidylate synthesis.  Since 
DHFR is the sole source of tetrahydrofolate, DHFR is a common therapeutic target for many 
antibiotics, autoimmune disorders, and cancers261.  As shown in Figure 6.7, MixMD correctly 
identifies the active site as the top-ranked site for every solvent mixture.  All ligands binding 
within the active-site of DHFR occupy a T-shaped cleft, which is identified as the most-highly 
occupied site in our simulations.  Some ligands extend beyond this core area to make additional 
interactions.  For example, methotrexate contains two carboxylate groups that bind at the very 
edge of the active-site region.  Identification of binding sites was based on neutral probe 
occupancy, so these sites are not visible in Figure 6.7, but are seen as local maxima of acetate in 
Figure 6.11.  This demonstrates the ability of MixMD to correctly identify the core active-site 




Figure 6.6: BACE contains an extended binding cleft, with inhibitors 7H3 (PDB: 5TOL)262 and 5E7 
(PDB:5DQC)263 shown for reference.  In every case, MixMD correctly identifies the active site as 
the region with the highest total occupancy, shown in dark blue.  The total occupancies of the 
top clusters are given in bold, with the remaining clusters shown in light blue.  The top cluster 
identified from solvent combinations A and B is smaller than that of the solo simulations, but 
overlaps with the subsites of BACE that have been targeted by small, high-affinity ligands260.  
  











Figure 6.7: The active site of DHFR is correctly identified as the top-ranked site (shown in dark 
blue) across all three sets of MixMD simulations.  The total occupancy for the top sites is given 
in bold, with the remaining clusters shown in light blue.  Methotrexate and the ligand 1DN are 
shown for reference (PDB:1DF7, MTX and PDB:4LEK,1DN)176, 264. 
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Comparing Local Maxima across Solvent Types 
 As demonstrated in the preceding sections, binding sites can be identified for any of the 
tested solvent mixtures by considering the total occupancy within a region as mapped by all of 
the neutral probes.  In addition to binding site prediction, however, cosolvent simulations are 
also frequently used to identify specific interactions of individual probes for use in structure-
based drug design.  It is possible that solvents run in combination may compete with each other 
for binding, leading to fewer local sites being identified when solvent mixtures are used rather 
than solo cosolvent simulations.  It is also possible that there may be cooperativity between 
probes, leading to additional local maxima in adjacent regions that cannot be observed in solo 
runs. 
 
In order to compare the occupancies across the three sets of simulations, grid points 
were clustered using the mean shift algorithm implemented in MixMD Probeview to identify 
local maxima and surrounding points.  Comparing the local maxima of each solvent within the 
active-site region shows differences for some systems between simulations done with each 
probe individually and those of combined solvent mixtures.  For example, simulations of 
individual probes with ABL kinase identify local maxima for acetonitrile, imidazole, and 
isopropyl alcohol within the ATP binding portion (left side) of the active site (Figure 6.8).  In 
solvent combination B, these three solvents are run in combination.  In this case, acetonitrile 
and imidazole preferentially occupy this site over isopropyl alcohol.  This result does not appear 
to be an artifact of system setup, as none of the simulations (either solo or combined) were 
initiated with these probe molecules directly in the active site.  Moreover, the occupancies 
shown were generated by averaging over ten individual runs, each with different initial 
velocities set from a random number seed.  Therefore, it appears that the differences in 
observed occupancies at this site are due to a preference for acetonitrile and imidazole over 
isopropyl alcohol.  While acetonitrile and imidazole still capture the tendency for hydrophobic 
and aromatic interactions within this region, hydrogen bonding information that may have 
been captured by isopropyl alcohol is lost.  The observed preferential binding also has 
implications for calculating binding affinities based on probe occupancy.  Most cosolvent 
124 
 
methods use the Boltzmann relationship (Eq. 1) to calculate binding affinities based on the 
occupancy of probe molecules.  In the event of preferential binding by some probes for a 
specific site, the non-favored probes would have artificially low occupancies relative to the 
expected distribution, leading to errors in the calculated binding affinities.  Individual probe 
occupancy for every system is included in the supplementary information. 
Figure 6.8: Acetonitrile (orange), imidazole (purple), and isopropyl alcohol (blue) grid points 
with greater than 10% occupancy are shown for the active-site region of ABL kinase.  Local 
maxima are shown as spheres, with surrounding grid points shown.  Imatinib (PDB:1OPJ)250 and 
B91 (PDB:3KFA)235 are shown for reference.  In the solo simulations, acetonitrile, imidazole, and 
isopropyl alcohol were each run individually.  In the combined set B simulations, these three 
solvents were run in combination.  Relative to the solo simulations, the occupancy in the 
combined simulations identifies fewer local maxima.  For example, the isopropyl occupancy 
seen in the left portion of the ABL active site is absent in the combined solvent simulations, and 




MixMD Probeview successfully identified known active and allosteric sites based on 
total occupancy of all neutral probe solvents for all systems tested.  For each system, the top-
ranked site was either the active or allosteric site.  For systems having both active and allosteric 
sites, all of the additional known binding sites were ranked above the remaining sites, with the 
exception of one set of simulations for AR.  As an easy-to-use plugin for the popular 
Solo Solvent Combination B 
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visualization software PyMOL, we expect that MixMD Probeview will facilitate identification of 
binding sites from cosolvent simulations performed on a wide range of systems. 
 
 In addition to Probeview’s ability to find regions containing multiple probe molecules, it 
automates identification and ranking of local maxima of each individual probe solvent by 
occupancy.  Validation studies across both single and combined cosolvent mixtures allowed us 
to compare the differences in probe sampling across setup procedures.  While the top-ranked 
sites identify the allosteric and active sites for every setup procedure tested, the solo probe 
simulations show the greatest separation between real binding sites and the rest of the protein 
surface.  As shown in the boxplots in Figures 6.4-6.7, when a greater number of simulations are 
used for analysis, there is a greater separation in total occupancy between known binding sites 
and less meaningful sites on the protein surface.  However, the number of simulations that can 
be completed is limited by system size and computational resources.  Researchers have 
frequently turned to combined solvent mixtures to reduce the overall number of simulations 
that must be completed, which appears to be an acceptable choice when the end goal is 
binding site identification.  In regards to mapping all potential interactions within a binding site, 
the single probe simulations show the best ability to identify all potential interactions.  When 
combined simulations are used, not all local maxima found in solo probe simulations are seen.  
This is due to other probe types binding more favorably and displacing the other potential 
probes.  Therefore, when the goal of cosolvent simulations is to uncover all potential 





6.6 Supplementary Information 
Local Maxima for Simulations of ABL Kinase 
  

































Local Maxima for ABL Kinase, continued 
 
 
Figure 6.9: MixMD Probeview identified the active site as one of the highest ranked hotspots in 
ABL kinase.  Grid points with 10% or greater occupancy within the active site are shown for 
each solvent across the three MixMD setups.  Local maxima are shown as spheres, with 
surrounding grid points shown. Imatinib (PDB:1OPJ)250 and B91 (PDB:3KFA)235 are shown for 
reference.  Solo simulations accurately map the active site region, in agreement with known 
ligands.  Imidazole shows the most extensive mapping, with local maxima corresponding to 
aromatic portions of the ligands.  Solvent combinations A and B map the active site as well, but 
with fewer local maxima due to competition between solvents.  For example, in solvent 
combination B the N-methylacetamide occupancy seen within the left-hand side of the ligand in 
the solo simulations is displaced by pyrimidine.  This is consistent with ligand-bound structures 
which place aromatic rings at this site.  However, N-methylacetamide serves to identify 
hydrogen-bonding interactions, which may not be observed if the site is preferentially bound by 
other probe molecules. 






















Local Maxima of Androgen Receptor 
 
  

































Local Maxima of Androgen Receptor, continued 
 
Figure 6.10: MixMD Probeview identified the allosteric site as one of the highest ranked 
hotspots in androgen receptor.  Grid points with 10% or greater occupancy within this site are 
shown for each solvent across the three MixMD setups.   Local maxima are shown as spheres 
with surrounding grid points shown.  The active site of AR has minimal solvent exposure, and so 
differences in sampling between solvent sets are expected.  For this reason, we have shown 
local maxima for one of the allosteric sites.  The allosteric site ligand, flufenamic acid 
(PDB:2PIX)254, is shown for reference.  Solo simulations show each probe accurately maps the 
allosteric site ligand but with different occupancy strengths. Acetonitrile, isopropyl alcohol, and 
imidazole all had similar top occupancies for the solo simulations, with the two charged probes, 
methylammonium and acetate, having the least occupancy. Solvent combinations A and B 
mirror the solo simulations, but with a few noticeable differences. First, the charged probes fail 
to map the ligand at all in both solvent combos A and B. This is likely due to the site’s 
preference for other types of interactions, leading to the charged probe’s displacement.  
Isopropyl alcohol shows strong mapping in combination A, whereas in combination B it is 
displaced by acetonitrile and imidazole.  Visualizing the occupancy at lower levels reveals that 
isopropyl alcohol does sample this site, but is below the 10% cutoff. Additionally, acetonitrile 
has only one local maximum in solvent combination A, but two in combination B. 
 






















Local Maxima of BACE 
  

































Local Maxima of BACE, continued 
 
Figure 6.11: MixMD Probeview identified the active site as the highest ranked hotspots in BACE.  
Grid points with 10% or greater occupancy within the active site are shown for each solvent 
across the three MixMD setups.  Local maxima are shown as spheres, with surrounding grid 
points shown.  Ligands LY2811376 (PDB:4YBI, 4B2)260, 5E7 (PDB:5DQC)263, and 7H3 
(PDB:5TOL)262 are shown for reference.  Solo simulations show each probe accurately mapping 
the active site in agreement with known ligands. The neutral probes mapped the active site 
ligand extensively, while the two charged probes, acetate and methylammonium, had 
significantly less mapping within the site. Solvent combinations A and B mapped the active site 
similarly to the solo simulations, with the charged probes being the primary difference. In the 
combined simulations, the charged probes were displaced in favor of the neutral probes. 
 
  






















Local Maxima of DHFR 
 
  

































Local Maxima of DHFR, continued 
 
Figure 6.12: MixMD Probeview identified the active site as the highest ranked hotspots in 
DHFR.  Grid points with 10% or greater occupancy within the active site are shown for each 
solvent across the three MixMD setups, with the exception of the charged probes for which 
nearby sites are shown.  Local maxima are shown as spheres, with surrounding grid points 
shown.  Methotrexate and the ligand 1DN are shown for reference (PDB:1DF7, MTX and 
PDB:4LEK,1DN)176, 264.  Mapping of the binding site was similar between all solvents sets, 
although solvent combination B showed preferential binding to portions of the active-site by 
acetonitrile and isopropyl alcohol when run in combination with imidazole.  The charged probes 
indicate favorable interactions outside of the core region of the ligand, which mimic the 
interactions made by the carboxylate groups of methotrexate.   
 






















Chapter 7. Conclusions 
 
7.1 Overview and Significant Contributions
 
  The initial chapters of this thesis describe my research contributions aside from 
development of the mixed-solvent molecular dynamics (MixMD) method.  Chapter 2 details the 
research I completed in fulfillment of the Translational Research Education Certificate (TREC) 
through the Michigan Institute for Clinical & Health Research (MICHR).  This study focused on 
the spread of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli, which are 
becoming increasingly prevalent.  The CTX-M group of ESBLs have become the most common 
ESBL in E. coli102, and confer resistance to penicillins and 3rd generation cephalosporins101.  The 
spread of CTX-M containing E. coli is frequently attributed to sequence type 131 (ST131)107-109.  
However, studies of ST131 have primarily focused on resistant isolates, so the contributions of 
ST131 to the spread of ESBL-positive E. coli are difficult to determine.  Using a 2006-2008 
collection of 1,658 E. coli isolates from Gachon University Gil Medical Center in Korea114, we 
screened all viable ESBL-positive isolates and a representative sample of ESBL-negative isolates 
for ST131.  We found that among the tested isolates, there was no significant difference in the 
prevalence of ST131 between ESBL-positive (14% ST131) and -negative (9% ST131) groups265.  
However, ST131 isolates did have greater levels of antibiotic resistance than non-ST131 isolates 
and were more likely to contain CTX-M-1 groups ESBLs (including CTX-M-15) than other CTX-M 
types265.  Additionally, we compared ST131 classification based on two typing methods.  The 
gold-standard for sequence type assignment is multi-locus sequence typing, but this is time-
consuming and expensive.  Alternatively, the Clermont PCR-based method to identify O25b-
ST131111 or the Weissman method of fumC and fimH sequencing112 (CH-typing) may be used to 
identify ST131-positive isolates.  We found that many of the isolates that were classified as 
ST131 using the PCR-based method were non-ST131 using the sequencing-based CH-typing 
135 
 
method.  Furthermore, CH-typing results were in better agreement with previous studies of 
ST131 prevalence and antibiotic resistance phenotypes. This emphasizes the effect that 
different testing methods can have on reported prevalence values, which should be taken into 
consideration when comparing across studies. 
 
 Chapter 3 describes our work to better understand the dynamic motions of the H3K36 
histone methyltransferase NSD1.  The crystal structure of NSD1 has the important post-SET 
loop in an autoinhibitory position that blocks the entrance of the lysine binding channel137.  This 
loop must move in order for the methylation reaction to occur, but it is unclear from the crystal 
structure if the loop moves spontaneously in solution, or if its movement is induced upon 
interaction with the nucleosome.  A second autoinhibitory conformation is observed in the 
homologous protein ASH1L138, which has been shown by mutagenesis studies to be a critical 
component to enzymatic function142.  Using long timescale molecular dynamics studies, we 
simulated the post-SET loop of NSD1 in the crystallographic conformation and the ASH1L 
conformation.  During the simulations, NSD1 adopted three distinct, stable conformations: 1) 
resembling the starting NSD1 crystal structure, 2) resembling the ASH1L conformation, and 3) 
rotation of the post-SET loop resulting in widening of the peptide binding cleft266.  However, in 
every case the lysine binding channel was still blocked by the auto-inhibitory loop.  This 
suggests that additional interactions, likely with the nucleosome, are required to induce full 
movement of the autoinhibitory post-SET loop.  This finding is consistent with a previous study 
which combined short timescale MD with docking studies that positioned the nucleosomal DNA 
against the post-SET loop of NSD1137. 
 
 The remaining chapters and appendices focus on the continued development of the 
MixMD method.  Previous work by our group has primarily focused on validating proper 
parameters73 and simulation methods52.  They have also shown the ability to identify both 
active and allosteric sites for a number of target proteins51, 79.  These studies have verified the 
ability of MixMD to map biologically relevant sites, but do not provide a framework for using 
MixMD studies in a prospective manner for structure-based drug design.  Developments of 
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other cosolvent simulation techniques, including MDmix and SILCS, have likewise shown the 
ability to identify binding sites and reproduce favorable interaction sites63, 72.  A thorough 
overview of these methods is given in the introduction (Chapter 1).   
 
In the further development of MixMD, we first focused on mapping water within 
MixMD-identified binding sites (Chapter 4).  Cosolvent simulations are performed with a 
mixture of small molecular probes and water molecules, which directly compete for binding to 
the protein’s surface.  Previous studies have focused primarily on the behavior and binding of 
probe molecules rather than that of water, but MixMD simulations should reproduce favorable 
water binding sites equally as well as probe binding positions.  Moreover, the presence of 
competing probe molecules allows for the identification of sites which are more favorably 
occupied by water molecules rather than probes.  Using a test set of 10 systems, we performed 
over 1 µs of MD simulation for the apo structure of each system in the presence of either water 
or a mixture of water and one of five probe types.  This enabled us to determine which water 
sites were displaceable by specific probe types based on the occupancy level of water at each 
site.  Sites which are highly occupied by water even in the presence of probe molecules are 
considered to be conserved, while sites which are less frequently occupied by water are 
considered to be displaceable.  Comparison with ligand-bound structures for each of the 
systems showed a good ability to identify conserved, displaced, and selectively displaced water 
sites for each system.  These occupancy cutoff guidelines can be used to analyze water 
occupancy from cosolvent simulations, and to determine which sites should be included vs. 
displaced in structure-based drug design efforts. 
 
 Next, we turned our attention to the use of MixMD simulation results for the 
prospective screening of ligands (Chapter 5).  Using the inactive conformation of ABL kinase as a 
test system, we developed a series of scripts that allow for conversion of MixMD occupancy 
maps into pharmacophore models for use with the program MOE30.  First, the AmberTools 
cpptraj module157 is used to calculate the occupancy of each functional group within a probe 
molecule at every point on the protein’s surface over the course of the simulation.  This yields a 
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PDB-formatted file of xyz grid points and associated occupancies.  The DBSCAN clustering 
algorithm is used to cluster all grid points above a certain occupancy cutoff into groups.  Within 
each of these clusters, the highest occupancy point is selected to represent the pharmacophore 
feature’s center, and the RMSD of each point within the cluster to the center is calculated to 
determine the radius.  Overlapping clusters are consolidated into joint pharmacophore features 
when appropriate.  Lastly, the pharmacophore model is converted into MOE format to allow for 
virtual screening.  The performance of the pharmacophore model of ABL kinase was tested by 
screening all ligands that bind to the inactive form of ABL kinase230-240 and all decoys from the 
DUD-E ABL inactive set241 against the pharmacophore model.  The stringency of the 
pharmacophore model was varied by allowing partial matches of the pharmacophore features 
along with an RMSD multiplier to increase the size of the pharmacophore features.  In every 
model tested, a larger proportion of known active ligands than decoy compounds satisfied the 
pharmacophore model.  Work is currently underway to apply this method in a prospective 
manner to SRC kinase to screen for new allosteric inhibitors. 
 
 Lastly, we sought to simplify the MixMD analysis process in order to make it more 
accessible to users and facilitate its application to a greater number of systems (Chapter 6).  
Previously, MixMD analysis was done by loading the resulting probe occupancy maps into 
PyMOL and manually adjusting the occupancy level to identify high occupancy sites.  However, 
this process is time-consuming and provides a mostly qualitative ranking of occupancy.  To aid 
in the analysis of MixMD data, we developed a PyMOL100 plugin, which we call MixMD 
Probeview, to automate the ranking and identification of probe binding sites.  MixMD 
Probeview performs two analyses: first, it serves to identify local maxima from a single probe 
type and second, it identifies overlapping regions of occupancy from multiple probe types.  
Identified sites can then be ranked by either maximal or total occupancy.  MixMD Probeview 
was tested on four systems using occupancy results from three different cosolvent simulation 
procedures.  In each case, MixMD Probeview successfully identified known binding sites based 
on ranking by maximal occupancy. 
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 These developments provide a strong foundation upon which to build future MixMD 
studies.  The MixMD Probeview tool allows for a quantitative comparison of predicted binding 
sites, allowing for true ligand-binding sites to be distinguished from other easily desolvated 
regions.  The MixMD pharmacophore generation procedure allows for the occupancy maps 
within these identified regions to be converted into pharmacophore models.  This translates 
the MixMD occupancy maps into a suitable form so that they can be used to inform ligand 
discovery.  Finally, we showed that MixMD simulations can be used to determine a water 
molecule’s potential for displacement.  This makes it possible to improve the accuracy of 
predicted protein-ligand interactions by properly accounting for essential bridging water sites.  
Altogether, these improvements to the MixMD method are expected to enable its application 
in a prospective manner, thereby aiding in future drug discovery efforts. 
 
7.2 Future Directions 
 
 MixMD simulations are a promising means to identify important interactions on a 
protein’s surface, but they are limited in scope because of the computationally-intensive nature 
of the simulations.  Enhanced sampling methods may be used alongside MixMD simulations to 
avoid this limitation, by increasing the extent of sampling that can be achieved in a single 
simulation.  This would allow for bigger systems or systems with larger conformational changes 
to be simulated.  Appendix B explores this possibility, by considering the potential of the 
accelerated molecular dynamics method of McCammon20 to aid conformational sampling and 
promote convergence during the simulations.  Using HEWL as a test system, accelerated 
MixMD was found to cut the required simulation time in half relative to standard MixMD 
simulations.  In addition, aMixMD reduced the number of spurious sites that were identified.  
When applied to systems with known conformational changes, aMixMD was shown to promote 
conformational sampling.  However, the presence of probe molecules also hindered transitions 
by stabilizing intermediate states.  This prevented the full transition between conformational 
states, but probe molecules did identify sites that are known to be occupied in ligand-bound 
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structures.  These preliminary studies demonstrate the ability of accelerated MixMD to 
enhance sampling and decrease required computational time.  
  
Future developments could also focus on extending MixMD occupancy maps to be used 
directly for virtual screening.  The current pharmacophore generation procedure represents the 
MixMD occupancy maps as spheres.  While these models show reasonably good performance 
in virtual screening, it would be desirable to improve their specificity.  One way to achieve this 
would be to develop a virtual screening program that could use the occupancy maps directly.  
This would include greater shape information, allowing for a more fine-grained representation 
of the favorable interactions over that of spheres.  It would also be possible to incorporate a 
scoring mechanism into the virtual screening procedure.  In standard pharmacophore-based 
virtual screening, ligands are classified as either satisfying or not satisfying the pharmacophore 
model.  However, this does not take into account how well a ligand satisfies the model.  Since 
the MixMD occupancy maps describe the strength of the interaction at each point, it is possible 
to identify ligands that best satisfy the pharmacophore model over those that only marginally 
match the specific interactions.  This would allow for ligands that best match the 







Appendix A: Validation of MixMD Setup and Analysis Procedures 
 
Initial Probe Placement  
 The first Mixed-Solvent Molecular Dynamics (MixMD) studies relied on pre-equilibrated 
probe and water boxes at a 50%/50% w/w ratio52, 78, 79.  However, experimental studies of 
proteins are not typically performed with such high concentrations of organic solvent, making 
experimental validation of MixMD studies done at 50% concentration difficult.  Switching to a 
5%/95% v/v concentration of layered probe molecules and water allowed for identification of 
the same binding sites as studies done at 50%/50% w/w concentrations79, while ensuring that 
solvent concentrations did not exceed experimentally feasible values.  In the layered setup 
procedure, the crystal structure of the protein of interest is surrounded with a layer of small 
molecule probes, followed a box of water in a 5%/95% v/v ratio (Figure A.1).  A layered setup 
was chosen rather than pre-equilibrated boxes as this is the most efficient way of facilitating 
probe sampling at the protein surface.  Pre-equilibrated boxes with low probe concentrations 
would necessitate long simulation times for a sufficient number of probes to reach the protein’s 
surface, and even longer to allow sufficient sampling.  In the layered setup, probes are placed 
near the protein’s surface, with the relatively large quantity of surrounding water molecules 
effectively competing for binding to the protein’s surface during the simulation. 
Layer of Probes Layer of Water 
Figure A.1: The current MixMD procedure utilizes a layered cosolvent approach, where the 
crystal structure of the protein is surrounded with a layer of small molecule probes followed by 
a box of water molecules.  
142 
 
 Nevertheless, it is important to determine the most appropriate method of system 
setup to ensure that our simulations are effectively and efficiently exploring potential probe 
binding sites.  In the layered approach used in this thesis, the same starting structure is used to 
initiate each of the ten separate molecular dynamics simulations (ie. the probe and water 
molecules are in the same locations at the beginning of each simulation).  In the first step of a 
molecular dynamics simulation, each atom in the system must be given an initial random 
velocity.  The current procedure uses a unique random seed number (generated from the 
current time) for each simulation so that no two simulations are assigned the same initial 
velocities.  This ensures that although each starting structure is the same, the trajectories (and 
therefore the sampled probe positions) are not identical.  However, it is possible that using the 
same starting structures is biasing our simulations in some manner.   
 
To test this, we performed simulations using Hen Egg White Lysozyme (HEWL) as a test 
system.  MixMD simulations have been previously performed on HEWL and have successfully 
identified the main binding site as the site having the highest occupancy of probes during the 
simulation52.  Using the PACKMOL utility, pyrimidine probe molecules were randomly placed 
around the structure of HEWL (Figure A.2)267.  Ten separate starting structures were generated.  
No probe molecules were directly placed in the binding site, with the closest probe molecule 
positioned more than 4 Å away from the observed acetonitrile binding site (PDB: 2LYO)77.   
Figure A.2: Starting structures were generated using the PACKMOL utility to randomly 
place pyrimidine probe molecules around HEWL.  Ten such starting structures were 
generated, each shown in a different color.  This setup procedure resulted in varied 
probe positions, with minimal direct overlap of probe molecules. 
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 Simulations were carried out according to published protocols for 1.75 ns of 
equilibration and 20 ns of production MD per run51.  The last 10 ns of each individual trajectory 
were used for analysis.  Following alignment, the trajectories were overlaid with a 0.5 Å cubic 
grid, and the occupancy of probe molecules at every grid point was calculated separately for 
each trajectory.  To determine if the highest occupancy point successfully identified the active 
site, the resulting occupancy grids were normalized into units of standard deviations away from 
the mean (termed σ units), and visualized in PyMOL100.  In all but 1 of the trajectories, the 
active site of HEWL is identified as the most occupied site (Figure A.3, Table A.1).  This 
demonstrates that the active site is identified regardless of initial probe placement.  
Furthermore, using the same starting structures in each run but with random initial velocities 


















Figure A.3: Pyrimidine atomic occupancy during the last 10 ns 
of the simulation is shown contoured at 100 σ for each of the 
ten simulations.  The observed acetonitrile binding site (PDB: 
2LYO) is shown in green77.  In 9 out of 10 simulations, the 
acetonitrile binding site (active site) is the most occupied 
position.  Run 6 is the exception, which shows the highest 
occupancy site outside of the active-site region. 
1 3 2 
7 9 8 













Table A.1: The highest occupancy and corresponding location in each of the ten simulations is 
given.  The active-site region is indicated by the green acetonitrile in Figure A.3. 
 
Adequate Solvent Sampling 
 A second consideration in the MixMD protocol is the need to ensure adequate sampling.  
This goal is actually two-fold, in that protein and solvent sampling must both be adequate.  
Prior work has shown the protein conformational sampling within the standard MixMD 
protocol to be sufficient, so we turn our focus to the sampling of probe and water positions52.  
Previous MixMD studies have used either the last 5 or 10 ns of a 20 ns production run for 
analysis of probe occupancy51, 79.  This allows for the first 10-15 ns to serve as an extended 
“equilibration”, or sampling period, with the goal of minimizing biases from the initial probe 
placement while allowing for sufficient sampling of potential probe locations.  However, this 
10-15ns time period was chosen somewhat arbitrarily, and it is not clear if shorter time periods 
will yield equivalent results.  Alternatively, simulation parameters can also be altered to speed 
up solvent sampling.  In order to test for sufficient probe sampling in the context of MixMD, we 
have compared two sets of simulations.  First, standard MixMD simulations of HEWL in 
pyrimidine and secondly, MixMD simulations of HEWL in pyrimidine with non-hydrogen solvent 
atoms reassigned a new mass of half the original.  These “half-mass” simulations are expected 
to increase solvent sampling, by allowing for faster solvent motions over the course of the 
simulation.  Ten simulations of HEWL in pyrimidine and water were performed for both the 
Run Highest Probe Occupancy Location 
1 348 σ active site 
2 385  σ active site 
3 174  σ active site 
4 399  σ active site 
5 413  σ active site 
6 170  σ other 
7 390  σ active site 
8 346  σ active site 
9 362  σ active site 
10 350  σ active site 
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standard MixMD and “half-mass” setups following standard protocol51.  The resulting 
trajectories were aligned, and overlaid with a grid.  Segments of 2.5ns from each group of 
trajectories were then analyzed to identify the position of maximal occupancy in each case 
(Figure A.4).  The occupancy is shown as a fraction of the maximal occupancy, ranging from 0 to 
1.  A value of 1 indicates that the site has the highest occupancy for the tested time period.  
Values less than 1 are proportional to the maximum value in each segment.  The occupancy at 
the location of the main spurious site in the standard MixMD simulations is also shown for 
reference on the graph of the “half-mass” simulations.   
 
Standard MixMD Simulations 
“Half-mass” MixMD Simulations 
Figure A.4: Total occupancy for pyrimidine across all 10 simulations is shown for each portion 
of the trajectories.  For easier comparison, the occupancy shown is the fraction of the 
maximum occupancy.   For reference, the occupancy of the primary spurious site for the 
standard MixMD simulations is also shown for the “half-mass” simulations.  
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 Figure A.5 shows the density from the standard MixMD simulations for the first and last 
2.5 ns of the 10 trajectories and for the 2.5-5ns portion of the “half-mass” trajectories.  Initial 
portions of the trajectory incorrectly identify a spurious site (circled) as the top-ranked site.  
After approximately 10 ns (Figure A.4), the active site is correctly identified as the top-ranked 
site in the standard MixMD simulations.  Interestingly, the “half-mass” simulations correctly 
identify the active site of HEWL at earlier time periods.  From 2.5 ns onwards, the majority of 
time periods have the maximum occupancy within the HEWL active-site.   
 
 
An important consideration when using altered solvent parameters is the potential to 
visit unrealistic conformational states.  Lighter solvent masses may allow for faster and 
Figure A.5: Left) Pyrimidine atomic occupancy from the first 2.5 ns of all 10 standard 
MixMD trajectories ranks the spurious site (circled) higher than the active site 
(Acetonitrile from PDB:2LYO, green stick).  Right) Pyrimidine occupancy from the last 2.5 
ns of the standard simulations identifies the active site as the top ranked site.  Bottom) 
The 2.5-5 ns time period of the “half-mass” simulations correctly identifies the active 
site.  All figures are contoured at 100 σ.   
0-2.5 ns Standard MixMD 17.5-20 ns Standard MixMD 
2.5-5 ns Half-mass MixMD 
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potentially larger protein motions than would be observed with standard solvent parameters.  
In the present simulations, no such behavior was observed, but this may be a possibility with 
longer simulations or different solvents.  As shown in Figure A.6, the RMSD of the protein 
backbone relative to the crystal structure over the course of the production portion of the 
trajectory is in the 0.5 to 1.5 Å range for both the standard and “half-mass” simulations.  Such 
small values indicate only minor deviation from the starting structure, and are not indicative of 
unrealistic conformational sampling.  Therefore, using “half-mass” solvent parameters are a 
viable way to increase the efficiency of MixMD simulations.  This is possible due to the decrease 
in required simulation time to achieve sufficiently converged results.  However, the standard 
MixMD analysis procedure using the last 5-10 ns of a 20 ns total trajectory also achieves 




Figure A.6: The backbone RMSD relative to the crystal structure of the production portion of 
the 10 standard and 10 “half-mass” simulations is shown.  Both sets of simulations deviate 
from the starting structure to a similar extent.  RMSD values of 2 Å or less are typically 
indicative of normal conformational sampling within an MD simulation.  
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Appendix B: Exploring the Potential of Accelerated Mixed-Solvent Molecular Dynamics 





 Molecular dynamics simulations are routinely used to study conformational changes in 
proteins, but the extent of such studies are limited by computational resources.  In order to 
generate a sufficient amount of data to yield insight into the dynamics of a protein, a large 
number of simulations must be completed.  This can be extremely difficult, especially in the 
case of large systems or for systems with conformational changes that occur on long 
timescales.  Enhanced sampling methods, including accelerated molecular dynamics (aMD), are 
a promising means of bypassing this limitation by increasing the efficiency of conformational 
sampling20.  In aMD, the extent of sampling is increased by altering the energy landscape.   As 
shown in Figure B.1 (reproduced from Figure 1.2 in the introduction), when the potential 
energy is above a predetermined energy cutoff, the system evolves according to the original 
energy surface.  However, when the energy dips below this cutoff value (E), a modified 
potential (V(r) + ΔV(r)) is used that decreases the depth of the well: 
 
𝑉𝑉∗(𝑟𝑟) = �
𝑉𝑉(𝑟𝑟),                       𝑉𝑉(𝑟𝑟) ≥ 𝐸𝐸
𝑉𝑉(𝑟𝑟) + ∆𝑉𝑉(𝑟𝑟),       𝑉𝑉(𝑟𝑟) < 𝐸𝐸
  (1)   
 
By raising the bottom of the well, the energy barrier between states is effectively decreased, 




Figure B.1: In the accelerated molecular dynamics method of McCammon20, a boost is added to 
the potential energy when the potential energy is below a specified energy cutoff, which 
effectively decreases the barrier between related conformations.  In regions below the energy 
cutoff, the system evolves according to the modified, “boosted” potential energy surface, 
depicted as the gray dashed line.  
  
The ability of accelerated dynamics to enhance conformational sampling is especially 
appealing for structure-based drug design pursuits, which require adequate conformational 
sampling in order to predict which conformations may be targeted by bound ligands.  aMD has 
previously been used in combination with cosolvent simulation techniques to generate 
ensembles of protein structures for docking of known small molecule inhibitors to Bcl-2268.  The 
ensembles of structures derived from cosolvent aMD simulations resulted in better scores than 
ensembles from either experimental crystal structures or conventional MD simulations268.  This 
increase in performance was attributed to the superior conformational sampling obtained with 
the combined cosolvent/aMD method.  While this study focused on the generation of 
ensembles of structures for subsequent docking, cosolvent simulations can be used directly to 
predict binding sites and identify favorable interactions on the protein’s surface.  MixMD, the 
cosolvent simulation method developed by our group, has shown an exceptional ability to 
identify binding sites across a wide range of targets51.  However, MixMD simulations require a 
large number of simulations to ensure adequate sampling of probe and water molecules.  
Furthermore, while some small-scale conformational changes are observed in standard MixMD 
simulations (such as the bending of the C-terminus in ABL kinase), larger-scale changes such as 












molecular dynamics with MixMD (aMixMD) to enhance conformational sampling, we have 




Prior to aMD simulations, systems must be heated and equilibrated to the desired 
temperature.  Hen Egg White Lysozyme (HEWL, PDB:2LYO77), USP9x deubiquitinase 
(unpublished crystal structure from Matthew Young, University of Michigan), and ABL Kinase 
(PDB:1M52269) were selected as test systems.  Crystallographic waters were removed for HEWL 
and ABL, but were retained for USP9x deubiquitinase.  Hydrogens were added and side chain 
positions optimized with MolProbity182 and MOE30.  The systems were surrounded in a layer of 
probe molecules (acetonitrile, acetate/methylammonium, isopropyl alcohol, N-
methylacetamide, or pyrimidine)51, 73 followed by a layer of TIP3P water155 in a 5%/95% v/v 
ratio.  Sodium or chloride ions were added to achieve an overall neutral system.  System setup 
was performed in tleap with the FF99SB force field247.  Following setup, the systems were 
minimized for 5000 steps with restraints on the protein and 2500 steps without restraints.  The 
systems were then heated to 300 K at constant volume for 80 ps with a 2 fs time step and 
restraints of 10 kcal/mol-Å2 on the protein.  Once the correct temperature was reached, the 
systems were equilibrated for 350 ps at constant pressure while the restraints were gradually 
removed.  A final equilibration step of 1.4 ns without restraints was completed, which was used 
to calculate the average energy values for the aMD boost levels.  Production runs were carried 
out for a minimum of 20 ns with the GPU enabled version of PMEMD at constant pressure and 
at 300 K using the Andersen thermostat 185-187.  Accelerated molecular dynamics has been 
implemented in AMBER, and follows standard simulation procedures with the exception of four 
additional parameters which control the level of boost applied to the system. 
 
 In order to identify appropriate aMD parameters, HEWL was simulated at varying boost 
levels.  HEWL is known to be extremely stable, and so it served as a guide for setting 
appropriate limits of boosting for MixMD simulations.  Boost levels that lead to unfolding in 
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HEWL are likely to be too great for realistic conformational sampling of other proteins.  The 








  (2)   
 
where a modified potential ΔV(r) is used to boost both the overall potential and torsional 
terms22.  This dual form was introduced to focus the enhanced sampling on the protein while 
preserving local water structure22.  The level of boost is controlled by two parameters, a 
threshold value (Ethresh) below which to apply the boost, and a parameter α that controls the 
strength of the boost.  Ethresh and α are independently set for the potential and dihedral terms, 
yielding four parameters which can be adjusted to control the level of accelerated sampling.  In 
order to determine the appropriate levels of boost for use in cosolvent simulations, we tested 
several different combinations of αpot and Ethresh-pot.  To avoid excessive boosting to the solvent, 
we have focused our adjustments on the torsional terms.  Across each level of boost, the values 
of Ethresh-pot and αpot were unchanged, and were given by the following equation: 
 
𝐸𝐸𝑡𝑡ℎ𝑒𝑒𝑎𝑎𝑏𝑏ℎ−𝑜𝑜𝑏𝑏𝑡𝑡𝑎𝑎𝑏𝑏𝑡𝑡𝑑𝑑𝑎𝑎𝑎𝑎 = 𝐴𝐴𝐴𝐴𝐴𝐴.𝑃𝑃𝑃𝑃𝑃𝑃𝑒𝑒𝑛𝑛𝑃𝑃𝑃𝑃𝑃𝑃𝑇𝑇 𝐸𝐸𝑛𝑛𝑒𝑒𝑟𝑟𝐴𝐴𝑃𝑃 + 𝛼𝛼𝑃𝑃𝑏𝑏𝑡𝑡𝑎𝑎𝑏𝑏𝑡𝑡𝑑𝑑𝑎𝑎𝑎𝑎 
 𝛼𝛼𝑃𝑃𝑏𝑏𝑡𝑡𝑎𝑎𝑏𝑏𝑡𝑡𝑑𝑑𝑎𝑎𝑎𝑎 =  𝑁𝑁𝑎𝑎𝑡𝑡𝑏𝑏𝑎𝑎 ∗ 0.2     (3)  
   
where Natom is the total number of atoms in the system.  This equation is given in the AMBER 
manual, and it is suggested to give acceptable performance for most users.   
 
The recommended values for the dihedral threshold and boosting parameter αD are less 
clear-cut.  The recommended starting dihedral bias αD is 1/5th of the number of residues, 
multiplied by the approximate energy contribution per degree of freedom (3.5 
kcal/mol/residue).  In order to account for the presence of probe molecules in our system, we 
tested several levels of boost, including only protein atoms in the calculation, or both the 
number of protein residues and the number of probe molecules.  In addition, the level of boost 
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can also be adjusted by adding multiples of αD to the dihedral energy threshold.  This gave us 
four potential boost levels, given below: 
 
Level 1 
𝐸𝐸𝑡𝑡ℎ𝑒𝑒𝑎𝑎𝑏𝑏ℎ−𝛼𝛼 = 𝐴𝐴𝐴𝐴𝐴𝐴.𝐷𝐷𝑃𝑃ℎ𝑒𝑒𝑒𝑒𝑟𝑟𝑃𝑃𝑇𝑇 𝐸𝐸𝑛𝑛𝑒𝑒𝑟𝑟𝐴𝐴𝑃𝑃 +  3.5 ∗  𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 
𝛼𝛼𝛼𝛼 = 0.2 ∗ 3.5 ∗ 𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 
 
Level 2 




𝛼𝛼𝛼𝛼 = 0.2 ∗ 3.5 ∗ �





𝐸𝐸𝑡𝑡ℎ𝑒𝑒𝑎𝑎𝑏𝑏ℎ−𝛼𝛼 = 𝐴𝐴𝐴𝐴𝐴𝐴.𝐷𝐷𝑃𝑃ℎ𝑒𝑒𝑒𝑒𝑟𝑟𝑃𝑃𝑇𝑇 𝐸𝐸𝑛𝑛𝑒𝑒𝑟𝑟𝐴𝐴𝑃𝑃 +  3.5 ∗  𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 + 4 ∗  𝛼𝛼𝛼𝛼 
𝛼𝛼𝛼𝛼 = 0.2 ∗ 3.5 ∗ 𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 
 
Level 4 
𝐸𝐸𝑡𝑡ℎ𝑒𝑒𝑎𝑎𝑏𝑏ℎ−𝛼𝛼 = 𝐴𝐴𝐴𝐴𝐴𝐴.𝐷𝐷𝑃𝑃ℎ𝑒𝑒𝑒𝑒𝑟𝑟𝑃𝑃𝑇𝑇 𝐸𝐸𝑛𝑛𝑒𝑒𝑟𝑟𝐴𝐴𝑃𝑃 +  3.5 ∗  (𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 +  𝑁𝑁𝑃𝑃𝑅𝑅𝑂𝑂𝐵𝐵𝐸𝐸) +  4 ∗  𝛼𝛼𝛼𝛼 
𝛼𝛼𝛼𝛼 = 0.2 ∗ 3.5 ∗ (𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 +  𝑁𝑁𝑃𝑃𝑅𝑅𝑂𝑂𝐵𝐵𝐸𝐸) 
 
Higher Ethresh-D values will result in higher levels of boost, while higher αD values result in a 
modified potential that is closer to the original potential due to their presence in the 
denominator of Equation 2.  Each of these boosting levels was tested on HEWL in order to 





 Ten simulations of 20 ns were completed for each probe type with standard molecular 
dynamics (no boost) and accelerated MD with each of the four boost levels.  In order to assess 
the stability of HEWL at each level of accelerated sampling, the RMSD relative to the starting 
crystal structure was calculated over the course of each of the trajectories.  A single RMSD 
summary statistic was generated by averaging over the RMSD vs. time data for each set of 
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simulations.  These values are shown in Table B.1.  As expected, the standard MD simulations 
show the smallest mean RMSD values.  Typically, simulations which deviate by less than 2 Å 
relative to the crystal structure are considered to be stable.  Accelerated MD simulations using 
boost levels 1-3 show higher RMSD values compared to the standard MD simulations, but are 
within the expected range.  On the other hand, aMD simulations of HEWL at boost level 4 give 
mean RMSD values greater than 2 Å, indicating unrealistic conformational sampling.  HEWL is 
an extremely stable protein, containing four disulfide bonds.  There are no expected 
conformational changes in HEWL, and so large RMSD values are indicative of excessive 
sampling induced by aMD.  
 
Mean RMSD (Å) of HEWL Relative to Crystal Structure over Ten Sets of Simulations 
 
Pyrimidine Acetonitrile Isopropyl Alcohol 
Acetate/ 
Methyl-Ammonium N-methylacetamide 
MD 0.89  ±  0.16 0.87  ±  0.14 0.91  ±  0.18 0.84  ±  0.14 0.87  ±  0.12 
aMD 1 1.06  ±  0.23 1.22  ±  0.30 1.19  ±  0.29 1.23  ±  0.35 1.18  ±  0.31 
aMD 2 1.09  ±  0.33 1.69  ±  0.56 1.15  ±  0.29 1.81  ±  0.47 1.11  ±  0.27 
aMD 3 1.18  ±  0.27 1.97  ±  0.46 1.47  ±  0.38 1.71  ±  0.47 1.33  ±  0.34 
aMD 4 1.61  ±  0.38 3.51  ±  0.90 2.74  ±  0.71 3.65  ±  1.12 1.92  ±  0.49 
Table B.1: Ten sets of 20 ns simulations were completed for HEWL with either standard or 
accelerated MixMD with boost levels 1-4.  The mean RMSD (Å) ± the standard deviation is 
shown.  These values were calculated by averaging the RMSD relative to the crystal structure 
over the course of each of the simulations.  Only the highest level of boost exceeds the 2 Å limit 
that is typically used to classify a simulation as stable.   
 
 Once appropriate boosting levels have been established, the ability of accelerated 
molecular dynamics to enhance sampling efficiency can be assessed.  For each system and 
probe type, the current MixMD protocol requires ten simulations of 20 ns, yet only the last 5-10 
ns of each simulation are used for analysis.  aMD could potentially reduce the length of 
simulations required by enhancing conformational sampling of the protein and solvent 
molecules.   To test this, we have compared the mapping of the binding site in HEWL between 
standard MD and accelerated MD simulations.  The center-of-mass occupancy over the 5-10ns 
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portion of the aMixMD boost level 2 simulations and 5-10ns and 10-20ns portion of the 
standard MixMD simulations was calculated using an in-house modified version of the 
cpptraj157 utility in AmberTools187.  Using the MixMD Probeview tool, high occupancy clusters 
were identified and ranked based on the total occupancy contained within each cluster.  HEWL 
contains a single ligand binding site at its center.  As shown in Figure B.2, the active site is 
identified as the site with the highest total occupancy for each portion of the trajectory.  
However, the aMixMD simulations showed a much larger difference in occupancy between the 
top ranked cluster and other spurious sites (Figure B.3).  For example, the top ranked cluster 
from the 5-10ns portion of the boost level 2 aMixMD trajectories had an occupancy that was 
~19 times greater than the next highest ranked site, compared to a factor of 2.6 between the 
first and second ranked sites in the 10-20ns portion of the standard MixMD simulations.  The 
same starting structures were used for both standard and accelerated MD runs, with the level 
of boost being the only difference between simulations.  These differences in observed 
occupancy can therefore be attributed to the additional boost provided by aMD, which 
promotes more efficient sampling between states and thus likely leads to faster convergence.  
Boost level 2 was chosen for use in subsequent studies as it allowed for enhanced convergence 
at a moderate boost level that accounted for both the number of protein residues and the 
number of probe molecules without excessive sampling.  Therefore, while the standard MixMD 
procedures correctly identify the active site, using aMD with moderate boost levels enhances 




Figure B.2: The highest occupied site identified using the MixMD Probeview tool is shown in 
dark blue for each of the simulations, with lower occupancy clusters shown in light blue. 
aMixMD Boost Level 2: 5-10ns 
MixMD: 5-10ns MixMD: 10-20ns 
aMixMD Boost Level 2: 10-20ns 
aMixMD Boost Level 1: 5-10ns aMixMD Boost Level 1: 10-20ns 




Figure B.3: The graph shows the total occupancy for each cluster in the aMixMD and standard 
MixMD simulations.  The top-ranked site is shown in dark blue, while all other sites are shown 
in gray.  Relative to the standard MixMD simulations, the accelerated MixMD simulations 
identified fewer spurious sites.  As shown in the graph, the difference in total occupancy 
between the active site and other spurious sites is much larger in the aMixMD simulations, 



























 Ubiquitination of proteins plays an important role in regulating cellular processes270.  
Mediated by three major classes of enzymes, which have been termed the “readers”, “writers”, 
and “erasers”, the number and linkage of ubiquitin molecules controls the fate of the target 
protein270.  For example, lysine 48 linked ubiquitin chains signal for proteasome-mediated 
degradation of the protein they are attached to271.  Deubiquitinases have the opposite effect, 
by removing ubiquitin molecules from the target protein and thereby blocking subsequent 
degradation.  Within the cell, these enzymes promote a balance between degradation and 
maintenance of necessary proteins.  USP9x is one such deubiquitinase enzyme that is capable 
of cleaving several types of ubiquitin linkages272, thereby promoting the survival of the target 
proteins.  Deregulation of USP9x is implicated in a number of disease states, including cancer272.  
For example, MCL1 promotes survival of cells and is overexpressed in several types of cancer.  
MCL1 would normally be targeted for degradation by the presence of K48 linked ubiquitin 
chains, but co-occurring overexpression of USP9x upsets this balance, and promotes the 
maintenance of MCL1273.  This balance can be restored by knockdown of USP9x in cell lines, 
which results in decreased levels of MCL1273.  Inhibition of deubiquitinase with the small 
molecule WP1130 also results in decreased MCL-1 levels and anti-proliferation of tumor cells274, 
demonstrating the potential of deubiquitinases as a therapeutic target275.  
 
 One of the main challenges in targeting deubiquitinases is the need to ensure specificity 
of the inhibitors.  There are almost 100 deubiquitinases which all bind ubiquitin molecules, 
though with differing specificity for ubiquitin chain types276.  As each of the deubiquitinases 
plays a specific role within the cell, it is imperative that inhibitors are sufficiently selective.  In 
order to identify regions on USP9x that may be targeted by inhibitors, we have performed 
MixMD simulations.  Starting from the apo structure of USP9x, ten simulations of 20 ns were 
completed for each of the probes types with either standard MixMD or accelerated MixMD 
with boost level 2.  Following simulation, the trajectories were aligned and the occupancies 
over the protein’s surface were calculated.  MixMD Probeview was used to rank regions based 
on total probe occupancy over the analyzed time period.  As shown in Figure B.4, the 
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simulations identified the active-site region, as well as two main areas of the deubiquitin-
ubiquitin interface as binding hotspots.  Site 2 for the 5-10ns portion of the aMixMD 
trajectories is situated near the site of K48 in ubiquitin bound structures.  K48 is one of the 
linkage sites for the formation of ubiquitin chains and K48-linked chains have been shown to be 
cleavable by USP9x277.  USP9x has been shown to yield polyubiquitin species (chains of 2+ 
linked ubiquitins) upon cleavage, indicating that it is capable of binding to and cleaving within 
the center of a ubiquitin chain rather than just the most distal ubiquitin molecule278.  Therefore, 
this site likely corresponds to protein-protein interactions that would occur between ubiquitin 
chains and USP9x upon binding.  The second site, found in both the standard MixMD and 
accelerated MixMD simulations also occurs at the ubiquitin-deubiquitinase interface.  Studies 
by Ernst and coworkers aimed at producing ubiquitin variants with increased selectivity for 
specific deubiquitinases found that mutations at this site (among others) were capable of 
increasing affinity for selected deubiquitinases279.  As MixMD occupancy is known to identify 
binding hotspots, this may represent a potential site that could be targeted to block the 





Figure B.4: The top-3 ranked sites by occupancy for the standard MixMD and accelerated 
MixMD simulations are shown as colored surfaces.  Ubiquitin is shown in green for reference, 
but was not included in the simulations.  











 Kinases undergo a number of conformational changes between active and inactive 
states1.  The most well-known and frequently studied conformational change is undoubtedly 
the DFG-flip.  In the active state of kinases, the aspartate of the DFG-motif is oriented into the 
ATP-binding site (“DFG-in”) where it forms important interactions with one of the magnesium 
ions1.  In the inactive state, the activation loop reorients, flipping the aspartate away from the 
active-site and positioning the phenylalanine in its place.  Inhibitors targeting the active site 
region of kinases are classified as type I or type II inhibitors, depending on which conformation 
they bind to280.  Type I inhibitors bind to the active conformation, while type II inhibitors bind to 
the inactive conformation280.  A number of molecular dynamics studies have been performed 
on kinases with the goal of capturing this conformational change281-284.  However, standard 
molecular dynamics simulations are not sufficient to observe the DFG-flip, leading researchers 
to utilize enhanced sampling techniques in order to simulate this conformational change.  As 
these different conformations of kinases may be stabilized by inhibitors, enhanced sampling 
techniques could potentially be combined with cosolvent simulations in order to 
simultaneously capture conformational changes while determining favorable interactions that 
may be targeted by inhibitors.   
 
In order to explore this possibility, we have performed aMixMD simulations at multiple 
boost levels starting from the DFG-out conformation.  The proportion of observed DFG-out and 
DFG-in states is influenced by the protonation state of the aspartate residue of the DFG 
motif282.  Protonation of this residue favors the DFG-out conformation while deprotonation 
favors DFG-in282.  Therefore, the simulations were performed with a deprotonated Asp which 
should promote transitions to the DFG-in state.  The conformational transition between the 
DFG-out and DFG-in states was assessed using the metrics developed by Meng et al281.  As 
shown in Figure B.5, the dihedral angles between the alanine proceeding the DFG-motif and 
either the aspartate or phenylalanine of the DFG-motif characterize two low-energy states 
corresponding to the DFG-out and DFG-in conformations. 
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Figure B.5: Adapted from Meng et al281.  The transition between DFG-in and DFG-out states can 
be assessed using dihedral angles measured from the preceding alanine to the aspartate of the 
DFG-motif and from the preceding alanine to the phenylalanine of the DFG-motif.   
 
 In order to determine what level of boosting is necessary to induce conformational 
changes in ABL kinase, several boost levels were tested.  Simulations were first performed for 
ten runs of 20 ns for each of the five solvent types using accelerated MD with boost level 2, 
yielding 1 µs of total simulation time.  This level of boost resulted in conformational sampling 
that was very close to the initial conformation, as shown in graph A of Figure B.6.  Performing 
the same number of simulations using boost level 3 resulted in additional sampling (graph B of 
Figure B.6), but again no transitions to the DFG-in state were observed.  aMixMD simulations at 
boost level 4 caused excessive conformational changes in HEWL, but it is possible that these 
same boost levels may be suitable to drive sampling in proteins with known or expected 
conformational changes.  Using the original boost level 4, and a modified version, level 4* given 
below, long timescale simulations of ABL were performed. 
 
Level 4* 
𝐸𝐸𝑡𝑡ℎ𝑒𝑒𝑎𝑎𝑏𝑏ℎ−𝛼𝛼 = 𝐴𝐴𝐴𝐴𝐴𝐴.𝐷𝐷𝑃𝑃ℎ𝑒𝑒𝑒𝑒𝑟𝑟𝑃𝑃𝑇𝑇 𝐸𝐸𝑛𝑛𝑒𝑒𝑟𝑟𝐴𝐴𝑃𝑃 +  3.5 ∗  (𝑁𝑁𝑅𝑅𝐸𝐸𝑆𝑆 + 𝑁𝑁𝑃𝑃𝑅𝑅𝑂𝑂𝐵𝐵𝐸𝐸) 
 
Level 4* results in a smaller amount of boost compared to the original level 4, and was 
introduced in order to reduce the possibility of unrealistic conformational sampling.  Using 
boost level 4, ten simulations of 40 ns were completed for each of the five solvent types.  To 
account for the lower degree of boost with level 4*, longer simulations of 100 ns were 
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completed for ten runs with each of the solvent types.  As shown in Figure B.6 panels C and D, 
both boosting levels resulted in sampling of an intermediate conformational state, with the Asp 
pointing towards the active site and the phenylalanine positioned upward towards the αC helix.  
In order to understand the reason for this stabilized intermediate positon, we calculated the 
occupancy of the probe molecules from all frames in the trajectory having this intermediate 
conformation (lower right quadrant of Figure B.6 panel D).  The position that is normally 
occupied by a phenylalanine in the DFG-in state was occupied by probe molecules (panel E of 
Figure B.6), blocking the complete transition to the DFG-in state.  This mapping is consistent 
with known inhibitors of ABL kinase that bind in this pocket, but impedes sampling of the full 





Figure B.6:  
A-D) The transition between the DFG-out and DFG-in 
states is characterized by the Ala-Phe and Ala-Asp dihedral 
angles.  Sampling during the respective trajectories is 
shown, colored according to the frequency of the observed 
angles.  The black star indicates the dihedral angles 
characteristic of the DFG-in conformation.  E) Pyrimidine 
occupancy from the frames falling within the frequently 
sampled region in the right lower quadrant of graph D, 
from point (-50,-60) to (30,-180).  The DFG-out and DFG-in 
states are shown in green and cyan, respectively.  The 
pyrimidine occupancy overlaps with the region that is occupied by phenylalanine in the DFG-in 
conformation. 
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 Previous studies have highlighted the ability of cosolvent simulations in combination 
with enhanced sampling techniques to identify druggable conformations.  For example, 
Kalenkiewicz et al. used aMD, cosolvent simulations, and combined cosolvent aMD simulations 
to create ensembles of structures that were used for docking268.  It was found that the 
combined cosolvent aMD simulations resulted in better docking scores, implying that 
conformations sampled during the cosolvent aMD simulations were more representative of 
ligand-bound states than conformations obtained from aMD or cosolvent simulations alone.  
Studies by Oleinikovas et al. found similar results285.  Using a combined cosolvent procedure 
with a Hamiltonian replica exchange-based method of enhanced sampling, they identified 
cryptic pockets that were not identified with enhanced sampling techniques alone.  Our results 
indicate that while enhanced sampling simulations serve to increase the accessible 
conformational space within a single simulation, the use of cosolvent probes can also lead to 




 These simulations demonstrate the ability of aMD to enhance sampling during MixMD 
simulations.  Low to moderate levels of boost result in increased conformational sampling that 
is within the expected limits of traditional MD simulations.  This additional sampling leads to 
faster convergence and reduces the number of spurious sites.  For systems without known or 
expected large-scale conformational changes, aMixMD can decrease the computational time 
required and enable the study of a greater number of systems.  On the other hand, higher 
boosting levels promote more extensive conformational changes, as in the case of ABL kinase.  
This led to the capture of intermediate conformational states, but it did not allow for full 
transitions between active and inactive conformations.  During simulations of ABL kinase, probe 
molecules blocked sites typically occupied by side chains in different conformations, which 
prevented full conformational sampling.  It is not clear if this would occur with other systems or 
if it is a specific effect to ABL kinase.  Regardless, aMixMD did promote conformational 
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